<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004389.pub2" GROUP_ID="INFECTN" ID="180902071219103578" MERGED_FROM="" MODIFIED="2013-10-21 09:39:17 +0100" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2013-10-21 09:20:47 +0100" MODIFIED_BY="Anne-Marie Stephani">
<TITLE MODIFIED="2013-10-17 17:12:52 +0100" MODIFIED_BY="[Empty name]">Primaquine for preventing relapse in people with <I>Plasmodium vivax</I> malaria treated with chloroquine</TITLE>
<CONTACT>
<PERSON ID="14296" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gawrie</FIRST_NAME>
<MIDDLE_INITIALS>NL</MIDDLE_INITIALS>
<LAST_NAME>Galappaththy</LAST_NAME>
<SUFFIX>MSc, MD</SUFFIX>
<POSITION>Consultant Community Physician</POSITION>
<EMAIL_1>hapugalleg@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>National Malaria Control Programme</DEPARTMENT>
<ORGANISATION>Ministry of Health</ORGANISATION>
<ADDRESS_1>45/2C Auburn Side</ADDRESS_1>
<ADDRESS_2/>
<CITY>Dehiwala</CITY>
<ZIP/>
<REGION>Colombo</REGION>
<COUNTRY CODE="LK">Sri Lanka</COUNTRY>
<PHONE_1>+94 011 2368173/4</PHONE_1>
<PHONE_2>+94 011 2368885</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-10-21 09:16:51 +0100" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="14296" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gawrie</FIRST_NAME>
<MIDDLE_INITIALS>NL</MIDDLE_INITIALS>
<LAST_NAME>Galappaththy</LAST_NAME>
<SUFFIX>MSc, MD</SUFFIX>
<POSITION>Consultant Community Physician</POSITION>
<EMAIL_1>hapugalleg@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>National Malaria Control Programme</DEPARTMENT>
<ORGANISATION>Ministry of Health</ORGANISATION>
<ADDRESS_1>45/2C Auburn Side</ADDRESS_1>
<ADDRESS_2/>
<CITY>Dehiwala</CITY>
<ZIP/>
<REGION>Colombo</REGION>
<COUNTRY CODE="LK">Sri Lanka</COUNTRY>
<PHONE_1>+94 011 2368173/4</PHONE_1>
<PHONE_2>+94 011 2368885</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16290" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Prathap</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tharyan</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Psychiatry and Director,</POSITION>
<EMAIL_1>prathap@cmcvellore.ac.in</EMAIL_1>
<EMAIL_2>cochrane@cmcvellore.ac.in</EMAIL_2>
<URL>www.cochrane-sacn.org</URL>
<MOBILE_PHONE>+91 9443743851</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>South Asian Cochrane Network &amp; Centre, Prof. BV Moses &amp; ICMR Advanced Centre for Research &amp; Training in Evidence Informed Health Care</DEPARTMENT>
<ORGANISATION>Christian Medical College</ORGANISATION>
<ADDRESS_1>Carman Block II Floor</ADDRESS_1>
<ADDRESS_2>CMC Campus, Bagayam</ADDRESS_2>
<CITY>Vellore</CITY>
<ZIP>632002</ZIP>
<REGION>Tamil Nadu</REGION>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1>+91 416 2284499</PHONE_1>
<PHONE_2>+91 416 2284519</PHONE_2>
<FAX_1>+91 416 2261632</FAX_1>
<FAX_2>+91 416 2262268</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DF4BD88882E26AA20125F76B55DDF1ED" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Richard</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kirubakaran</LAST_NAME>
<SUFFIX/>
<POSITION>Bio-statistician</POSITION>
<EMAIL_1>richrichigo@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>09500292922</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>South Asian Cochrane Network &amp; Centre, Prof. BV Moses &amp; ICMR Advanced Centre for Research &amp; Training in Evidence Informed Health Care</DEPARTMENT>
<ORGANISATION>Christian Medical College</ORGANISATION>
<ADDRESS_1>Carman Block II Floor</ADDRESS_1>
<ADDRESS_2>CMC Campus, Bagayam</ADDRESS_2>
<CITY>Vellore</CITY>
<ZIP>632002</ZIP>
<REGION>Tamil Nadu</REGION>
<COUNTRY CODE="IN">India</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-10-21 09:20:12 +0100" MODIFIED_BY="Harriet MacLehose">
<UP_TO_DATE>
<DATE DAY="8" MONTH="10" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="10" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="10" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-21 09:20:47 +0100" MODIFIED_BY="Harriet MacLehose">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-21 09:20:47 +0100" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="17" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>We included six additional trials in this update: Alvarez 2006; Leslie 2008; Carmona-Fonseca 2009; Yeshiwondim 2010; Kim 2012; Ganguly 2013,</P>
<P>One new author (Richard Kirubakaran) contributed to this review update and replaced an author (Aika Omari) of the 2007 review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-10-17 11:01:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>We updated the conclusions of this review from the 2007 review:</P>
<P>New comparisons demonstrate the relative inefficacy of three shorter primaquine regimens versus the standard 14-days of primaquine; and uncertain benefits with weekly primaquine dosing for eight weeks over the standard 14-day primaquine regimen in preventing relapses of vivax malaria.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-09-02 09:57:13 +0100" MODIFIED_BY="Harriet MacLehose">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-09-02 09:57:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>
We correct
ed
 d
osage figures.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-10-03 10:18:46 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-10-03 10:18:46 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-10-03 10:18:46 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Malaria Control Programme</NAME>
<COUNTRY CODE="LK">Sri Lanka</COUNTRY>
<DESCRIPTION>
<P>Salary support for Dr. Gawrie</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-04-11 13:32:53 +0100" MODIFIED_BY="[Empty name]">
<NAME>Christian Medical College, Vellore</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION>
<P>Salary and logistic support for Dr. Tharyan</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-10-03 10:18:33 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-10-03 10:18:20 +0100" MODIFIED_BY="[Empty name]">
<NAME>Indian Council of Medical Research</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION>
<P>Funding for Prof. BV Moses &amp; ICMR Centre for Advanced Research in Evidence-Informed Healthcare; salary support for Richard Kirubakaran during the initial period of the review update</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-10-03 10:18:33 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department for International Development (DFID)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Project funding for the Effective Healthcare Research Consortium; salary for Richard Kirubakaran during the latter part of this review update</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-07-27 15:43:55 +0100" MODIFIED_BY="Prathap  Tharyan">
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Support for Dr. Gawrie to develop the protocol for the initial version of the review via funds from DFID (UK)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-10-21 09:36:17 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-10-17 17:24:50 +0100" MODIFIED_BY="[Empty name]">
<TITLE NOTES="&lt;p&gt;&lt;span modified=&quot;2013-07-03 18:35:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;unless we quantify &amp;quot;few&amp;quot; and the methods for monitoring-hb checkes etc. I would be careful in repeating what the clinical &lt;/span&gt;&lt;span modified=&quot;2013-07-03 18:36:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;reports say. Unless we go back and look at how they measured it all, as with pyronaridine. because when it is expressed like it is expressed, it really in effect dismisses th&lt;/span&gt;&lt;span modified=&quot;2013-07-03 18:37:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;e problem.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2013-07-03 18:37:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2013-09-25 13:35:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;This is not in the abstract.&lt;/span&gt;&lt;/p&gt;">Primaquine for preventing relapses in people with <I>Plasmodium vivax </I>malaria</TITLE>
<SUMMARY_BODY MODIFIED="2013-10-17 17:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Malaria due to <I>Plasmodium vivax </I>parasites is widespread. The World Health Organization (WHO) recommends that people with <I>P. vivax</I> malaria are treated with chloroquine for three days to eliminate the parasites in the blood that cause the symptoms of malaria, followed by 15 mg/day of primaquine for 14 days to treat the liver stage of the infection to prevent the disease recurring. However, many people do not complete the primaquine treatment once they feel better after chloroquine treatment. In addition, primaquine can destroy red blood cells in people with a genetic enzyme deficiency (glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency), and clinicians avoid giving primaquine in areas where people commonly have this deficiency. Shorter courses of primaquine could potentially increase treatment completion and reduce adverse events.</P>
<P>The review authors included 15 trials of 4377 adults and children older than one year with vivax malaria. All were treated with chloroquine for the blood stage infection, and then randomized to the 14-day primaquine course, or to shorter primaquine courses (three, five, or seven days); or to higher doses of primaquine given once a week for eight weeks; or to a placebo or no treatment. In twelve studies, treatments were supervised. The evidence is current to 8 October 2013.</P>
<P>Relapse over six months to one year is probably higher with shorter regimens when compared to the standard 14-day primaquine regimen (<I>moderate quality evidence</I>). We do not know from the available evidence whether the number of relapses with weekly primaquine differs from 14 days of primaquine treatment based on one study of 126 people followed up for nine months (<I>very low quality evidence</I>). Better conducted studies on more people are needed to be sure that they are equally effective against relapse. Five days of primaquine was as ineffective against relapse as placebo or no treatment over six months to 15 months based on four studies (<I>high quality evidence</I>). The 14-day primaquine course prevented many more people relapsing with vivax malaria over 12 months than placebo (<I>high quality evidence</I>). No serious adverse reactions to primaquine were reported.</P>
<P>This review update confirms that the 14-day primaquine course recommended by the WHO is more effective against relapse of vivax malaria than treatment with shorter courses of primaquine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-10-17 17:19:27 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-10-17 17:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Plasmodium vivax</I> infections are an important contributor to the malaria burden worldwide. The World Health Organization recommends a 14-day course of primaquine (0.25 mg/kg/day, giving an adult dose of 15 mg/day) to eradicate the liver stage of the parasite and prevent relapse of the disease. Many people find a 14-day primaquine regimen difficult to complete, and there is a potential risk of haemolytic anaemia in people with glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency. This review evaluates primaquine in <I>P. vivax</I>, particularly alternatives to the standard 14-day course.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-10-03 05:02:35 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>To compare alternative primaquine regimens to the recommended 14-day regimen for preventing relapses (radical cure) in people with <I>P. </I>vivax<I> </I>malaria treated for blood stage infection with chloroquine. We also summarize trials comparing primaquine to no primaquine that led to the recommendation for the 14-day regimen.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-10-17 17:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group's Specialized Register, CENTRAL (<I>The Cochrane Library</I>), MEDLINE, EMBASE and LILACS up to 8 October 2013. We checked conference proceedings, trial registries and reference lists and contacted researchers and pharmaceutical companies for eligible studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-10-03 05:03:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) and quasi-RCTs comparing various primaquine dosing regimens with the standard primaquine regimen (15 mg/day for 14 days), or with no primaquine, in people with vivax malaria treated for blood stage infection with chloroquine.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-10-03 05:03:20 +0100" MODIFIED_BY="[Empty name]">
<P>We independently assessed trial eligibility, trial quality, and extracted data. We calculated risk ratios (RR) with 95% confidence intervals (CI) for dichotomous data, and used the random-effects model in meta-analyses if there was significant heterogeneity. We assessed the overall quality of the evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-10-17 17:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>We included 15 trials (two cluster-RCTs) of 4377 adult and child participants. Most trials excluded people with G6PD deficiency. Trials compared various regimens of primaquine with the standard primaquine regimen, or with placebo or no treatment. All trials treated blood stage infection with chloroquine.</P>
<P>
<U>Alternative primaquine regimens compared to 14-day primaquine</U>
</P>
<P>Relapse rates were higher over six months with the five-day primaquine regimen than the standard 14-day regimen (RR 10.05, 95% CI 2.82 to 35.86; two trials, 186 participants, <I>moderate quality evidence). </I>Similarly, relapse over six months was higher with three days of primaquine than the standard 14-day regimen (RR 3.18, 95% CI 2.1 to 4.81; two trials, 262 participants, <I>moderate quality evidence</I>; six months follow-up<I>)</I>;<I> </I>and with primaquine for seven days followed up over two months, compared to 14-day primaquine (RR 2.24, 95% CI 1.24 to 4.03; one trial, 126 participants, <I>low quality evidence</I>).</P>
<P>Relapse with once-weekly supervised primaquine for eight weeks was little different over nine months follow-up compared to 14-day self-administered primaquine in one small study (RR 2.97, 95% CI 0.34 to 25.87; one trial, 129 participants, <I>very low quality evidence</I>)<I>.</I>
</P>
<P>
<U>Primaquine regimens compared to no primaquine</U>
</P>
<P>The number of people that relapsed was similar between people given five days of primaquine or given placebo or no primaquine (four trials, 2213 participants, <I>high quality evidence</I>;<I> </I>follow-up six to 15 months); but lower with 14 days of primaquine (RR 0.6; 95% CI 0.48 to 0.75; ten trials, 1740 participants, <I>high quality evidence</I>; follow-up seven weeks to 15 months).</P>
<P>No serious adverse events were reported. Treatment-limiting adverse events were rare and non-serious adverse events were mild and transient. Trial authors reported that people tolerated the drugs.</P>
<P>We did not find trials comparing higher dose primaquine regimens (0.5 mg/kg/day or more) for five days or more with the 14-day regimen.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-10-03 05:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>The analysis confirms the current World Health Organization recommendation for 14-day primaquine (15 mg/day) to prevent relapse of vivax malaria. Shorter primaquine regimens at the same daily dose are associated with higher relapse rates. The comparative effects with weekly primaquine are promising, but require further trials to establish equivalence or non-inferiority compared to the 14-day regimen in high malaria transmission settings.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-10-21 09:36:17 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-18 03:45:09 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-10-17 17:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Malaria is usually caused by the parasites <I>Plasmodium vivax and Plasmodium falciparum.</I> In 2010, malaria episodes occurred in an estimated 149 million to 274 million people worldwide, approximately 81% of whom were living in Africa, and 13% in South-East Asia (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). In 2010, malaria killed between 537,000 to 907,000 people; and 86% of these deaths were children under five years of age (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>). <I>P. vivax </I>infects an estimated 130 million to 391 million people annually (<LINK REF="REF-Hay-2004" TYPE="REFERENCE">Hay 2004</LINK>; <LINK REF="REF-Price-2007" TYPE="REFERENCE">Price 2007</LINK>). Around 40% of the world's population living in 95 countries in Central, South East, and South Asia; Africa; and South America are at risk of <I>P. vivax</I> infection. The geographical distribution of vivax malaria is more widespread than falciparum malaria (<LINK REF="REF-Guerra-2010" TYPE="REFERENCE">Guerra 2010</LINK>). Co-infection with <I>P. falciparum</I> is also common in many of these regions (<LINK REF="REF-Kumar-2007" TYPE="REFERENCE">Kumar 2007</LINK>; <LINK REF="REF-Mueller-2009" TYPE="REFERENCE">Mueller 2009</LINK>). Vivax infections during pregnancy increase neonatal, infant, and maternal morbidity and mortality (<LINK REF="REF-Poespoprodjo-2008" TYPE="REFERENCE">Poespoprodjo 2008</LINK>; <LINK REF="REF-ter-Kuile-2008" TYPE="REFERENCE">ter Kuile 2008</LINK>; <LINK REF="REF-Poespoprodjo-2009" TYPE="REFERENCE">Poespoprodjo 2009</LINK>; <LINK REF="REF-Price-2009" TYPE="REFERENCE">Price 2009</LINK>). Case series studies of adults and children in endemic areas have documented severe disease in people with confirmed<I> P. vivax</I> mono-infections,<I> </I>similar to that produced by <I>P. falciparum</I> (<LINK REF="REF-Anstey-2007" TYPE="REFERENCE">Anstey 2007</LINK>; <LINK REF="REF-Barcus-2007" TYPE="REFERENCE">Barcus 2007</LINK>; <LINK REF="REF-Beg-2008" TYPE="REFERENCE">Beg 2008</LINK>; <LINK REF="REF-Genton-2008" TYPE="REFERENCE">Genton 2008</LINK>; <LINK REF="REF-Tjitra-2008" TYPE="REFERENCE">Tjitra 2008</LINK>; <LINK REF="REF-Mueller-2009" TYPE="REFERENCE">Mueller 2009</LINK>; <LINK REF="REF-Price-2009" TYPE="REFERENCE">Price 2009</LINK>; <LINK REF="REF-Valecha-2009" TYPE="REFERENCE">Valecha 2009</LINK>; <LINK REF="REF-Kochar-2010" TYPE="REFERENCE">Kochar 2010</LINK>; <LINK REF="REF-Maguire-2010" TYPE="REFERENCE">Maguire 2010</LINK>; <LINK REF="REF-Saravu-2011" TYPE="REFERENCE">Saravu 2011</LINK>; <LINK REF="REF-Srivastava-2011" TYPE="REFERENCE">Srivastava 2011</LINK>; <LINK REF="REF-Singh-2011" TYPE="REFERENCE">Singh 2011</LINK>; <LINK REF="REF-Tanwar-2011" TYPE="REFERENCE">Tanwar 2011</LINK>). Also, less severe forms of vivax malaria can adversely affect personal well-being, growth, and economic performance at the individual, family, community, and national level (<LINK REF="REF-Breman-2001" TYPE="REFERENCE">Breman 2001</LINK>; <LINK REF="REF-Mendis-2001" TYPE="REFERENCE">Mendis 2001</LINK>).</P>
<P>In addition,<I> </I>people infected with <I>P. vivax </I>may have relapses of the disease. The infective stage of the parasite (sporozoites) is injected into a person's bloodstream through the bite of a female anopheline mosquito, enters the liver within minutes, invades liver cells, and develops into either of two stages. The asexual blood-stage infection results in the clinical symptoms of vivax malaria; while a dormant liver-stage infection (hypnozoite) that can be activated weeks to years after the initial infection, causes relapses of the blood-stage infection, and increases the potential for transmission of the sexual gametocyte forms (<LINK REF="REF-Krotoski-1985" TYPE="REFERENCE">Krotoski 1985</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>; <LINK REF="REF-Doolan-2009" TYPE="REFERENCE">Doolan 2009</LINK>; <LINK REF="REF-Mueller-2009" TYPE="REFERENCE">Mueller 2009</LINK>). Relapse occurrence varies depending on the genetic makeup of the sporozoites (<LINK REF="REF-Cogswell-1992" TYPE="REFERENCE">Cogswell 1992</LINK>; <LINK REF="REF-Craig-1996" TYPE="REFERENCE">Craig 1996</LINK>; <LINK REF="REF-Rowland-2001" TYPE="REFERENCE">Rowland 2001</LINK>), the number of sporozoites inoculated, and climatic conditions that favour transmission (<LINK REF="REF-White-2011" TYPE="REFERENCE">White 2011</LINK>). In general, people infected with tropical strains from Asia have high relapse rates (80% to 100%), with relapses usually occurring within six months of treatment (<LINK REF="REF-Fonseka-1987" TYPE="REFERENCE">Fonseka 1987</LINK>; <LINK REF="REF-Looareesuwan-1997" TYPE="REFERENCE">Looareesuwan 1997</LINK>; <LINK REF="STD-Luxemburger-1999" TYPE="STUDY">Luxemburger 1999</LINK>; <LINK REF="REF-Pukrittayakamee-2004" TYPE="REFERENCE">Pukrittayakamee 2004</LINK>; <LINK REF="REF-Krudsood-2008" TYPE="REFERENCE">Krudsood 2008</LINK>). Relapse rates with vivax strains from India are reportedly lower, but are highly variable (8% to 40%); and although the majority occur within the first six months (<LINK REF="REF-Gogtay-2000" TYPE="REFERENCE">Gogtay 2000</LINK>) relapses can also occur within a few weeks to a year or more, in different parts of the country (<LINK REF="REF-White-2011" TYPE="REFERENCE">White 2011</LINK>). People infected with tropical strains from New Guinea (the Chesson strain) relapse within or shortly after a month and relapses occur several times over a period of a year or more (<LINK REF="REF-Collins-1996" TYPE="REFERENCE">Collins 1996</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). Relapses usually occur much later with temperate strains, such as the North Korean strain (<LINK REF="REF-Collins-1996" TYPE="REFERENCE">Collins 1996</LINK>; <LINK REF="REF-White-2011" TYPE="REFERENCE">White 2011</LINK>).</P>
<P>Re-infection is also a problem with vivax malaria. Apart from innate (or natural) immunity to malaria, a partial immunity (acquired immunity) that mitigates the clinical effects of malaria develops in individuals who live in areas where malaria is highly endemic (<LINK REF="REF-Doolan-2009" TYPE="REFERENCE">Doolan 2009</LINK>). This clinical immunity is lost when individuals living in endemic areas move to non-endemic areas (<LINK REF="REF-Maguire-2010" TYPE="REFERENCE">Maguire 2010</LINK>). In highly endemic areas, the risk of severe <I>P. vivax</I> disease is highest among children less than two years of age, while uncomplicated <I>P. vivax </I>illness is less common in children over five years of age, though infections occur even in adolescents and adults (<LINK REF="REF-Michon-2007" TYPE="REFERENCE">Michon 2007</LINK>; <LINK REF="REF-Genton-2008" TYPE="REFERENCE">Genton 2008</LINK>; <LINK REF="REF-Lin-2010" TYPE="REFERENCE">Lin 2010</LINK>). However, in many parts of the world, relapses caused by the hypnozoite represent the dominant source of recurrences of parasitaemia compared to new infections (<LINK REF="REF-Maguire-2010" TYPE="REFERENCE">Maguire 2010</LINK>; <LINK REF="REF-White-2011" TYPE="REFERENCE">White 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-17 17:29:49 +0100" MODIFIED_BY="[Empty name]">
<P>People with vivax<I> </I>malaria require effective treatment with a combination of chloroquine to treat the blood-stage infection, and primaquine to treat hypnozoites and prevent relapses (radical cure). The recommended adult treatment with chloroquine is 25 mg/kg body weight administered daily over three days. Chloroquine is inexpensive and people usually tolerate it well. People frequently report itching from chloroquine but they do not usually discontinue treatment for this reason (<LINK REF="REF-Valecha-2006" TYPE="REFERENCE">Valecha 2006</LINK>). The standard recommended dose of primaquine is 15 mg per day (0.25 mg/kg) for 14 days, delivering a total dose of 210 mg of primaquine. Primaquine may cause abdominal pain, nausea, and vomiting, but these adverse events are dose-dependant and are minimized if people take the drug after meals (<LINK REF="REF-Parfitt-1999" TYPE="REFERENCE">Parfitt 1999</LINK>; <LINK REF="REF-Vale-2008" TYPE="REFERENCE">Vale 2008</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency</HEADING>
<P>Primaquine also causes the destruction of red blood cells (haemolysis) in people with a hereditary enzyme deficiency known as glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency, which occurs due to mutations in the G6PD gene (q28 locus on the X chromosome) (<LINK REF="REF-Beutler-2007" TYPE="REFERENCE">Beutler 2007</LINK>; <LINK REF="REF-Cappellini-2008" TYPE="REFERENCE">Cappellini 2008</LINK>). Over 400 million people worldwide have this enzyme deficiency; and the enzyme deficiency variant and dose of primaquine determine the severity of haemolytic anaemia (<LINK REF="REF-Hill-2006" TYPE="REFERENCE">Hill 2006</LINK>; <LINK REF="REF-Beutler-2007" TYPE="REFERENCE">Beutler 2007</LINK>). G6PD deficiency that is common in Africa, and the Mahidol variant seen in Thailand and Malaysia, result in mild and self-limiting haemolysis that permits primaquine use even at high doses (<LINK REF="REF-Beutler-2007" TYPE="REFERENCE">Beutler 2007</LINK>). In the Middle East and India, where over 60% of G6PD deficient individuals carry the Mediterranean variant, haemolysis due to primaquine can be severe and prolonged (<LINK REF="REF-Beutler-2007" TYPE="REFERENCE">Beutler 2007</LINK>). Variations in the frequency and variants of G6PD enzyme deficiency occur within countries, and even within tribal communities in the same country (<LINK REF="REF-Bouma-1995" TYPE="REFERENCE">Bouma 1995</LINK>; <LINK REF="REF-Tripathy-2007" TYPE="REFERENCE">Tripathy 2007</LINK>). This deficiency can be detected by various tests, but these may not always be affordable or feasible in many parts of the developing world.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methaemoglobinaemia</HEADING>
<P>Less commonly, primaquine treatment can result in methaemoglobinaemia. Methaemoglobin (MetHB) is a reduced form of haemoglobin that results from oxidative stress, which normally is kept under 1% within the red blood cells through normal enzymatic activity. When this level exceeds 2%, methaemoglobinaemia is diagnosed. Levels greater than 30% can lead to breathing difficulties, cardiovascular and neurological symptoms; and levels above 70% are invariably fatal. However, in usual practice this increase in methaemoglobin levels with primaquine is usually less than 20%, and symptoms are mild, self-limited, and well-tolerated in otherwise healthy people, even at higher than normal doses (<LINK REF="REF-Hill-2006" TYPE="REFERENCE">Hill 2006</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009a" TYPE="STUDY">Carmona-Fonseca 2009a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other drugs for radical cure of vivax malaria</HEADING>
<P>Artemesinin-based combination therapy (ACT) is at least as effective as chloroquine in treating the blood stage <I>P. vivax </I>infection, but current drugs that constitute ACT are not effective against the liver stage of <I>P. vivax </I>(<LINK REF="REF-Douglas-2010" TYPE="REFERENCE">Douglas 2010</LINK>; <LINK REF="REF-Sinclair-2011" TYPE="REFERENCE">Sinclair 2011</LINK>). Primaquine is still the only commercially available drug for widespread use to achieve radical cure. Two longer-acting synthetic analogues of primaquine undergoing evaluation and not yet available for widespread commercial use are tafenoquine (<LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>; <LINK REF="REF-Kitchner-2007" TYPE="REFERENCE">Kitchner 2007</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>) and bulaquine (also called elubaquine; CDRI 80/53) (<LINK REF="REF-Adak-2001" TYPE="REFERENCE">Adak 2001</LINK>; <LINK REF="REF-Krudsood-2006" TYPE="REFERENCE">Krudsood 2006</LINK>; <LINK REF="REF-Vale-2008" TYPE="REFERENCE">Vale 2008</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2013-10-18 03:45:09 +0100" MODIFIED_BY="[Empty name]">
<P>Chloroquine acts on the blood stages of the parasite and also has schizonticidal activity (against the mature, infective stage of the malaria parasite). Chloroquine-sensitive <I>P. vivax</I> are suppressed by whole-blood concentrations of 70 to 90 ng/mL of chloroquine and its metabolite, mono-desethyl-chloroquine (<LINK REF="REF-WHO-2010b" TYPE="REFERENCE">WHO 2010b</LINK>). Due to the persistence of therapeutic blood levels for 21 to 35 days, chloroquine also eliminates blood forms that emerge from hypnozoites within the first month (<LINK REF="REF-Baird-1997" TYPE="REFERENCE">Baird 1997</LINK>). Primaquine has some schizonticidal activity against the blood stages of vivax malaria, but is more effective against hypnozoites (liver stage) and gametocytes (only the mature sexual gametocytes) of <I>P. vivax</I>;<I> </I>it therefore has the potential to block the transmission of vivax malaria, if used with a drug active against blood forms of the parasite (<LINK REF="REF-Pukrittayakamee-2008" TYPE="REFERENCE">Pukrittayakamee 2008</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>; <LINK REF="REF-Maguire-2010" TYPE="REFERENCE">Maguire 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Differentiating recrudescence, relapse and re-infection</HEADING>
<P>Following treatment of the blood stage of malaria, <I>P. vivax </I>parasites may be found in peripheral blood smears because of r<I>ecrudescence</I> (due to blood stage parasites that were not eliminated from the original infection due to a failure of chloroquine); <I>relapse</I> (due to new parasites emerging from hypnozoites due to failure of primaquine); or a <I>re-infection </I>due to new parasites from fresh mosquito bites (<LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). The term<I> recurrence</I> is used for parasitaemia of unknown origin (unclear if a recrudescence, relapse, or re-infection) (<LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). Recrudescence and relapse of vivax malaria may also be due to inadequate doses or drug levels of either drug, apart from drug resistance (<LINK REF="REF-Duarte-2001" TYPE="REFERENCE">Duarte 2001</LINK>).</P>
<P>Primaquine treatment failure or relapse is defined as the presence of <I>P. vivax</I> parasites more than 28 to 30 days after the full course of primaquine in people living in a non-endemic area (<LINK REF="REF-Looareesuwan-1997" TYPE="REFERENCE">Looareesuwan 1997</LINK>). In endemic areas with a high risk of re-infection, microscopy cannot reliably differentiate new infections with the same or different strains of <I>P. vivax </I>from relapses of the original infecting strain due to failure of primaquine. Attempts to differentiate a new infection (re-infection) from a relapse of the initial infection using the polymerase chain reaction (PCR) technique, which compares parasite genotypes (gene types), were based on the assumption that parasites causing a relapse would be a sub-set of the parasites that caused the primary infection. A true relapse was confirmed when the genotypes of parasites collected on the first day of the infection were similar to those that re-appeared during the follow-up period, and a new infection when the genotypes were different (<LINK REF="REF-Craig-1996" TYPE="REFERENCE">Craig 1996</LINK>; <LINK REF="REF-Looareesuwan-1997" TYPE="REFERENCE">Looareesuwan 1997</LINK>).</P>
<P>However, due to the considerable genetic diversity seen in vivax infections, relapses (particularly in adults) may originate from reactivation of either the same parasite clone found in the primary blood-stage infection (homologous hypnozoites) or another genetically different clone (heterologous hypnozoites); or due to relapses from infections with multiple <I>P. vivax </I>strains (<LINK REF="REF-Chen-2007" TYPE="REFERENCE">Chen 2007</LINK>; <LINK REF="REF-Imwong-2007a" TYPE="REFERENCE">Imwong 2007a</LINK>; <LINK REF="REF-Karunaweera-2008" TYPE="REFERENCE">Karunaweera 2008</LINK>; <LINK REF="REF-Orjuela_x002d_Sanchez-2009" TYPE="REFERENCE">Orjuela-Sanchez 2009</LINK>; <LINK REF="REF-Imwong-2012" TYPE="REFERENCE">Imwong 2012</LINK>). Thus, mismatched primary and secondary parasite populations may represent either a new infection or a relapse, and this genetic diversity makes current methods of genotyping of recurrent infections with PCR in differentiating relapse from re-infections of limited utility in vivax malaria (<LINK REF="REF-Imwong-2007a" TYPE="REFERENCE">Imwong 2007a</LINK>). This is in contrast to the value of molecular techniques in falciparum malaria, where three-loci genotyping has proved useful in detecting recrudescence (<LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). Increasing the number of genetic markers also increases the possibility of detecting multiple clones in vivax recurrence; and micro-satellite genotyping, using five to eight or more genetic loci, appears promising as a method to reliably differentiate relapses, recrudescence or re-infection with <I>P. vivax </I>(<LINK REF="REF-Imwong-2007b" TYPE="REFERENCE">Imwong 2007b</LINK>; <LINK REF="REF-Havryliuk-2009" TYPE="REFERENCE">Havryliuk 2009</LINK>; <LINK REF="REF-Gunawardena-2010" TYPE="REFERENCE">Gunawardena 2010</LINK>; <LINK REF="REF-Van-den-Eede-2010a" TYPE="REFERENCE">Van den Eede 2010a</LINK>; <LINK REF="REF-Van-den-Eede-2011" TYPE="REFERENCE">Van den Eede 2011</LINK>; <LINK REF="REF-Imwong-2012" TYPE="REFERENCE">Imwong 2012</LINK>). However, these methods have yet to be validated for widespread use.</P>
<P>Therefore, the demonstration of clearance of parasite within the first month after treatment with chloroquine, and the timing of recurrences after primaquine are used to determine the efficacy of radical cure in vivax malaria (<LINK REF="REF-Baird-2003a" TYPE="REFERENCE">Baird 2003a</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). Recurrence of parasitaemia in the three to six months after primaquine is likely to be a relapse (<LINK REF="REF-Alves-2002" TYPE="REFERENCE">Alves 2002</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2006" TYPE="STUDY">Carmona-Fonseca 2006</LINK>). Differentiating a relapse from a re-infection beyond six months is more difficult, as the chances of re-infections (new primary infections) increases. This time frame may also differ in areas of high transmission, with the strain of parasite, due to seasonal variations, and due to unstable transmission patterns from year to year.</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2013-10-17 18:44:51 +0100" MODIFIED_BY="[Empty name]">
<P>Although policies regarding radical cure of vivax malaria in India and Sri Lanka changed from five day to 14-day primaquine regimens (<LINK REF="REF-NIMR-2011" TYPE="REFERENCE">NIMR 2011</LINK>) following the 2007 version of this review (<LINK REF="REF-Galappaththy-2007" TYPE="REFERENCE">Galappaththy 2007</LINK>), five days of primaquine is still used in many parts of South Asia, South-East Asia, and Latin America for radical cure of vivax malaria (<LINK REF="REF-Leslie-2010" TYPE="REFERENCE">Leslie 2010</LINK>). The main problems with the standard 14-day course of 15 mg/day of primaquine following chloroquine are:</P>
<OL>
<LI>Poor adherence, since people become rapidly asymptomatic after treatment with chloroquine and are poorly motivated to complete primaquine treatment (<LINK REF="REF-Grietens-2010" TYPE="REFERENCE">Grietens 2010</LINK>);</LI>
<LI>The risk (perceived and real) of adverse events;</LI>
<LI>The lack of availability of cheap, rapid and practical tests for G6PD deficiency; and</LI>
<LI>Less than optimal prevention of relapses in spite of adherence to the regimen, due to primaquine resistance in some areas of the world.</LI>
</OL>
<P>Thus practitioners are still struggling to successfully implement the 14-day regimen. The alternatives suggested to the five and 14-day primaquine treatments include:</P>
<P>
<U>
<I>Using higher doses of primaquine (after chloroquine) for shorter periods to overcome problems with adherence</I>:</U> Case series studies have shown that higher doses of primaquine given over fewer days are highly effective, well-tolerated, and equivalent to the standard 15 mg/day for 14 days regimen for radical cure in vivax malaria (<LINK REF="REF-Schmidt-1977" TYPE="REFERENCE">Schmidt 1977</LINK>; <LINK REF="REF-Baird-2003a" TYPE="REFERENCE">Baird 2003a</LINK>; <LINK REF="REF-Krudsood-2008" TYPE="REFERENCE">Krudsood 2008</LINK>; <LINK REF="REF-Ebringer-2011" TYPE="REFERENCE">Ebringer 2011</LINK>). In order to overcome adherence problems, the national drug policy in Peru recommends a shortened regimen of seven days of primaquine at an increased daily dosage of 0.5 mg/kg/day combined with three days of chloroquine (<LINK REF="REF-Van-den-Eede-2010a" TYPE="REFERENCE">Van den Eede 2010a</LINK>).</P>
<P>
<U>
<I>Using higher doses of primaquine (after chloroquine) for 14 days or longer to overcome primaquine resistance</I>:</U>
<I> </I>Primaquine resistance is particularly important in<I> </I>some countries in the Western Pacific, South-East Asia, South America, and parts of Africa (<LINK REF="REF-Charoenlarp-1973" TYPE="REFERENCE">Charoenlarp 1973</LINK>; <LINK REF="REF-Hill-2006" TYPE="REFERENCE">Hill 2006</LINK>; <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). The Centres for Disease Control (<LINK REF="REF-CDC-2005" TYPE="REFERENCE">CDC 2005</LINK>; <LINK REF="REF-CDC-2011" TYPE="REFERENCE">CDC 2011</LINK>) recommends a dose of 30 mg of primaquine for 14 days as standard therapy for radical cure of vivax<I> </I>malaria. This higher dose is also recommended for travellers with vivax malaria acquired in SE Asia and Oceania (<LINK REF="REF-Lalloo-2007" TYPE="REFERENCE">Lalloo 2007</LINK>; <LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>; <LINK REF="REF-CDC-2011" TYPE="REFERENCE">CDC 2011</LINK>). It is also used in Thailand as second-line treatment (<LINK REF="REF-Looareesuwan-1997" TYPE="REFERENCE">Looareesuwan 1997</LINK>). In parts of Latin America, primaquine is given at 0.25 (15 mg/day) or 0.5 mg/kg (30 mg/day) for longer courses up to 28 days in people who relapse with the standard 14-day course (<LINK REF="STD-Carmona_x002d_Fonseca-2006" TYPE="STUDY">Carmona-Fonseca 2006</LINK>). Resistance to chloroquine is less of a global problem (<LINK REF="REF-Naing-2010" TYPE="REFERENCE">Naing 2010</LINK>), except in Indonesia, the Solomon Islands, and Vanuatu, where ACTs are used due to extensive chloroquine resistance (<LINK REF="REF-WHO-2010b" TYPE="REFERENCE">WHO 2010b</LINK>).</P>
<P>
<U>
<I>Ensuring an adequate total dose of primaquine:</I>
</U>
<B> </B>
<LINK REF="REF-Alving-1960" TYPE="REFERENCE">Alving 1960</LINK> attempted to reduce the incidence of haemolysis with primaquine treatment and demonstrated good efficacy against relapse with eight weekly doses of 45 mg (360 mg in total). Some guidelines recommend 30 mg/day (0.5 mg/kg) for 14 days, or even higher doses of 45 mg/day (0.75 mg/kg) due to concerns about relapses because of inadequate doses in heavier people (<LINK REF="REF-Duarte-2001" TYPE="REFERENCE">Duarte 2001</LINK>; <LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>). <LINK REF="REF-Goller-2007" TYPE="REFERENCE">Goller 2007</LINK> demonstrated that the total dose of primaquine, as well as the dose per kilogram of body weight, affects relapse rates. The relapse risk decreased by 60% for a total adult dose of 75 mg (15 mg/day for five days); by 80% for a total primaquine regimen of 210 mg (15 mg/day for 14 days), and by 95% for regimens of 315 mg (22.5 mg/day for 14 days) and 420 mg (30 mg/day for 14 days), compared to no primaquine (<LINK REF="REF-Goller-2007" TYPE="REFERENCE">Goller 2007</LINK>).</P>
<P>
<U>
<I>Concurrent (instead of sequential) administration of chloroquine and primaquine</I>
</U>:<B> </B>Since primaquine has some activity against the asexual blood stages, <LINK REF="REF-Alving-1955" TYPE="REFERENCE">Alving 1955</LINK> suggested that the efficacy of primaquine in preventing relapses may be greater when chloroquine is co-administered with primaquine, than if it is administered sequentially, as is current practice. <LINK REF="STD-Carmona_x002d_Fonseca-2006" TYPE="STUDY">Carmona-Fonseca 2006</LINK> demonstrated the safety of giving the two drugs in combination, but more data are needed to clarify the effects of concurrent versus sequential administration of chloroquine and primaquine on recrudescence and relapse. On the other hand, others postulate that since the long half life of chloroquine suppresses early relapses of blood stage infections from activation of hypnozoites, the delayed administration of primaquine after chloroquine (administering primaquine towards the latter part of the 28 to 35 day period of chloroquine's schizonticidal activity) has a greater likelihood to effect radical cure than if used immediately after chloroquine (<LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>).</P>
<P>
<U>
<I>Chloroquine monotherapy</I>:</U> Some policy experts recommend the use of only chloroquine to treat blood-stage infection, in areas of low transmission; and the use of primaquine for 14 days only in those who relapse (<LINK REF="REF-Kshirsagar-2006" TYPE="REFERENCE">Kshirsagar 2006</LINK>). Chloroquine monotherapy is also used in some parts of the world due to fears of haemolysis with primaquine in people with G6PD deficiency (<LINK REF="REF-Beutler-1994" TYPE="REFERENCE">Beutler 1994</LINK>).</P>
<P>The burden of disease caused by <I>P. vivax </I>infection and the substantial amount of money governments have to spend to treat relapses makes effective treatment a priority. With several primaquine regimens currently in use, it is important to determine the comparative effects of the different regimens.</P>
<P>This is an update of a Cochrane Review first published in <I>The Cochrane Library</I> in Issue 1, 2007.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-10-17 18:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>To compare alternative primaquine regimens to the recommended 14-day regimen for preventing relapses (radical cure) in people with <I>P. </I>vivax<I> </I>malaria treated for blood stage infection with chloroquine. We also summarize the evidence from trials comparing primaquine to no primaquine that led to the recommendation for the 14-day regimen.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-10-18 03:09:45 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-10-03 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-10-03 05:07:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) and quasi-RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-10-03 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Adults and children with microscopically confirmed asexual <I>P. vivax </I>malaria. We excluded trials that recruited people with co-infection with <I>P. vivax </I>and <I>P. falciparum</I> (mixed infections).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-10-03 05:08:32 +0100" MODIFIED_BY="Harriet MacLehose">
<SUBSECTION>
<HEADING LEVEL="4">Efficacy of alternative regimens</HEADING>
<P>Intervention: primaquine (any dose or duration other than used in control group) plus chloroquine*.<BR/>Control: primaquine (15 mg/day for 14 days) plus chloroquine*.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Efficacy of regimens compared to either placebo or no treatment</HEADING>
<P>Intervention: primaquine (any dose or duration) plus chloroquine*.<BR/>Control: placebo or no intervention plus chloroquine*.</P>
<P>*same dose in each group</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-03 08:41:09 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-03 08:41:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<I>P. vivax </I>parasitaemia detected more than 30 days after starting primaquine.</LI>
<LI>Serious adverse events (fatal, life threatening, or requiring hospitalization).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-10-03 08:41:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Adverse events that result in the discontinuation of treatment.</LI>
<LI>Events known to occur with primaquine (cyanosis, leucopenia, methaemoglobinaemia, hypertension, cardiac arrhythmia, abdominal pain, nausea, vomiting, and haemolysis) or those due to a comparator drug used along with primaquine.</LI>
<LI>Other adverse events.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-18 03:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-10-18 03:09:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Databases</HEADING>
<P>On 8 October 2013, Vittoria Lutje (VL), the Cochrane Infectious Diseases Review Group's Information Specialist, updated searches of the following databases: Cochrane Infectious Diseases Group Specialized Register (August 2006 to October 2013); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library </I>(2013, Issue 10); MEDLINE (August 2006 to October 2013); EMBASE (August 2006 to October 2013); and LILACS (August 2006 to November 2010), using the search terms and strategies described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. PT also searched the South Asian Database of Controlled Clinical Trials (<A HREF="http://www.cochrane-sadcct.org/">http://www.cochrane-sadcct.org/</A>) on 4 February 2013 using the search terms "primaquine" AND "vivax", to identify trials from journals that may not be indexed in these databases,.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conference proceedings</HEADING>
<P>We have listed the details of the conference proceedings searched in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical Trials Registries</HEADING>
<P>On 8 October 2013, VL searched the WHO International Clinical Trials Platform Search Portal (<A HREF="http://www.who.int/ictrp/search/en/">http://www.who.int/ictrp/search/en/</A> ) and the metaRegister of Controlled Trials (mRCT) (<A HREF="http://www.controlled-trials.com/mrct/">http://www.controlled-trials.com/mrct/</A> ) for ongoing trials using the terms "primaquine" AND "vivax".</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-10-17 18:53:58 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Researchers, organizations and pharmaceutical companies</HEADING>
<P>On 18 November 2011, we contacted individual researchers working in the field, the WHO, and the pharmaceutical companies GlaxoSmithKline and Novartis for unpublished data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We checked the reference lists of all studies identified by the above methods.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-10-17 20:27:10 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-10-03 08:41:26 +0100" MODIFIED_BY="[Empty name]">
<P>We independently assessed the full reports of all potentially relevant studies for inclusion using an eligibility form based on the inclusion and exclusion criteria. We scrutinized trial reports for multiple publications from the same data set. We stated the reasons for excluding studies in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table and we resolved any disagreements through discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-10-17 18:55:23 +0100" MODIFIED_BY="[Empty name]">
<P>We independently extracted data using data extraction forms. We resolved any disagreements by referring to the trial report and through discussion. Where data were insufficient or missing, we contacted authors for additional information.</P>
<P>Where possible, we extracted data to allow an intention-to-treat analysis, in which all randomized participants should have been analyzed in the groups to which they were originally assigned. If we identified any discrepancies in the number randomized to and analyzed in each treatment group, we calculated the percentage loss to follow-up in each group and reported this information.</P>
<P>For dichotomous outcomes from individually randomized trials, we recorded the number of participants experiencing the event and the number analyzed in each treatment group.</P>
<P>For cluster-RCTs, we recorded the number of clusters in the trial, the average size of clusters and the unit of randomization (for example, household or institution), when trial authors provided this data. We also documented the statistical methods trial authors used to analyze the trial, along with details describing whether these methods adjusted for clustering or other covariates. When reported, we recorded estimates of the intra-cluster correlation (ICC) coefficient for each outcome.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-10-17 19:33:48 +0100" MODIFIED_BY="[Empty name]">
<P>We independently assessed the risk of bias in the included trials on six domains: sequence generation; allocation concealment; blinding; incomplete outcome data; selective outcome reporting; and other biases. For each of these components, we assigned a judgment regarding the risk of bias as either high, low or unclear based on guidance in <LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>. We attempted to contact the trial authors if details were missing in the publications or were unclear. We resolved disagreements through consensus. We recorded our judgements and justifications in risk of bias tables for each included study and generated a risk of bias summary graph and figure. We used these judgements while grading of the overall quality of evidence for outcomes in the summary of findings tables for each comparison.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-03 08:41:56 +0100" MODIFIED_BY="[Empty name]">
<P>We compared dichotomous outcomes using the risk ratio (RR) and presented all results with their 95% confidence intervals (CIs).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-10-17 20:23:52 +0100" MODIFIED_BY="[Empty name]">
<P>Pooling data from cluster randomized trials (such as randomization by family or household) without accounting for intra-class correlation leads to 'unit of analysis' errors in the analysis of treatment effects, whereby P values are spuriously low and CIs are unduly narrow (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>). We extracted the adjusted point estimates and their 95% CIs from cluster randomised trials that had adjusted results for clustering. We attempted to account for clustering in trials where authors had not provided adjusted results using approximate methods described in the Cochrane Handbook, Chapter 16.3.4 and 16.3.5 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). When data were insufficient to ensure the accuracy of the assumptions used to derive the adjusted effect estimates, we extracted the data as for the individually randomized trials and compared the results in sensitivity analyses.</P>
<P>In order to avoid a unit of analysis error in interpreting cumulative episodes of relapses (count data) as relapse rates (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>), we extracted data for relapse rates only (the first relapse per individual) and subgrouped them according to the duration of follow-up (more or less than six months).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-17 20:24:28 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted an intention-to-treat analysis in trials with no loss to follow-up and completed-case analysis for trials with incomplete follow-up. We attempted to obtain missing data from study authors. We made no assumptions about those lost to follow-up but utilised this information in assessing each study for the risk of attrition bias due to incomplete outcome data reporting; and in assessing the overall quality of evidence for each outcome in the summary of findings tables for each comparison.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-10-17 20:24:56 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity between the trials by examining the forest plot to check for overlapping CIs, using the Chi<SUP>2</SUP> test for heterogeneity with a 10% level of significance to detect inconsistency in study results that were not due to random error (chance), and the I<SUP>2 </SUP>statistic to denote the percentage of inconsistency in results due to inter-trial variability that exceeded chance. In general, we interpreted an I<SUP>2</SUP> value of 50% or greater to denote significant heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We acknowledged that this cut-off is arbitrary. We therefore interpreted I<SUP>2</SUP> values between 0% to 40% as possibly unimportant, 30% to 60% as possibly significant, 50% to 90% as possibly substantial, and 75% to 100% as possibly considerable; depending on whether the inconsistency in results were due to differences in the direction of effects estimates between trials, rather than due to differences in the magnitude of effect estimates favouring an intervention; as well as the strength of the evidence for heterogeneity from the P value for the Chi<SUP>2</SUP> test for heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-10-03 08:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use funnel plots to assess publication bias if we included 10 or more trials in a meta-analysis. </P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-10-03 08:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>We analyzed data using <LINK REF="REF-Review-Manager-5.2" TYPE="REFERENCE">Review Manager 5.2</LINK>. When data from trials using similar comparisons were available, we synthesized data using the Mantel-Haenszel method to derive pooled, weighted risk ratios in fixed-effect meta-analyses. We used the random-effects model for data synthesis when we identified heterogeneity was significant (see <LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK>) and we could not be explain it by subgroup analyses (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
<P>We stratified (subgrouped) the data by length of follow-up: six months or less and greater than six months.</P>
<P>We combined the results of cluster-RCTs that had been adjusted for clustering with that of individually RCTs using the generic inverse variance method (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-10-03 08:43:50 +0100" MODIFIED_BY="[Empty name]">
<P>We undertook two of the planned subgroup analyses to explore potential sources of heterogeneity, for the primary outcome of <I>P. vivax</I> parasitaemia detected after day 30: based on 1) the length of follow-up: six months or less; and greater than six months, and 2) chloroquine and primaquine doses supervised versus unsupervised. We intended to explore potential sources of heterogeneity in four additional subgroup analyses (defined in <LINK REF="REF-Galappaththy-2007" TYPE="REFERENCE">Galappaththy 2007</LINK>, and in the <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK> section). We did not undertake them since heterogeneity, when noted, was explained by differences in the duration of follow-up or supervision of treatment.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-10-17 20:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>When there were sufficient data, we undertook sensitivity analyses to investigate the robustness of the estimates for the primary outcome to the exclusion of trials at high risk of bias. We also undertook sensitivity analyses in order to explore assumptions used in cluster RCTs.</P>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Summarising and interpreting results</I>
</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Schunemann-2008" TYPE="REFERENCE">Schunemann 2008</LINK>). We used GRADE Profiler software (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>), and imported data from <LINK REF="REF-Review-Manager-5.2" TYPE="REFERENCE">Review Manager 5.2</LINK> to create 'Summary of findings' tables for each comparison included in this review. These tables provide information concerning the overall quality of the evidence from the trials, the magnitude of effect of the interventions examined, and the sum of available data on the primary outcome and secondary outcomes rated as important or critically important to health decision-making.</P>
<P>The outcomes we selected for inclusion in these tables were:</P>
<OL>
<LI>
<I>P. vivax</I> parasitaemia detected more after than 30 days after starting primaquine;</LI>
<LI>Serious adverse events;</LI>
<LI>Adverse events leading to treatment discontinuation.</LI>
</OL>
<P>We used these summary findings to guide our conclusions and recommendations.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-10-21 09:29:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-10-21 09:29:59 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-10-21 09:29:59 +0100" MODIFIED_BY="[Empty name]">
<P>We included 15 trials described in 18 reports in quantitative synthesis (meta-analysis) in this review. No trials currently await classification (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We identified 64 reports, of which we screened 53 abstracts for eligibility after removing duplicates and irrelevant reports. We obtained and scrutinized 24 potentially relevant full text articles. We included 10 trials from 14 reports in this review update. When we added these to the nine trials (described in eight reports) from the 2007 review, we included a total of 19 trials from 22 reports in the qualitative synthesis of this review update. Of these trials, four were on-going trials that are described in <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>. Excluded studies are detailed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> section.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-10-21 09:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>We have described these 15 trials in more detail in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. <LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK> and <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK> were described in the same publication.</P>
<P>This 2013 update has, in addition to the previous addition, six new trials, conducted between 1997 to 2012, adding 4377 adults and children (aged older than one year) from Africa (Ethiopia, one trial), Asia (India, five trials; Pakistan, four trials; Thailand, two trials), South America (Brazil, one trial; and Columbia, two trials). . </P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>Of the 15 trials, one was a cluster RCT(<LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>) that randomized households, and another used mixed cluster and individual randomization (<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>). One of the other 13 trials that individually randomized was a quasi-RCT (<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>). Seven trials had multiple treatment arms, ranging from three (<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>; <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>; <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>), and four (<LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>) to six (<LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>) intervention arms. We did not include some of the trial arms in this review as they were not relevant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>All the included trials treated the blood stage of the parasite with identical chloroquine courses in the treatment arms.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primaquine (any dose or duration) versus the standard regimen of primaquine (15 mg/day for 14 days)</HEADING>
<P>Six trials had treatment arms that compared different dosing schedules of primaquine versus the standard primaquine regimen:</P>
<UL>
<LI>Two trials compared three days of primaquine to standard primaquine treatment (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>);</LI>
<LI>Three trials compared five days of primaquine to the standard primaquine regimen (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>);</LI>
<LI>One trial compared seven days of primaquine to standard primaquine treatment (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>);</LI>
<LI>One trial compared primaquine (45 mg) given weekly for eight weeks, to 14 days of primaquine given at a higher dose than is standard (22.5 mg) daily(<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primaquine (any dose or duration) compared to no primaquine</HEADING>
<P>Fourteen trials compared participants receiving primaquine with placebo or no anti-relapse treatment:</P>
<OL>
<LI>Four trials examined primaquine given for five days (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>; <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>);</LI>
<LI>Ten trials evaluated primaquine given for 14 days (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>; <LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>; <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>; <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>; <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>; <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dosing regimens and supervision</HEADING>
<P>All trials used the standard primaquine 0.25 mg/kg (15 mg per day) dosing regimen, except <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> that used a higher dose of 22.5 mg primaquine base (0.5 mg/kg) in the 14-day primaquine arm and 45 mg/week (0.75 mg/kg) in the once-weekly primaquine arm. The total dose of primaquine delivered in different arms of the trials ranged from 45 mg (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>); 75 mg (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>; <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>; <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>); 105 mg (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>); 210 mg (<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>; <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>; <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>; <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>; <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>; <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>; <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>); to 315 mg in the 14-day daily primaquine arm; and 360 mg in the eight-week primaquine arm (<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>).</P>
<P>Two trials from the same region in Columbia initiated primaquine treatment concurrently with chloroquine (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>). One trial from Brazil (<LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>) compared five days of primaquine given concurrently with chloroquine versus the standard sequential administration of three days of chloroquine followed by 14 days of primaquine. In <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK> (Ethiopia), trial authors aimed to compare 14 days of primaquine versus chloroquine alone in treating acute symptoms, but they gave primaquine treatment for 14 days from day 29 in the chloroquine-only arm to prevent relapses. We thus directly studied (as suggested by <LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>), the effects of delayed sequential administration of primaquine following treatment of the blood-stage infection with chloroquine, compared with the control arm which was given the standard sequential regimen 14 days of primaquine immediately after three days of chloroquine treatment.</P>
<P>Eleven trials ensured compliance by directly supervising treatment in both arms for all participants. <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK> directly compared the effects of unsupervised and supervised 14 days of primaquine treatments (although we only used data from the unsupervised arm in meta-analysis) with a placebo arm. <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK> supervised chloroquine and the first seven of the 14-day primaquine regimen. Three studies only supervised the administration of chloroquine and not of primaquine (<LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>; <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>); trial authors did not describe any methods to ascertain adherence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Follow-up</HEADING>
<P>Trials varied the duration of follow-up and used 42 days (<LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>); two months (<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>); three months (<LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>; <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>); four months (<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>); six months (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>; <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>); nine months (<LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>; <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>); 12 months (<LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>; <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>; <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>); and 15 months (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>) follow-up. We could not ascertain from some of the trials with shorter follow-up periods whether the duration of follow-up was from initiation or end of treatment. We subgrouped the results according to duration of follow-up of six months or less, and greater than six months; this enabled us to evaluate the extent that relapses and re-infections contributed to vivax parasitaemia at follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cluster RCTs</HEADING>
<P>
<LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK> used cluster randomization of families but presented results for randomized individuals adjusted for clustering and also reported the number of clusters in each arm. For this update, since we chose to express results using relative risks rather than odds ratios (as in <LINK REF="REF-Galappaththy-2007" TYPE="REFERENCE">Galappaththy 2007</LINK>), we calculated and combined the log of the risk ratio (adjusted for clustering) with its standard error with log risk ratios and standard errors computed for the other individually randomized trials using the generic inverse variance method in <LINK REF="REF-Review-Manager-5.2" TYPE="REFERENCE">Review Manager 5.2</LINK>.</P>
<P>
<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> also used cluster randomization by household in two of the study sites (refugee camps at Baghicha and Khagan villages) and used individual randomization in a third site (Adizai) that was added subsequently after an unscheduled interim analysis due to low rates of enrolment downsized the sample size estimate. The number of participants they randomized to each arm of this three-armed trial were unequal with the majority recruited from Adizai (50%); and with Adizai accounting for the most treatment failures. The trial authors presented odds ratios, adjusted for clustering, village, age and sex; and we could not obtain intra-cluster coefficient coefficients from the report or the authors. We calculated the log of the risk ratio with its standard error for the primary outcome assessed beyond six months, adjusted for clustering using the approximate methods described in <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>. We also calculated and combined similar measures from the other relevant trials in meta-analysis using the generic inverse variance method. <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> did not report the number of participants randomized in clusters (families), and the number of clusters lost to follow-up. Unequal rates of completion in the arms with cluster randomization can introduce biases due to loss of clusters (households). We, therefore, used the unadjusted relapse rates presented in the trial report in sensitivity analyses (ignoring the cluster effect, since participants from Adizai that constituted the majority of trial participants were individually randomized) to compare the robustness of the results with data that were adjusted for clustering.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Funding</HEADING>
<P>One trial was partly funded by a drug company (<LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>). The remainder were funded by academic institutions, local governments, international aid agencies, charitable donors, or by the UN/WHO.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-10-18 03:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 65 studies (67 reports), including those excluded from the previous version of this review, and we listed the reasons for exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. Of these excluded trials, 26 were not RCTs. Of the 39 that were RCTs, four randomized healthy volunteers, and five randomized people with falciparum malaria or with mixed vivax and falciparum infections. The remainder had comparisons that did not fulfil the inclusion and exclusion criteria.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-10-17 21:22:11 +0100" MODIFIED_BY="[Empty name]">
<P>Most trials were at low risk of bias in many of the six domains we assessed (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a summary of the judgements of the risk of bias for each domain in each of the included trials.</P>
<ALLOCATION MODIFIED="2013-10-08 11:09:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> was at high risk of selection bias due to the mixed methods trial authors used to recruiting participants, with resultant imbalances in the proportions randomized to each site, and in baseline prognostic variables; as well as site-specific higher relapse rates. <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> was at high risk of bias for allocation concealment as the unequal numbers in the two primaquine arms were not explained by the methods of random sequence generation and allocation supposedly used. This suggested that allocation according to the randomization sequence was compromised; and although the presented baseline variables did not reveal serious imbalances across treatment arms, we could not rule out the risk of bias due to residual confounding. <LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>; <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>; <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK> were at unclear risk of selection bias since trial authors provided insufficient details in their trial reports. Although <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK> used quasi-random methods to recruit participants, an extensive list of baseline demographic, clinical, parasitological, and biochemical parameters were well-balanced between intervention arms, indicating a low risk of selection bias. <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK> did not describe the methods used to ensure allocation concealment, but described balanced prognostic variables at baseline in the intervention arms.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-10-03 08:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>All but one of the included trials (many open-label) were at low risk of performance and detection bias for objectively determined outcomes. <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> was at high risk of outcome detection bias for efficacy outcomes and for serious adverse events because the trial authors reported that those allotted unsupervised primaquine had probably not adhered to treatment. This raises the possibility of unreliable effect estimates, even if the outcomes were objective.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-10-08 11:09:39 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve trials included between 90% and 100% of randomized participants in the final analyses. <LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK> included 71%, and <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK> followed up 75% of participants. <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> reported results for 76% of randomized participants who completed six months follow-up, from a trial that appears to have been terminated early. <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK> reported results for 22/25 participants (88%) in the two arms that we included in this review. None of the trials with less than 90% follow-up had significantly different rates of trial completion in the intervention and control arms, and hence were at low risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-10-03 10:56:55 +0100" MODIFIED_BY="[Empty name]">
<P>Although only <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> and <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK> were prospectively registered, and only <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> (that was retrospectively registered) and <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> had available trial protocols, all trials reported all pre-stated outcomes and we did not detect instances of selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-10-17 21:22:11 +0100" MODIFIED_BY="[Empty name]">
<P>It was unclear whether the interim analysis and revised sample size estimates in <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> introduced biases other than the high risk of selection bias. Unequal rates of completion in treatment arms of cluster randomized trials can introduce biases due to loss of clusters (households); we were unable to obtain the data needed to evaluate this from the report. <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK> was also unclear for other biases as it was partly industry-funded. Trial authors did not clarify the role of the industry sponsor in the trial report. <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK> had a follow-up of only 42 days, and effectively 14 days where relapses that were not eliminated by chloroquine could be detected. This trial was biased and could not detect further early and late relapses after 42 days.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-08 11:09:54 +0100" MODIFIED_BY="Harriet MacLehose">
<SUBSECTION>
<HEADING LEVEL="3">Alternative regimens versus 14 days primaquine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Shorter daily regimens (five trials)</HEADING>
<P>We first evaluated the effects of the widely used five-day primaquine regimen (75 mg total dose) compared with the standard regimen (15 mg/day for 14 days; 210 mg in total). Three trials (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>) included 287 adults and children (aged older than three years). <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> was conducted in a hospital in Mumbai, India, where malaria transmission was stable and low, treatments were supervised, and participants were followed up for six months. <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> included outpatients attending a specialist malaria treatment centre in Kolkota, India. Chloroquine was supervised, and only the first dose of primaquine was supervised; follow-up was for fifteen months. <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> included outpatients in the Western Amazon region of Brazil, treatments were supervised, and participants were followed up for three months. The trials used standard dosing (0.25 mg/kg) for primaquine; but <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> used five days of chloroquine given concurrently with five days of primaquine, compared with the standard regimen of three days of chloroquine followed by 14 days of primaquine.</P>
<P>Relapse was common over the first six months with five days of supervised primaquine: 25% (16/62) in <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>, and 27% (8/30) in <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>, with no failures in <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> and two in <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> in the supervised 14-day primaquine arm (RR 10.05, 95% CI 2.82 to 35.86, I<SUP>2 </SUP>= 53%; two trials, 186 participants; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>, 27% (16/59) of participants given five days of unsupervised primaquine and 38% (16/42) given 14 days of unsupervised primaquine experienced a recurrence over 15 months of follow-up. This difference was not statistically significant (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), and the trial authors surmised that the lack of benefit seen with 14-day primaquine was most likely due to poor adherence to the unsupervised 14-day primaquine regimen.</P>
<P>We also included trials that evaluated three day regimens (two trials) and seven day regimens (one trial), both showing higher numbers of relapses in the shorter courses. For the three day regimen, we included two trials conducted in the same unstable malaria transmission area in Colombia on adults and children. Trial authors administered chloroquine and primaquine concurrently in these trials in both intervention arms. One trial (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>) administered a total dose of 45 mg primaquine in the three-day arm versus 210 mg in 14-day primaquine arm; and <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK> administered 210 mg of primaquine for three days at a dose of 3.5 mg/kg (or 1.17 mg/kg/day), compared to the 0.25 mg/kg/day used with the standard 14-day regimen in both trials. Relapse rates were significantly lower with 14-day primaquine in both trials (53% versus 17%) over 3 to 6 months of follow-up (RR 3.18, 95% CI 2.1 to 4.81; two trials, 262 participants; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>For the seven day regimen, <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK> examined seven days of primaquine (105 mg) given concurrently with chloroquine. Relapse rates were 42% with 7-day primaquine versus 19% with 14-day primaquine at two months follow-up (RR 2.24, 95% CI 1.24 to 4.03; one trial, 126 participants; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>For adverse events, none of the included trials reported severe or treatment limiting adverse events; and none provided numerical data on non-serious adverse events. <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> reported that nausea and skin rash were mild and infrequent; and <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> reported frequent, mild, transient headache, vertigo, abdominal pain, and nausea. The other trials reported that primaquine regimens were well-tolerated.</P>
<P>Sensitivity analysis was not indicated, as three of the trials were at low risk of bias; and we explained the heterogeneity detected when the results of <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> (that was at high risk of bias) were pooled with the results of <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> and <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> by follow-up duration and whether treatments were supervised or not.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Weekly primaquine (one trial)</HEADING>
<P>
<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> compared weekly supervised primaquine (45 mg/week; 360 mg in total) for eight weeks with self-administered primaquine (22.5 mg/kg) for 14 days (315 mg in total) among refugees in an area of unstable, seasonal, low malaria transmission near the Pakistan-Afganistan border. Relapses were infrequent over 11 months follow-up: 4/74 (5.4%) in the weekly regimen, and 1/55 (1.8%) in the self-treated regime; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>Trial authors did not report any adverse effects, except one person with G6PD directly allocated to the 8-week primaquine arm who experienced a transient and mild drop in hematocrit but otherwise tolerated treatment well.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Any primaquine regimens compared to no intervention or placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Five days primaquine (four trials)</HEADING>
<P>Four trials compared 5-day primaquine (75 mg primaquine) versus placebo and included 2213 adults and children. Relapse was more frequent with five days of primaquine compared to placebo over six months in one small trial conducted in a hospital in Mumbai (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>) with follow-up for six months (25% versus 12%, 122 participants; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), but this difference was not statistically significant. Relapse was little different in the two arms in three trials followed up over 12 to 15 months (18% versus 20%; 2091 participants; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), one of which was conducted in a mostly urban population in Kolkata, India (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>), the other in a refugee camp in Afghanistan (<LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>), and the third in tribal villages in Orissa, India (<LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>). The pooled results for relapse from the three trials did not significantly differ for 5-day primaquine or no primaquine (18% versus 19%; I<SUP>2</SUP> = 50%; 2213 participants; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fourteen days primaquine (ten trials)</HEADING>
<P>Ten trials evaluated primaquine given for 14 days versus placebo and randomized 1740 adults and children. Four were conducted in India: two in the same hospital in Mumbai (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>) with six months of follow-up and the other two included outpatients from the same centre in Kolkota (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>), and followed up participants for 42 days from treatment initiation (<LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>), to 15 months after primaquine (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>). Two trials were in refugee camps in Pakistan in an area with unstable malaria transmission, one (<LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>) during a period of high transmission, and the other (<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>) when transmission was low; follow-up was for nine months. Two trials were conducted in Bangkok, Thailand (<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>; <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>), where there is no local transmission of malaria; follow-up was for two months. One trial was in an area of seasonal, unstable malaria transmission in Ethiopia (<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>), with four months follow-up. Eight trials used standard 15 mg/day primaquine dosing with a total dose of 210 mg, but in <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>, the total dose in adults was (22.5 mg/day) 315 mg in the 14-day primaquine arm. In <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>, trial authors gave primaquine treatment for 14 days from day 29 in the chloroquine arm, compared to the standard sequential dosing in the chloroquine and primaquine arm. <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> was the only trial where trial authors did not supervise primaquine treatments and did not monitor adherence. Two trials (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>) supervised the first seven days of primaquine treatment and checked adherence for the remaining seven days of primaquine. The remaining trials supervised the 14 days of primaquine treatment.</P>
<P>With 14-day primaquine, fewer people relapsed than with placebo over six weeks to 15 months of follow-up (9% versus 18%; RR 0.60; 95% CI 0.48 to 0.75; 10 trials, 1740 participants; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). We consistently observed this benefit for 14-day primaquine in the subgroup of trials of supervised primaquine with follow-up from seven weeks to six months (six trials, 937 participants), and beyond six months to one year (three trials, 711 participants; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). The one trial of unsupervised primaquine (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>) failed to show any benefit for 14-day primaquine over placebo (92 participants; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), which the trial authors presumed was due to non-adherence to primaquine.</P>
<P>Sensitivity analysis using data unadjusted for clustering in <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>, since the majority of participants were individually randomized, did not alter these estimates (RR 0.53, 0.42, 0.67). Three trials at risk of bias (<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>) contributed 15.5% weight to the pooled effect estimates, and their removal from further sensitivity analysis also did not alter the results appreciably (RR 0.53, 95% CI 0.42 to 0.68; seven trials, 1318 participants).</P>
<P>For adverse effects, no serious adverse events were reported in any of the trials. Only one trial withdrew one person because of adverse events (<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>) but did not provide any details. Two trials (<LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>; <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>) reported headache, nausea, vomiting, abdominal pain, diarrhoea, and itching in both treatment arms which were mild and transient. <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK> measured methaemoglobin levels, and rises were mild and also transient. The few patients in <LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK> and <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> with G6PD deficiency reportedly tolerated the 14 days of primaquine treatment well.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-10-21 09:36:17 +0100" MODIFIED_BY="Harriet MacLehose">
<SUMMARY_OF_RESULTS MODIFIED="2013-10-08 11:10:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Efficacy</HEADING>
<P>In evaluating alternative regimens of primaquine for people with vivax malaria treated with chloroquine: 14 days of primaquine (0.25 mg/kg/day; 210 mg total dose) is probably more effective than shorter primaquine-containing regimens (total dose 45 mg to 105 mg) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>)</P>
<P>Weekly primaquine for eight supervised doses (45 mg; 360 mg in total) and 14 days of primaquine (22.5 mg/kg; 315 mg in total) were effective in reducing relapse but the weekly regimen needs further evaluation to show it is at least as good as 14-day primaquine (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>In trials of people with vivax malaria treated with chloroquine, and randomized to primaquine or placebo or no primaquine, five days of primaquine (0.25 mg/kg/day; 75 mg total dose) was associated with high relapse rates similar to relapse rates in those not given primaquine (<LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). Relapse rates were lower in people given 14 days of primaquine (0.25 mg/kg/day; 210 mg in total) compared to those given no primaquine (<LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>Most trials excluded people with G6PD deficiency and none of the primaquine dosing regimens (45 mg to 325 mg over three to 14 days and 360 mg given weekly over eight weeks) in the 15 included trials that treated 4377 adults and children were reported to cause serious or treatment limiting adverse events. The few people with G6PD deficiency included in some of the trials, and exposed to primaquine, did not experience serious or non-serious adverse events. Other adverse events were reportedly mild and transient. Elevated methaemoglobin levels, where measured, were not associated with symptoms of methaemoglobinaemia.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-10-17 16:14:04 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Completeness</HEADING>
<P>We identified six additional trials including one (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>) published before the updated 2007 review, but after the date of our last search in August 2006. None of the included trials compared higher doses of primaquine (0.5 mg/kg or 30 mg/day; 0.75 mg/kg or 45 mg per day) given for seven or 14 days; or the standard 0.25 mg/kg (15 mg/day) dose of primaquine given for periods longer than 14 days; with the standard 14-day primaquine dosing regimen. None of the included trials reported infection with temperate strains of <I>P. vivax. </I>
</P>
<P>The review did not specifically address the issues of treating mixed vivax and falciparum infections; preventing transmissibility of vivax infections to mosquitoes by the gametocidal activity of interventions, or directly evaluating the safety of different primaquine regimens in people with and without G6PD deficiency. We did not find any trials comparing alternative primaquine dosing regimens in people from regions with widespread resistance to the standard 0.25 mg per kg body weight of primaquine, and where other regimens are standard practice.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Applicability</HEADING>
<P>The trials in this review included children and adults with confirmed vivax mono-infections and evaluated a variety of primaquine dosing schedules that provide data to inform policy and practice. Most trials excluded people with G6PD deficiency.</P>
<SUBSECTION>
<HEADING LEVEL="4">Intermittent primaquine treatment requires further evaluation</HEADING>
<P>Intermittent dosing of primaquine at higher doses given at weekly intervals for eight weeks, after three days of chloroquine treatment, may be an effective alternative to the standard 14-day primaquine regimen in reducing relapses, but this needs evaluation in additional trials, powered to demonstrate equivalence or non-inferiority, compared to the standard 14-day primaquine regimen. Intermittent dosing is postulated to be safer in people with G6PD deficiency, but this also needs further evaluation in larger numbers of people with this deficiency.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">The total dose of primaquine is important</HEADING>
<P>The observations of <LINK REF="REF-Alving-1960" TYPE="REFERENCE">Alving 1960</LINK> and <LINK REF="REF-Goller-2007" TYPE="REFERENCE">Goller 2007</LINK> (see: <LINK TAG="IMPORTANCE" TYPE="SECTION">Why it is important to do this review</LINK>), and more recent observational data (<LINK REF="REF-John-2012" TYPE="REFERENCE">John 2012</LINK>) that total doses of primaquine of 210 mg or more result in greater reductions in relapse than with lower total doses of primaquine, were also evident in the randomized comparisons in this review. Significantly lower relapse occurred with primaquine doses of 210 mg or more, compared to primaquine given at lower doses. We presented relapse in the treatment arms of the trials in this review, grouped by the total dose and duration of primaquine, in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. The comparisons of relapse are confounded by variable rates of vivax transmission between trials; but on average relapse was less common in the treatment arms where primaquine was given at a total dose of 210 mg or more, compared to the treatment arms where the total dose of primaquine was lower.</P>
<P>The duration over which the total dose of primaquine was delivered also appeared to influence relapse (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK> directly compared the efficacy of the same total dose of primaquine in people randomized to shorter versus longer courses of treatment. Relapse was higher in those randomized to 210 mg of primaquine administered over three days, compared to those randomized to 210 mg of primaquine over 14 days (57% versus 14%, RR 3.9, 95% CI 2.1 to 7.1; one trial, 133 participants). Trial authors administered primaquine and chloroquine concurrently in the shorter three-day treatment arm and sequentially in the longer treatment arm of this trial (see next section below).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Concurrent versus sequential administration of chloroquine and primaquine</HEADING>
<P>Primaquine usually follows on from chloroquine treatment. As discussed in the background section "<LINK TAG="IMPORTANCE" TYPE="SECTION">Why it is important to do this review</LINK>", in some parts of the world (primarily in Latin America), primaquine is co-administered with chloroquine rather than sequentially after chloroquine. This is based on the premise that primaquine has some activity against the asexual blood stages, and the efficacy of primaquine in preventing relapses may be greater with the concurrent, rather than sequential, administration of chloroquine and primaquine.</P>
<P>Three trials in this review used concurrent chloroquine and primaquine in one or all their intervention arms. <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> (Brazil) directly compared the concurrent administration of chloroquine and primaquine, with each given for five days, versus the standard sequential administration of chloroquine for three days followed by primaquine for 14 days. Relapse was less frequent in the arm given sequential treatment of chloroquine and primaquine (3% versus 26%), but this result was confounded by the lower total dose of primaquine in the shorter concurrent treatment arm (105 mg) compared to the 210 total dose of primaquine in the longer sequential treatment arm.</P>
<P>Two trials conducted in Columbia (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>) used concurrent chloroquine and primaquine in all intervention arms. However <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK> used different total doses of primaquine in the three arms (210 mg, 105 mg, and 45 mg), again preventing unconfounded inferences of the efficacy of concurrent administration of the two drugs. As discussed previously, <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK> compared a total dose of 210 mg of primaquine co-administered with chloroquine over three days versus primaquine 210 mg co-administered with chloroquine for the first three days, and continued until day 14. Relapse was significantly less frequent with 210 mg of primaquine given for 14 days, providing limited direct evidence to suggest that the co-administration of primaquine with chloroquine may be less important than an adequate total dose of primaquine, given for a longer period after chloroquine, to eliminate emerging hypnozoites.</P>
<P>Another suggestion discussed in the background section to improve the efficacy of primaquine in preventing relapses is to delay the sequential administration of primaquine towards the latter part of the 28 to 35 day period of chloroquine's schizonticidal activity in order to increase the likelihood of radical cure, than if used immediately after chloroquine (<LINK REF="REF-Baird-2009" TYPE="REFERENCE">Baird 2009</LINK>). In <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK> (Ethiopia), relapse was more common in the treatment arm that delayed the sequential administration of 14-day primaquine (210 mg total dose) after chloroquine to commence at day 28, than in the comparator arm, where 14-day primaquine (210 mg total dose) was given sequentially but immediately after chloroquine (7% versus 3%). However, this difference was not statistically significant, possibly because this trial was primarily powered to demonstrate the efficacy of chloroquine against blood stage infections, and not the relative benefits of the delayed versus standard sequential administration of chloroquine and primaquine.</P>
<P>This review found evidence only to support the standard sequential administration of chloroquine followed by primaquine given for at least 14 days at a total dose of 210 mg or more of primaquine, or weekly treatment delivering 360 mg of primaquine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Differentiating relapses from re-infections may not be critical for reducing transmission of vivax malaria</HEADING>
<P>It is not possible to reliably differentiate vivax relapses from re-infections in endemic areas with currently available molecular techniques, and though newer techniques show promise, they are not available for routine use. However, the data in this review show that the 14-day and weekly primaquine regimens are effective in the first six months of follow-up in people living in endemic areas, as well as in trials with follow-up at nine months to one year. Since hypnozoites form the major source of recurrent malaria episodes in many parts of the world where vivax malaria is a burden, widespread use of 14 days of primaquine has the potential to effectively reduce the hypnozoite pool and reduce transmission, and the burden of vivax malaria; provided concerns about poor compliance and safety in people with G6PD deficiency can be addressed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ensuring adherence to 14-day primaquine regimens is important</HEADING>
<P>Assessing adherence to primaquine was not a primary objective of this review, but is an important issue to consider if governments and national programmes are to continue to endorse, or be encouraged to switch to, the 14-day regimen. All trials, apart from <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>, <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK> and <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>, provided supervised primaquine, and the efficacy of 14 days of primaquine was seemingly not influenced in <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>, and <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK> by the provision of supervision. The authors of <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> believe that people given 14-day primaquine were likely to have not been adherent, although they did not report the methods to monitor adherence, the proportions non-adherent, or the extent of non-adherence. Only <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK> formally evaluated the effects of supervised treatments, where in two of the three arms, 346 participants given chloroquine plus 14-days of primaquine were randomized equally to supervised therapy or unsupervised therapy. Efficacy did not significantly differ between supervised and non-supervised primaquine arms.</P>
<P>Although poor adherence with primaquine is reported as a major cause of relapse (<LINK REF="REF-Baird-2004" TYPE="REFERENCE">Baird 2004</LINK>; <LINK REF="REF-Hill-2006" TYPE="REFERENCE">Hill 2006</LINK>), recommending 14 days of primaquine should not be dismissed on grounds of adherence alone. Equally important are concerns expressed by some malaria experts that shorter courses of ineffective regimens could accelerate the selection of primaquine-resistant strains (<LINK REF="REF-Collins-1996" TYPE="REFERENCE">Collins 1996</LINK>; <LINK REF="REF-Price-2011" TYPE="REFERENCE">Price 2011</LINK>). <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK> demonstrated that, at least in the context of an RCT, simple measures such as health education messages were sufficient to improve adherence. If these measures were routinely employed in malaria control programmes, the effective life of this unique anti-malarial drug could be prolonged. Ensuring adherence for 14-day primaquine may not be as difficult as with long-term interventions, since improving short-term adherence is relatively successful with a variety of simple interventions (<LINK REF="REF-Haynes-2008" TYPE="REFERENCE">Haynes 2008</LINK>). The evidence specific to improving adherence in malaria, such as unit-dose packaging supported by educational interventions, though promising in general (<LINK REF="REF-Qingjun-1998" TYPE="REFERENCE">Qingjun 1998</LINK>), requires further evaluation (<LINK REF="REF-Orton-2005" TYPE="REFERENCE">Orton 2005</LINK>).</P>
<P>In contrast to the conclusions of <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>, two trials done along the Thai-Myanmar border demonstrated superior efficacy with the 14-day primaquine regimen following chloroquine in people randomized to receive primaquine by directly observed treatment (DOT) versus self-administered treatment (<LINK REF="STD-Takeuchi-2010" TYPE="STUDY">Takeuchi 2010</LINK>; <LINK REF="STD-Manneeboonyang-2011" TYPE="STUDY">Manneeboonyang 2011</LINK>). <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK> conducted the trial in the relatively structured confines of a refugee camp where geographical mobility is likely to have been less than in the Thai-Myanmar trials, and where health services were provided by a single agency. These conditions differ from the usual situations where vivax malaria is treated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primaquine and G6PD deficiency</HEADING>
<P>Most of the trials had G6PD deficiency as a criterion for exclusion, so it is not surprising that treatment limiting adverse events were uncommon in the 1209 people given the 14-day regimen. <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> included people with G6PD deficiency in a safety arm given eight weekly doses of 45 mg primaquine base, but reported that only one person with the deficiency was in this safety arm. This trial was conducted in an area of Pakistan where primaquine was not used routinely due to fears of haemolysis given the estimated 15% to 17% prevalence of G6PD deficiency (<LINK REF="REF-Beutler-1994" TYPE="REFERENCE">Beutler 1994</LINK>). The data from <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> suggest that these fears are based on overestimates of the prevalence and the relevance of G6PD deficiency to relapse prevention with primaquine. Observational data suggest that haemolytic anaemia due to G6PD deficiency following exposure to primaquine among people infected with <I>P. vivax</I> might be lower than previously assumed; leading to inferences that G6PD deficiency (at least certain types) may confer protection against <I>P. vivax</I> infection, and may thus be less common among <I>P. vivax</I>-infected patients than among the general population (<LINK REF="REF-Louicharoen-2009" TYPE="REFERENCE">Louicharoen 2009</LINK>; <LINK REF="REF-Leslie-2010" TYPE="REFERENCE">Leslie 2010</LINK>). These observations of the protection against <I>P. vivax</I> infection conferred by G6PD deficiency need replication in other settings, particularly where the Mediterranean variant is common and haemolysis due to primaquine can be severe and prolonged.</P>
<P>G6PD deficiency can be detected with either a quantitative determination of the enzyme level or a qualitative screening test; the latter is less expensive and is sufficient to identify individuals with a G6PD deficiency in most instances (<LINK REF="REF-Beutler-1994" TYPE="REFERENCE">Beutler 1994</LINK>). However, many low-income countries have limited facilities to detect this condition before administering primaquine. While eight weekly doses of primaquine may be safe in this population, data from the one person in the trial with this deficiency do not provide sufficient assurance to advocate the wider use of this regimen in people with this deficiency, without carefully monitoring their safety.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primaquine in vulnerable populations</HEADING>
<P>The trials in this review excluded very young children (younger than one year), pregnant and nursing mothers, people with severe malnutrition, and severe anaemia; and this review does not provide evidence of the safety of the 14-day or the 8-weekly dose primaquine regimens in these vulnerable populations.The data from <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK> and <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>, done during periods of high and low seasonal transmission respectively, indicate that very young children living in areas of high transmission are likely to have higher recurrence rates than older children and adults. The trial participants had lived in refugee camps for several years and hence differences in acquired immunity and re-infections probably explain the age-related recurrence rates, rather than differential efficacy of anti-relapse regimens. Hence, the pooled effect estimates for the 14-day and 8-week primaquine regimens in <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>, particularly in very young children, may differ when applied elsewhere according to local transmission intensities and population migration patterns.</P>
</SUBSECTION>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-10-21 09:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the overall quality of the evidence using the GRADE approach (<LINK REF="REF-Schunemann-2008" TYPE="REFERENCE">Schunemann 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Alternative primaquine dosing regimens compared to the standard 14-day primaquine regimen (blood stage infections treated with chloroquine)</HEADING>
<P>The overall quality of evidence for relapse over six months of follow-up with shorter courses of primaquine versus 14-day primaquine was of "<I>moderate quality</I>" for the commonly used 5-day primaquine regimen (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). This indicates that it is possible that further trials with follow-up beyond six months, and in settings with different transmission intensities, may alter these estimates. However, considering the magnitude of the estimates favouring 14 days of primaquine, it is unlikely that these will be altered significantly in favour of a 5-day primaquine regimen, unless primaquine doses higher than 0.25 mg/kg/day are used. The overall quality of the evidence of efficacy of the shorter 3-day primaquine regimen was also "<I>moderate quality</I>" (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Further research is likely to change these estimates; but unless higher doses given for five days or seven days are first shown effective, compared to 14-day primaquine, research evaluating 3-day regimens appear unwarranted. Data from the one trial evaluating the effects of seven days of primaquine were of "<I>low quality</I>" (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). It seems likely that the efficacy estimates will be significantly altered by further research, especially if higher primaquine doses (0.5 mg/kg or 0.75 mg/kg per day) are used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Weekly primaquine versus 14-day primaquine (blood stage infections treated with chloroquine)</HEADING>
<P>The "<I>very</I> <I>low quality" </I>evidenc<I>e</I> from a single multicentre, multicountry trial of weekly primaquine means that we do not know if eight weekly doses of primaquine is as effective, or even non-inferior to 14 days of primaquine in preventing recurrences over 11 months after an episode of vivax malaria (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). This uncertainty stems from very serious study limitations, serious indirectness, and very serious imprecision in the effect estimates of this trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primaquine regimens versus no treatment or placebo (blood stage infections treated with chloroquine)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primaquine (five days)</HEADING>
<P>We graded the pooled effect estimates for relapse prevention with 5-day primaquine versus placebo as "<I>high quality</I>"<I> </I>(<LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). Three of the four trials were free of the risk of bias, all four were consistent in their estimates in showing no significant difference, and were done in the usual situations and populations where vivax malaria is a burden. In spite of imprecision in the effect estimates, the trials had sufficient power (422 events in 2212 participants) to detect appreciable differences, had there been any. Additionally, the high estimated recurrence rates with five days of primaquine (mean 28%; 95% CI 27% to 30%) and with chloroquine alone (mean 22%; 95% CI 19% to 26%) in the treatment arms of the trials (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) provide sufficient evidence to refute any suggestions of its efficacy as an anti-relapse treatment for people with vivax malaria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primaquine (14 days)</HEADING>
<P>We assessed the pooled effect estimates for relapse prevention with chloroquine plus primaquine (14 days) versus placebo as "<I>high quality</I>" for follow-up periods ranging from one month to a year after interventions (<LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>). Further research to compare 14 days of treatment versus no anti-relapse treatment is unlikely to change this estimate, unless complemented by the use of multi-locus molecular genetic tests that have been pre-validated for the region, in order to correct for re-infections, in people whose adherence to treatments are supervised, and followed up for at least one year. The corrected estimates could differentiate between true relapses and re-infections (both early and late), but it is uncertain if this would significantly alter the estimates of the relative efficacy of the 14-day primaquine regimen. Considering the magnitude of benefit favouring 14-day primaquine, whatever contributions early and late new-infections may add to this estimate, appreciable clinical benefits are likely to accrue for people with vivax malaria with 14 days of primaquine.</P>
</SUBSECTION>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-10-03 09:06:50 +0100" MODIFIED_BY="[Empty name]">
<P>We stated that included trials should have used the same dose of chloroquine in all intervention arms, but in the 2007 version of this review we included <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> that used five days of chloroquine in one arm and three days in the other. We chose to retain this trial among the included trials because the trial ensured parasitic clearance in both arms by day 28 and they evaluated the anti-relapse potential of primaquine. We also reviewed all other excluded trials to ensure that none were excluded on the basis of different doses of chloroquine used in the interventions.</P>
<P>We identified and included <LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK> in this update, which gave primaquine, not immediately following chloroquine as is usually done, but after day 28 for 14 days in one intervention arm. We also included two trials where trial authors gave primaquine and chloroquine concurrently (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>; <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>). We chose these departures from our approach in the 2007 review in order to address issues highlighted in the <LINK TAG="IMPORTANCE" TYPE="SECTION">Why it is important to do this review</LINK> section regarding the relative merits of concurrent and delayed sequential administration. We also ensured that none of the trials that we had previously excluded were due to concurrent administration of the two interventions or because of delayed sequential administration.</P>
<P>We also included the sole trial that used intermittent primaquine dosing compared to the 14-day primaquine arm that used a dose was higher (22.5 mg/day) than the standard 15 mg/day dose recommended by the WHO. However, the WHO recommend 30 mg/day and even 45 mg/day for daily dosing (<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-10-03 09:09:05 +0100" MODIFIED_BY="[Empty name]">
<P>The updated WHO malaria treatment guidelines (<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>) recommend the standard oral regimen of chloroquine (25 mg base/kg body weight) given over three days plus primaquine at either a low dose (0.25 mg base/kg body weight per day) for 14 days; or high dose (0.5 to 0.75 mg base/kg body weight per day) for 14 days, as effective and safe for the radical cure of chloroquine-sensitive vivax malaria in patients with no G6PD deficiency. This review update provides direct and indirect evidence to support the efficacy and safety of 14 days of primaquine in reducing relapses due to vivax malaria. Only one of the included trials (<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>) used 0.5 to 0.75 mg base/kg body weight in the daily and intermittent dosing regimens; hence the recommendation for a higher daily dose requires further evaluation in head-to-head comparisons and in areas where there is a reported reduced efficacy of standard primaquine doses.</P>
<P>The strong recommendation of <LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK> endorsing 14 days of primaquine over five days of primaquine graded the overall evidence as<I> </I>"<I>low</I> <I>quality</I>" for the PCR-uncorrected efficacy estimates from the two contributory trials directly comparing the two regimens, and as "<I>very low quality</I>" for the PCR-corrected estimates from one of them. We did not include PCR-corrected estimates as an outcome in this review update due to the unavailability for routine use of validated methods of molecular differentiation of relapses from re-infections. Our judgements differ from the quality assessments for PCR-uncorrected estimates of the WHO recommendation. We graded the overall quality for the PCR-uncorrected efficacy estimates as of "<I>moderate</I> <I>quality</I>"<I>. </I>Additional unpublished information from the first author of one of the trials (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>) permitted a more accurate estimation of the risk of bias in this study,</P>
<P>
<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK> also recommended a primaquine regimen of 0.75 mg base/kg body weight once per week for eight weeks as anti-relapse therapy for <I>P. vivax</I> and <I>P. ovale</I> malaria in patients with mild G6PD deficiency, based on data from <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>. However they did not report the quality of the evidence supporting this recommendation. Our assessments of the same data suggest the <LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK> recommendation is based on "<I>very low quality evidence</I>".</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-08 11:10:49 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-03 10:56:55 +0100" MODIFIED_BY="[Empty name]">
<P>The standard 15 mg/day, 14-day primaquine regimen (210 mg primaquine) to prevent relapses, following chloroquine treatment of the blood stage infection is more effective than shorter primaquine regimens at the same dose. It was well-tolerated in people without G6PD deficiency. It also appears to be well-tolerated in people with mild forms of this deficiency, although adverse events and hematocrit should be monitored if primaquine is used in people with all forms of G6PD deficiency.</P>
<P>National programmes that use the 14-day primaquine, or do not recommend primaquine at all, should change such policies since the burden of vivax malaria is considerable, and the use of no primaquine, or shorter, ineffective primaquine regimens, is a waste of resources. They are likely to increase the risk of primaquine failure, and may result in primaquine resistance.</P>
<P>Even countries where relapse rates are low, and where anti-relapse prophylaxis may not be considered worthwhile (<LINK REF="REF-Kshirsagar-2006" TYPE="REFERENCE">Kshirsagar 2006</LINK>), should use the standard 14-day regimen in order to reduce the risk of transmission from the hypnozoite pool in infected people, and to prevent the development of resistance due to selective drug pressure and higher transmission intensities in the future due to relapses and re-infections.</P>
<P>Malaria control programmes that decide to change to the 14-day regimen should routinely screen for G6PD deficiency in populations with this deficiency and enhance health education activities routinely to improve adherence.</P>
<P>Patients and the communities they come from should implement general measures to reduce the risk of infection through insecticide treated bed-nets, mosquito source management and other methods to prevent being bitten (<LINK REF="REF-Lengeler-2004" TYPE="REFERENCE">Lengeler 2004</LINK>; <LINK REF="REF-Gamble-2006" TYPE="REFERENCE">Gamble 2006</LINK>; <LINK REF="REF-Tusting-2013" TYPE="REFERENCE">Tusting 2013</LINK>). </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-10-08 11:10:49 +0100" MODIFIED_BY="Harriet MacLehose">
<P>Further trials comparing the standard 14-day primaquine regimen (0.25 mg/kg body weight per day) with no primaquine, or with primaquine given for less than seven days at 15 mg/day, appear unwarranted as the perceived advantage for adherence and adverse events of these shorter courses are unlikely to be matched by the efficacy against relapse of the 14-day regimen.</P>
<P>However, research is needed on the efficacy and safety of higher doses of primaquine given for periods between seven and 14 days, conforming to international standards (<LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>). Trials using 0.5 mg/kg body weight per day (30 mg/day) of primaquine for seven to 10 days need to be evaluated against the standard 14-day primaquine regimen given at 0.25 mg/kg per day, and even 0.5 mg/kg per day. The recommendation of 30 mg/day of primaquine for 14 days (and even higher doses of 0.75 mg/kg body weight per day; 45 mg/day) (<LINK REF="REF-CDC-2005" TYPE="REFERENCE">CDC 2005</LINK>; <LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>) needs to be evaluated in the context of trials done in areas with different transmission intensities. The efficacy and safety of weekly primaquine at doses of 45 mg/week (0.75 mg/kg/day) given for eight weeks, needs to be re-evaluated against the standard 14-day primaquine regimen at doses of 22.5 mg/day and even 30 mg/day in adults and children with vivax malaria, stratified by the presence or absence of G6PD deficiency.</P>
<P>Such trials should ideally use equivalence or non-inferiority designs to estimate sample sizes and should also follow the CONSORT extension for reporting equivalence and non-inferiority trials (<LINK REF="REF-Piaggio-2006" TYPE="REFERENCE">Piaggio 2006</LINK>). If cluster randomized designs are used, then the number of clusters in each arm and the number of individuals randomized to each intervention should both be routinely reported, along with the ICC (if adjusted analyses are reported), so that the data from these trials can be properly analyzed in meta-analyses along with the results of parallel group randomized trials. The risk of bias in cluster RCTs differ from those in parallel group trials and the use of the appropriate CONSORT extension for cluster-RCTs (<LINK REF="REF-Campbell-2004" TYPE="REFERENCE">Campbell 2004</LINK>) will help improve transparency in reporting, and in their interpretation.</P>
<P>Trials should ensure parasitic clearance through serial blood smears until day 28, or even day 35, to confirm the efficacy of chloroquine in eradicating blood stage infections, and follow-up should be for at least one year after treatment with primaquine in order to detect late recurrences. . The adherence of people given longer or intermittent courses of primaquine, as well as methods to improve adherence also need to be systematically assessed. The results of two studies (<LINK REF="STD-Takeuchi-2010" TYPE="STUDY">Takeuchi 2010</LINK>; <LINK REF="STD-Manneeboonyang-2011" TYPE="STUDY">Manneeboonyang 2011</LINK>) indicate that DOT may increase the efficacy of the 14-day regimen; however, studies estimating resource use and costs, and the incremental cost efficacy or cost-savings of 14 days of primaquine, with and without DOT, would be required to inform health policy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-10-03 09:24:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>2013 review update:</I>
</P>
<P>We acknowledge the contributions of Aika Omari who was a co-author of the 2007 review. We are grateful for editorial support from the Cochrane Infectious Diseases Group (Anne-Marie Stephani; and Vittoria Lutje-for searching and locating trials). We are grateful to Patricia Graves for constructive editorial comments. We also acknowledge the suggestions provided by Paul Garner and Dave Sinclair. This review update is an output from the Effective Health Care Research Consortium; a project funded by UKaid, the UK Department for International Development (DFID) for the benefit of developing countries. The views expressed are not necessarily those of DFID.</P>
<P>
<I>2007, Issue 1 review:</I>
</P>
<P>Gawrie Galappaththy developed the protocol in July 2002 and the initial version of this review in July 2004 and July 2005 while visiting the Cochrane Infectious Diseases Group at the Liverpool School of Tropical Medicine. This fellowship was provided by the Effective Healthcare Research Alliance Programme (EHCAP), which was supported by the DFID. Prathap Tharyan helped re-write and complete the review while visiting Colombo, Sri Lanka as a funded partner of the Effective Health Care Research Programme Consortium (previously know as EHCAP) in June 2006. We are also grateful to Georgia Salanti for statistical advice for the initial version of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-10-03 09:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>GG, PT and RK have no known conflicts of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-10-03 09:25:12 +0100" MODIFIED_BY="[Empty name]">
<P>For the 2012 update, Gawrie Galappaththy contributed to the revised protocol, selected trials, assessed trial quality, checked extracted data, helped to interpret results, helped address editorial revisions and approved the final review version.</P>
<P>Prathap Tharyan re-wrote the protocol in the new format, updated the background and methods sections, selected trials, assessed risk of bias, extracted and entered data, synthesized data, performed sensitivity analyses, summarized findings using the GRADE approach, interpreted results, incorporated editorial revisions, and wrote the final version of the review update.</P>
<P>Richard Kirubakaran joined the author team in place of Aika Omari; helped re-draft the protocol of this update, selected trials, assessed quality, extracted data, checked data entry, calculated intra-cluster correlations and the design effect used in sensitivity analyses, synthesized data, checked GRADE assessments, helped interpret results, helped write the review, and approved the final version of this review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-10-03 09:26:11 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<I>2013 review update:</I>
</P>
<P>We changed the effect measure from odds ratios to relative risks to aid interpretability. </P>
<P>We updated the background to incorporate recent findings and issues relevant to this review. We also updated the methods section to incorporate changes in <LINK REF="REF-Review-Manager-5.2" TYPE="REFERENCE">Review Manager 5.2</LINK> such as 'Risk of bias' tables and 'Summary of findings' tables. We generated both of these for the included trials. For 'Summary of findings' tables, we used GRADE profiler (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>) and interpreted the evidence for each important and critically important outcome for the comparisons in the included trials using the GRADE approach (<LINK REF="REF-Schunemann-2008" TYPE="REFERENCE">Schunemann 2008</LINK>).</P>
<P>For this update, we did not include the secondary outcome <I>P. vivax</I> parasitaemia detected &gt; 30 days after starting primaquine corrected for new infections, since no valid tests are currently available for widespread use to assess this.</P>
<P>The subgroup analyses that we planned in the 2007 version protocol included: 1. Parasitic clearance before day 28 confirmed by microscopy <I>versus</I> not confirmed; 2. Tropical versus<I> </I>temperate strains; 3. Areas of high malaria transmission versus low or moderate transmission; 4. In children below 12 years versus older people. We had also hoped to expand the list of subgroup analyses to incorporate recent findings regarding potential confounders of primaquine efficacy such as chloroquine and primaquine given sequentially versus concurrently. (We defined concurrently primaquine started on any of the days of chloroquine administration; sequentially included primaquine administered from the day after chloroquine treatment to any time within or after the 28 days of initiating chloroquine and within 60 days). We did not undertake these subgroup analyses since the results were consistent within subgroups followed up for less than six months and more than six months, reflecting the contributions made by relapses and re-infections to the recurrence rates during these periods, and when subgrouped according to whether treatments were supervised or not. We have discussed the effect of sequential versus concurrent administration in the <LINK TAG="APPLICABILITY_OF_FINDINGS" TYPE="SECTION">Overall completeness and applicability of evidence</LINK> section.</P>
<P>We rechecked all extracted data and used the calculator function in <LINK REF="REF-Review-Manager-5.2" TYPE="REFERENCE">Review Manager 5.2</LINK>, instead of the manual calculations used for estimating log odds ratios and standard errors used in previous generic inverse variance meta-analysis. We rectified minor errors in extracted data for <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK> and <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> in the 2007 review.</P>
<P>
<I>2007, Issue 1 (review): </I>
</P>
<P>We stated in the protocol that we intended to stratify the results by length of follow-up: 40 days, 90 days, 120 days, six months, nine months, one year, and greater than one year. We could not do this because only nine trials met the inclusion criteria; so instead we analyzed the length of follow-up as less than or equal to six months and greater than six months. Prathap Tharyan joined the team as a co-author of this review after publication of the protocol.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-10-21 09:32:29 +0100" MODIFIED_BY="Harriet MacLehose">
<STUDIES MODIFIED="2013-10-17 16:54:32 +0100" MODIFIED_BY="Harriet MacLehose">
<INCLUDED_STUDIES MODIFIED="2013-10-08 11:17:00 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2006" MODIFIED="2013-10-03 09:54:40 +0100" MODIFIED_BY="[Empty name]" NAME="Alvarez 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-03 09:54:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez G, Pineros JG, Tobon A, Rios A, Maestre A, Blair S, et al</AU>
<TI>Efficacy of three chloroquine-primaquine regimens for treatment of <I>Plasmodium vivax </I>malaria in Colombia</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>75</VL>
<NO>4</NO>
<PG>605-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmona_x002d_Fonseca-2009" MODIFIED="2013-09-02 10:04:48 +0100" MODIFIED_BY="[Empty name]" NAME="Carmona-Fonseca 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-02 10:04:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmona-Fonseca J, Maestre A</AU>
<TI>Prevention of <I>Plasmodium vivax</I> malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days</TI>
<SO>Acta Tropica</SO>
<YR>2009</YR>
<VL>112</VL>
<NO>2</NO>
<PG>188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganguly-2013" MODIFIED="2013-10-03 09:55:25 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Ganguly 2013" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 09:55:07 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ganguly S, Saha P, Guha SK, Das S, Bera DK, Biswas A, et al</AU>
<TI>In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-0 genes</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2013</YR>
<VL>57</VL>
<NO>3</NO>
<PG>1246-51</PG>
<IDENTIFIERS MODIFIED="2013-09-02 15:20:07 +0100" MODIFIED_BY="Prathap  Tharyan"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-03 09:55:25 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="OTHER">
<AU>Ganguly S</AU>
<TI>Studies on <I>P. vivax</I> malaria in urban population of Kolkata with special reference to chloroquine sensitivity and relapse pattern</TI>
<SO>Clinical Trials Registry India</SO>
<IDENTIFIERS MODIFIED="2013-02-11 06:35:49 +0000" MODIFIED_BY="Prathap  Tharyan">
<IDENTIFIER MODIFIED="2013-02-11 06:35:49 +0000" MODIFIED_BY="Prathap  Tharyan" TYPE="OTHER" VALUE="Registration Number: CTRI/2011/09/002031"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-02-11 06:36:57 +0000" MODIFIED_BY="Prathap  Tharyan"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gogtay-1999" MODIFIED="2013-09-02 15:21:25 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Gogtay 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-02 15:21:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gogtay NJ, Deshai S, Kamtekar KD, Kadam VS, Dalvi SS, Kshirsagar NA</AU>
<TI>Efficacies of 5 and 14 day primaquine regimens in the prevention of relapses in <I>Plasmodium vivax</I> infections</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>8</NO>
<PG>809-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Kim-2012" MODIFIED="2013-10-08 11:16:31 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Kim 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 09:57:07 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN14027467</AU>
<TI>Open label comparison of chloroquine (CQ) alone versus CQ plus 5 days unobserved primaquine or CQ plus 14 days unobserved primaquine</TI>
<SO>http://www.controlled-trials.com/ISRCTN14027467/</SO>
<VL>(accessed 22 July 2013)</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-03 16:30:54 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="OTHER">
<AU>Kim J-R, Nandy A, Pukrittayakamee S, White NJ, Imwong M</AU>
<TI>A randomised trial to assess the effectiveness of different primaquine regimens for the radical treatment of vivax malaria in Kolkota</TI>
<SO>PLoS ONE</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>7</NO>
<PG>S1</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:30:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-08 11:16:31 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kim JR, Nandy A, Maji AK, Addy M, Dondorp AM, Day NPJ, et al</AU>
<TI>Genotyping of <I>Plasmodium vivax</I> reveals both short and long latency relapse patterns in Kolkata</TI>
<SO>PLoS ONE</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>7</NO>
<PG>e39645</PG>
<IDENTIFIERS MODIFIED="2013-09-02 15:29:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leslie-2004" MODIFIED="2013-10-08 11:16:45 +0100" MODIFIED_BY="[Empty name]" NAME="Leslie 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-08 11:16:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al</AU>
<TI>Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>3</NO>
<PG>168-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Leslie-2008" MODIFIED="2013-09-02 15:30:07 +0100" MODIFIED_BY="[Empty name]" NAME="Leslie 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-02 15:30:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al</AU>
<TI>A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of <I>Plasmodium vivax</I> in Northwest Frontier Province, Pakistan</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>8</NO>
<PG>e2861</PG>
<IDENTIFIERS MODIFIED="2013-09-02 15:30:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-02 15:26:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al</AU>
<TI>Abstract 337: A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of <I>Plasmodium vivax</I> in Pakistan</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2008</YR>
<VL>79</VL>
<NO>Suppl 6</NO>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-02-11 06:37:23 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pukrittayakamee-1994" MODIFIED="2013-09-02 15:27:26 +0100" MODIFIED_BY="[Empty name]" NAME="Pukrittayakamee 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-09-02 15:27:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ</AU>
<TI>Blood stage antimalarial efficacy of primaquine in <I>Plasmodium vivax</I> malaria</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1994</YR>
<VL>169</VL>
<NO>4</NO>
<PG>932-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rajgor-2003" MODIFIED="2013-10-03 09:57:40 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Rajgor 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-10-03 09:57:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajgor DD, Gogtay NJ, Kadam VS, Kamtekar KD, Dalvi SS, Chogle AR, et al</AU>
<TI>Efficacy of a 14-day primaquine regimen in preventing relapses in patients with <I>Plasmodium vivax</I> malaria in Mumbai, India</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>4</NO>
<PG>438-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rowland-1999a" MODIFIED="2013-10-08 11:17:00 +0100" MODIFIED_BY="[Empty name]" NAME="Rowland 1999a" YEAR="1999">
<REFERENCE MODIFIED="2013-10-08 11:17:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rowland M, Durrani N</AU>
<TI>Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>6</NO>
<PG>641-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rowland-1999b" MODIFIED="2013-10-02 11:07:44 +0100" MODIFIED_BY="[Empty name]" NAME="Rowland 1999b" YEAR="1999">
<REFERENCE MODIFIED="2013-09-02 15:39:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rowland M, Durrani N</AU>
<TI>Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>6</NO>
<PG>641-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villalobos-2000" MODIFIED="2013-10-03 10:00:07 +0100" MODIFIED_BY="[Empty name]" NAME="Villalobos 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-10-03 10:00:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH</AU>
<TI>In-vivo sensitivity of <I>Plasmodium vivax</I> isolates from Rondonia (western Amazon region, Brazil) to regimens including chloroquine and primaquine</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>8</NO>
<PG>749-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-2004" MODIFIED="2013-09-02 15:40:30 +0100" MODIFIED_BY="[Empty name]" NAME="Walsh 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-02 15:40:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, et al</AU>
<TI>Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing <I>Plasmodium vivax</I> malaria relapse</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>8</NO>
<PG>1095-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yadav-2002" MODIFIED="2013-10-03 09:58:19 +0100" MODIFIED_BY="[Empty name]" NAME="Yadav 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-10-03 09:58:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yadav RS, Ghosh SK</AU>
<TI>Radical curative efficacy of five-day regimen of primaquine for treatment of <I>Plasmodium vivax</I> malaria in India</TI>
<SO>Journal of Parasitology</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>5</NO>
<PG>1042-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeshiwondim-2010" MODIFIED="2013-09-02 15:41:23 +0100" MODIFIED_BY="[Empty name]" NAME="Yeshiwondim 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-02 15:41:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeshiwondim AK, Tekle A, Dengela DO, Yohannes AM, Teklehaimanot A</AU>
<TI>Therapuetic efficacy of chloroquine and chloroquine plus primaquine for the treatment of <I>Plasmodium vivax</I> in Ethiopia</TI>
<SO>Acta Tropica</SO>
<YR>2010</YR>
<VL>113</VL>
<NO>2</NO>
<PG>105-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-10-17 16:50:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdon-2001" MODIFIED="2013-09-02 15:42:20 +0100" MODIFIED_BY="[Empty name]" NAME="Abdon 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-02 15:42:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdon NP, Pinto AY, das Silva Rdo S, de Souza JM</AU>
<TI>Assessment of the response to reduced treatment schemes for vivax malaria</TI>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>4</NO>
<PG>343-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACTRN1261000055406" MODIFIED="2013-10-08 11:23:20 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN1261000055406" YEAR="2010">
<REFERENCE MODIFIED="2013-10-08 11:23:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Congpuong K</AU>
<TI>Efficacy and safety of chloroquine for the treatment of uncomplicated <I>Plasmodium</I> <I>vivax</I> malaria in Mae Hong Son and Kanchanaburi provinces in Thailand</TI>
<SO>http://www.anzctr.org.au/ACTRN12610000554066.aspx</SO>
<YR>(accessed November 28, 2010)</YR>
<IDENTIFIERS MODIFIED="2013-10-08 11:23:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-05-15 20:10:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-15 20:10:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN1261000055406"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACTRN12613000003774" MODIFIED="2013-10-17 14:02:39 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12613000003774" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 14:02:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sim K</AU>
<TI>Assessing the safety of weekly administered primaquine in vivax malaria infected Cambodians</TI>
<SO>http://www.anzctr.org.au/ACTRN12613000003774.aspx</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 13:59:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-17 13:59:28 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12613000003774"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appavoo-1984" MODIFIED="2013-09-02 15:44:50 +0100" MODIFIED_BY="[Empty name]" NAME="Appavoo 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-09-02 15:44:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appavoo NC, Roy RG, Kapali V</AU>
<TI>Results of 3-day radical treatment of <I>Plasmodium vivax</I> in North Arcot and South Arcot Districts of Tamil Nadu</TI>
<SO>Indian Journal of Malariology</SO>
<YR>1984</YR>
<VL>21</VL>
<NO>1</NO>
<PG>21-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arango-2012" MODIFIED="2013-10-03 10:00:46 +0100" MODIFIED_BY="[Empty name]" NAME="Arango 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 10:00:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arango EM, Upegui YA, Carmona-Fonseca J</AU>
<TI>Efficacy of different primaquine-based antimalarial regimens against <I>Plasmodium falciparum</I> gametocytemia</TI>
<SO>Acta Tropica</SO>
<YR>2012</YR>
<VL>122</VL>
<NO>2</NO>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baird-1995" MODIFIED="2013-09-02 15:45:40 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-09-02 15:45:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, et al</AU>
<TI>Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>6</NO>
<PG>479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baird-2001" MODIFIED="2013-09-02 15:46:06 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-02 15:46:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, et al</AU>
<TI>Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>12</NO>
<PG>1990-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baird-2003b" MODIFIED="2013-09-02 15:46:31 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 2003b" YEAR="2003">
<REFERENCE MODIFIED="2013-09-02 15:46:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK, Fryauff DJ, Hoffman SL</AU>
<TI>Primaquine for prevention of malaria in travellers</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>12</NO>
<PG>1659-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basavaraj-1960" MODIFIED="2013-09-02 15:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="Basavaraj 1960" YEAR="1960">
<REFERENCE MODIFIED="2013-09-02 15:47:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basavaraj HR</AU>
<TI>Observations on the treatment of 678 malaria cases with primaquine in an area free from malaria transmission in Mysore State, India</TI>
<SO>Indian Journal of Malariology</SO>
<YR>1960</YR>
<VL>14</VL>
<PG>269-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Betuela-2012a" MODIFIED="2013-10-03 10:01:03 +0100" MODIFIED_BY="[Empty name]" NAME="Betuela 2012a" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 10:01:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Betuela I, Bassat Q, Kiniboro B, Robinson LJ, Rosanas-Urgell A, Stanisic D, et al</AU>
<TI>Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>4</NO>
<PG>2146-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Betuela-2012b" MODIFIED="2013-10-03 10:01:33 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Betuela 2012b" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 10:01:24 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Betuela I, Rosanas A, Kiniboro B, Stanisic D, Samol L, Lazzari E, et al</AU>
<TI>Relapses are contributing significantly to risk of P. vivax infection and disease in Papua New Guinean children 1-5 years of age</TI>
<SO>Tropical Medicine and International Health. 7th European Congress on Tropical Medicine and International Health; 2011 October 03-06; Barcelona</SO>
<YR>2011</YR>
<VL>16</VL>
<PG>60-61</PG>
<PB>Tropical Medicine and International Health</PB>
<CY>Barcelona</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-03 10:01:33 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al</AU>
<TI>Relapses contribute significantly to the risk of <I>Plasmodium vivax</I> infection and disease in Papua New Guinean children 1-5 years of age</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2012</YR>
<VL>206</VL>
<NO>11</NO>
<PG>1771-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchachart-2001" MODIFIED="2013-09-02 15:55:22 +0100" MODIFIED_BY="[Empty name]" NAME="Buchachart 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-02 15:55:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, et al</AU>
<TI>Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>4</NO>
<PG>720-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunnag-1994" MODIFIED="2013-10-03 10:01:44 +0100" MODIFIED_BY="[Empty name]" NAME="Bunnag 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-10-03 10:01:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, et al</AU>
<TI>High dose of primaquine in primaquine resistant vivax malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>2</NO>
<PG>218-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmona_x002d_Fonseca-2003" MODIFIED="2013-09-16 10:49:38 +0100" MODIFIED_BY="[Empty name]" NAME="Carmona-Fonseca 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-16 10:49:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmona-Fonseca J, Alvarez G</AU>
<TI>
<I>Plasmodium vivax </I>malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004</TI>
<SO>Biomedica</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>353-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmona_x002d_Fonseca-2006" MODIFIED="2013-09-02 15:57:21 +0100" MODIFIED_BY="[Empty name]" NAME="Carmona-Fonseca 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-02 15:57:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmona-Fonseca J, Alvarez G</AU>
<TI>
<I>Plasmodium vivax</I> malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004</TI>
<SO>Biomedica</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>353-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmona_x002d_Fonseca-2009a" MODIFIED="2013-10-08 11:17:16 +0100" MODIFIED_BY="[Empty name]" NAME="Carmona-Fonseca 2009a" YEAR="2009">
<REFERENCE MODIFIED="2013-10-08 11:17:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmona-Fonseca J, Álvarez G, Maestre A</AU>
<TI>Methemoglobinemia and adverse events in <I>Plasmodium vivax </I>malaria patients associated with high doses of primaquine treatment</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>2</NO>
<PG>188-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmona_x002d_Fonseca-2010" MODIFIED="2013-10-03 10:02:01 +0100" MODIFIED_BY="[Empty name]" NAME="Carmona-Fonseca 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-03 10:02:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmona-Fonseca J</AU>
<TI>Vivax malaria in children: recurrences with standard total dose of primaquine administered in 3 versus 7 days</TI>
<TO>Malaria vivax en ninos: recurrencias con dosis total estandar de primaquina administrada durante 3 frente a 7 dias</TO>
<SO>Iatreia</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>1</NO>
<PG>10-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cedillos-1978" MODIFIED="2013-09-02 16:01:54 +0100" MODIFIED_BY="[Empty name]" NAME="Cedillos 1978" YEAR="1978">
<REFERENCE MODIFIED="2013-09-02 16:01:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cedillos RA, Warren M, Jeffery GM</AU>
<TI>Field evaluation of primaquine in the control of <I>Plasmodium vivax</I>
</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1978</YR>
<VL>27</VL>
<NO>3</NO>
<PG>466-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clyde-1977" MODIFIED="2013-09-02 16:01:59 +0100" MODIFIED_BY="[Empty name]" NAME="Clyde 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-09-02 16:01:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clyde DF, McCarthy VC</AU>
<TI>Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1977</YR>
<VL>26</VL>
<NO>3</NO>
<PG>562-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Contacos-1974" MODIFIED="2013-09-02 16:02:20 +0100" MODIFIED_BY="[Empty name]" NAME="Contacos 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-09-02 16:02:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Contacos PG, Collins WE, Chin W, Jeter MH, Briesch PE</AU>
<TI>Combined chloroquine-primaquine therapy against vivax malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1974</YR>
<VL>23</VL>
<NO>2</NO>
<PG>310-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CTRI_x002f_2011_x002f_09_x002f_002031" MODIFIED="2013-10-03 10:02:19 +0100" MODIFIED_BY="[Empty name]" NAME="CTRI/2011/09/002031" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:02:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Maji A</AU>
<TI>A study to determine the effectiveness of two drugs chloroquine and primaquine in <I>P. vivax</I> malaria in Kolkata</TI>
<SO>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3592</SO>
<YR>(accessed April 10, 2012)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CTRI/2011/09/002031"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CTRI_x002f_2012_x002f_03_x002f_002511" MODIFIED="2013-10-03 10:02:30 +0100" MODIFIED_BY="[Empty name]" NAME="CTRI/2012/03/002511" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 10:02:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Joglekar S, Jalal, J</AU>
<TI>TAF112582- A multi-centre, double-blind, randomised, parallel-group, active-controlled study to evaluate the efficacy, safety and tolerability of tafenoquine (SB-252263,WR238605) in subjects with <I>Plasmodium vivax</I> malaria</TI>
<SO>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4295</SO>
<YR>(accessed 13 April 2012)</YR>
<IDENTIFIERS MODIFIED="2012-05-15 19:50:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-15 19:50:03 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-05-15 19:50:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-15 19:50:43 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CTRI/2012/03/002511"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dao-2007" MODIFIED="2013-09-02 16:04:53 +0100" MODIFIED_BY="[Empty name]" NAME="Dao 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-02 16:04:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dao NV, Cuong BT, Ngoa ND, Thuy le TT, The ND, Duy DN, et al</AU>
<TI>Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>6</NO>
<PG>534-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-da-Silva-2003" MODIFIED="2013-10-08 11:17:35 +0100" MODIFIED_BY="[Empty name]" NAME="da Silva 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-10-08 11:17:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>da Silva Rdo S, Pinto AY, Calvosa VS, de Souza JM</AU>
<TI>Short course schemes for vivax malaria treatment</TI>
<TO>Esquemas terapeuticos encurtados para o tratamento de malaria por <I>Plasmodium vivax </I>
</TO>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>2</NO>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dua-2001" MODIFIED="2013-09-02 16:06:25 +0100" MODIFIED_BY="[Empty name]" NAME="Dua 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-02 16:06:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dua VK, Sharma VP</AU>
<TI>
<I>Plasmodium vivax</I> relapses after 5 days of primaquine treatment, in some industrial complexes of India</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>7</NO>
<PG>655-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elmes-2008" MODIFIED="2013-09-02 16:06:50 +0100" MODIFIED_BY="[Empty name]" NAME="Elmes 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-02 16:06:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko D A, Edstein MD</AU>
<TI>The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of <I>Plasmodium vivax </I>malaria in the Southwest Pacific</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene.</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>11</NO>
<PG>1095-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fryauff-1997" MODIFIED="2013-09-02 16:07:16 +0100" MODIFIED_BY="[Empty name]" NAME="Fryauff 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-02 16:07:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fryauff DJ, Baird JK, Purnomo, Awalludin M, Jones T, Subianto B, et al</AU>
<TI>Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>2</NO>
<PG>137-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gogtay-1998" MODIFIED="2013-09-02 16:08:10 +0100" MODIFIED_BY="[Empty name]" NAME="Gogtay 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-02 16:08:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gogtay N, Garg M, Kadam V, Kamtekar K, Kshirsagar NA</AU>
<TI>A 5 days primaquine regimen as anti-relapse therapy for <I>Plasmodium vivax</I>
</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>3</NO>
<PG>341</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamedi-2004" MODIFIED="2013-10-03 10:02:47 +0100" MODIFIED_BY="[Empty name]" NAME="Hamedi 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-03 10:02:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S</AU>
<TI>Therapeutic efficacy of artesunate in <I>Plasmodium vivax</I> malaria in Thailand</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>3</NO>
<PG>570-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-2011" MODIFIED="2013-10-03 10:02:55 +0100" MODIFIED_BY="[Empty name]" NAME="Herrera 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:02:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrera S, Solarte Y, Jordán-Villegas A, Echavarría JF, Rocha L, Palacios R, et al</AU>
<TI>Consistent safety and infectivity in sporozoite challenge model of <I>Plasmodium vivax</I> in malaria-naive human volunteers</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2011</YR>
<VL>2 Suppl</VL>
<PG>4-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN82366390" MODIFIED="2013-10-17 11:34:32 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN82366390" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 11:34:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nelwn EJ</AU>
<TI>Randomized, open-label trial of the safety, tolerability and efficacy of primaquine against relapse when combined with pyronaridine tetraphosphate-artesunate or dihydroartemisinin-piperquine phosphate for radical cure of acute <I>Plasmodium vivax </I>malaria in soldiers</TI>
<SO>http://isrctn.org/ISRCTN82366390</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS MODIFIED="2013-10-17 11:34:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 11:31:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-17 11:31:57 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="82366390"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolaczinski-2012" MODIFIED="2013-09-02 16:10:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kolaczinski 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-02 16:10:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolaczinski K, Leslie T, Ali I, Durrani N, Lee S, Barends M, et al</AU>
<TI>Defining <I>Plasmodium falciparum</I> treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>1</NO>
<PG>e28957</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Looareesuwan-1999" MODIFIED="2013-09-02 16:10:36 +0100" MODIFIED_BY="[Empty name]" NAME="Looareesuwan 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-02 16:10:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Wilairatana P, Krudsood S, Treeprasertsuk S, Singhasivanon P, Bussaratid V, et al</AU>
<TI>Chloroquine sensitivity of <I>Plasmodium vivax</I> in Thailand</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>3</NO>
<PG>225-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luxemburger-1999" MODIFIED="2013-09-02 16:11:31 +0100" MODIFIED_BY="[Empty name]" NAME="Luxemburger 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-02 16:11:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, et al</AU>
<TI>Treatment of vivax malaria on the western border of Thailand</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>4</NO>
<PG>433-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manneeboonyang-2011" MODIFIED="2013-10-03 10:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Manneeboonyang 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:03:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P, et al</AU>
<TI>Directly observed therapy with primaquine to reduce the recurrence rate of <I>Plasmodium vivax</I> infection along the Thai-Myanmar border</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasveld-2010" MODIFIED="2013-09-02 16:13:07 +0100" MODIFIED_BY="[Empty name]" NAME="Nasveld 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-02 16:13:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, et al</AU>
<TI>Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>2</NO>
<PG>792-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01074905" MODIFIED="2013-10-03 10:03:22 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01074905" YEAR="2010">
<REFERENCE MODIFIED="2013-10-03 10:03:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Chu C, Chia PY</AU>
<TI>A randomised open label study comparing the efficacy of chloroquine/primaquine, chloroquine and artesunate in the treatment of vivax malaria along the Thai-Burmese border</TI>
<SO>http://clinicaltrials.gov/show/NCT01074905</SO>
<YR>(accessed 13 April 2012)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SMRU0908 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-03 10:03:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nosten F, Cheah PY</AU>
<TI>Study on the treatment of vivax malaria (VHX)</TI>
<SO>http://clinicaltrials.gov/ct2/show/record/NCT01074905</SO>
<YR>(accessed November 28, 2010)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01074905"/>
<IDENTIFIER OTHERTYPE="Secondary ID" TYPE="OTHER" VALUE="SMRU0908"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01288820" MODIFIED="2013-10-17 16:50:03 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01288820" YEAR="2011">
<REFERENCE MODIFIED="2013-10-17 16:50:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pasaribu AP</AU>
<TI>Comparison of the efficacy and safety of two ACTs plus primaquine for uncomplicated <I>Plasmodium vivax</I> malaria in North Sumatera, Indonesia: 1 year follow up</TI>
<SO>http://clinicaltrials.gov/show/NCT01288820</SO>
<YR>(accessed 13 April 2012)</YR>
<IDENTIFIERS MODIFIED="2013-10-17 16:50:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-05-15 20:08:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-15 20:08:47 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01288820"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01290601" MODIFIED="2013-10-03 10:03:39 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01290601" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:03:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Looareesuwan S, Miller RE</AU>
<TI>Study to evaluate the efficacy and safety of tafenoquine for the treatment of <I>Plasmodium vivax</I> in adults</TI>
<SO>http://clinicaltrials.gov/show/NCT01290601</SO>
<YR>(accessed 13 April 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01290601"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01716260" MODIFIED="2013-10-17 14:08:58 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01716260" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 14:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Dorjey Y</AU>
<TI>Parasitic clearance and recurrence rates among patients with vivax malaria on chloroquine and primaquine therapy</TI>
<SO>http://clinicaltrials.gov/show/NCT01716260</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 14:06:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-17 14:06:55 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01716260"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01780753" MODIFIED="2013-10-17 14:16:04 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01780753" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 14:16:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McGready R</AU>
<TI>A study of the pharmacokinetics of primaquine in lactating women and breastfed infants for the radical treatment of uncomplicated maternal P. vivax</TI>
<SO>http://clinicaltrials.gov/show/NCT01780753</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 14:13:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-17 14:13:41 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01780753"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01814683" MODIFIED="2013-10-17 11:40:49 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01814683" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 11:40:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Price R</AU>
<TI>Improving the radical cure of vivax malaria: A multicentre randomised comparison of short and long course primaquine regimens</TI>
<SO>http://clinicaltrials.gov/show/NCT01814683</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 11:40:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-17 11:40:49 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01814683"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01837992" MODIFIED="2013-10-17 11:11:57 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01837992" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 11:11:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mueller I</AU>
<TI>Evaluation of Safety and Efficacy of Two Primaquine Dosing Regimens for the Radical Treatment of Plasmodium Vivax Malaria in Vanuatu and Solomon Islands</TI>
<SO>http://clinicaltrials.gov/show/NCT01837992</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01837992"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasaribu-2013" MODIFIED="2013-10-17 10:46:29 +0100" MODIFIED_BY="[Empty name]" NAME="Pasaribu 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-10-17 10:46:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, et al</AU>
<TI>A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined With primaquine for radical treatment of vivax malaria in Sumatera, Indonesia</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2013</YR>
<VL>Aug 28</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS MODIFIED="2013-10-17 10:46:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1998" MODIFIED="2013-09-02 16:16:26 +0100" MODIFIED_BY="[Empty name]" NAME="Pinto 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-02 16:16:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto AY, Ventura AM, Calvosa VS, Silva Filho MG, Santos MA, Silva RS, et al</AU>
<TI>Clinical efficacy of four schemes for vivax malaria treatment in children</TI>
<SO>Jornal de Pediatria</SO>
<YR>1998</YR>
<VL>74</VL>
<NO>3</NO>
<PG>222-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prasad-1991" MODIFIED="2013-09-02 16:17:17 +0100" MODIFIED_BY="[Empty name]" NAME="Prasad 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-09-02 16:17:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prasad RN, Virk KJ, Sharma VP</AU>
<TI>Relapse/reinfection patterns of <I>Plasmodium vivax</I> infection: a four year study</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>1991</YR>
<VL>22</VL>
<NO>4</NO>
<PG>499-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pukrittayakamee-2010" MODIFIED="2013-10-03 10:03:56 +0100" MODIFIED_BY="[Empty name]" NAME="Pukrittayakamee 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-03 10:03:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White NJ</AU>
<TI>A comparison of two short-course primaquine regimens for the treatment and radical cure of <I>Plasmodium vivax</I> malaria in Thailand</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>4</NO>
<PG>542-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-RBR_x002d_77q7t3" MODIFIED="2013-10-03 10:04:05 +0100" MODIFIED_BY="[Empty name]" NAME="RBR-77q7t3" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:04:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pereira D</AU>
<TI>Study of efficacy and safety of a new co-blister packs of chloroquine and primaquine for malaria treatment of uncomplicated <I>Plasmodium vivax</I> in Brasil</TI>
<SO>http://www.ensaiosclinicos.gov.br/rg/RBR-77q7t3/v1/</SO>
<YR>(accessed 13 April 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roy-1977" MODIFIED="2013-09-02 16:18:38 +0100" MODIFIED_BY="[Empty name]" NAME="Roy 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-09-02 16:18:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roy RG, Chakrapani KP, Dhinagaran D, Sitaraman NL, Ghosh RB</AU>
<TI>Efficacy of 5-day radical treatment of <I>P. vivax </I>infection in Tamil Nadu</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>1977</YR>
<VL>65</VL>
<NO>5</NO>
<PG>652-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saint_x002d_Yves-1977" MODIFIED="2013-09-02 16:19:33 +0100" MODIFIED_BY="[Empty name]" NAME="Saint-Yves 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-09-02 16:19:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saint-Yves IF</AU>
<TI>Comparison of treatment schedules for <I>Plasmodium vivax</I> infections in the Solomon Islands</TI>
<SO>Papua New Guinea Medical Journal</SO>
<YR>1977</YR>
<VL>20</VL>
<NO>2</NO>
<PG>62-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-2000" MODIFIED="2013-09-02 16:19:55 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartz 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-02 16:19:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz E, Regev-Yochay G, Kurnik D</AU>
<TI>Short report: a consideration of primaquine dose adjustment for radical cure of <I>Plasmodium vivax</I> malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>62</VL>
<NO>3</NO>
<PG>393-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1973" MODIFIED="2013-09-02 16:42:56 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 1973" YEAR="1974">
<REFERENCE MODIFIED="2013-09-02 16:42:56 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;.&lt;/p&gt;" NOTES_MODIFIED="2013-09-02 16:42:56 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma MID, Sehgal PN, Vaid BK, Dubey RC, Nagendra S, Paithne PK, et al</AU>
<TI>Effectiveness of drug schedule being followed under the National Malaria Eradication Programme, India, for radical cure of vivax malaria cases</TI>
<SO>Journal of Communicable Diseases</SO>
<YR>1973</YR>
<VL>5</VL>
<PG>167-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shekalaghe-2010" MODIFIED="2013-10-08 11:17:44 +0100" MODIFIED_BY="[Empty name]" NAME="Shekalaghe 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-08 11:17:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, et al</AU>
<TI>In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>5</NO>
<PG>1762-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shekalaghe-2011" MODIFIED="2013-10-03 10:04:26 +0100" MODIFIED_BY="[Empty name]" NAME="Shekalaghe 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:04:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shekalaghe SA, Drakeley C, van den Bosch S, Ter Braak R, van den Bijllaardt W, Mwanziva C, et al</AU>
<TI>A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania</TI>
<SO>Malaria Journal</SO>
<YR>2011</YR>
<VL>10</VL>
<PG>247</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shin-2011" MODIFIED="2013-10-03 10:04:54 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Shin 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:04:54 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shin CS, Kwak YG, Lee KD, Borghini-Fuhrer I, Miller RM, Duparc S</AU>
<TI>Treatment of Korean vivax malaria patients with the fixed-dose combination of pyronaridine/artesunate</TI>
<SO>Tropical Medicine and International Health. 7th European Congress on Tropical Medicine and International Health; January 3 to 6, 2011; Barcelona</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>1</NO>
<PG>149</PG>
<PB>Tropical Medicine and International Health</PB>
<CY>Barcelona</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1990" MODIFIED="2013-09-02 16:55:51 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-09-02 16:55:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh N, Mishra AK, Sharma VP</AU>
<TI>Radical treatment of vivax malaria in Madhya Pradesh, India</TI>
<SO>Indian Journal of Malariology</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>1</NO>
<PG>55-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sinha-1989" MODIFIED="2013-09-02 16:56:21 +0100" MODIFIED_BY="[Empty name]" NAME="Sinha 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-09-02 16:56:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sinha S, Dua VK, Sharma VP</AU>
<TI>Efficacy of 5 day radical treatment of primaquine in <I>Plasmodium vivax</I> cases at the BHEL industrial complex, Hardwar (U.P.)</TI>
<SO>Indian Journal of Malariology</SO>
<YR>1989</YR>
<VL>26</VL>
<NO>2</NO>
<PG>83-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smithuis-2010" MODIFIED="2013-09-02 16:56:42 +0100" MODIFIED_BY="[Empty name]" NAME="Smithuis 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-02 16:56:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, et al</AU>
<TI>Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>10</NO>
<PG>673-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soto-1998" MODIFIED="2013-09-02 16:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Soto 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-02 16:57:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al</AU>
<TI>Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1998</YR>
<VL>129</VL>
<NO>3</NO>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soto-1999" MODIFIED="2013-09-02 16:58:18 +0100" MODIFIED_BY="[Empty name]" NAME="Soto 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-02 16:58:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al</AU>
<TI>Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>1</NO>
<PG>199-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutanto-2012" MODIFIED="2013-10-03 10:05:13 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Sutanto 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-10-03 10:05:13 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al</AU>
<TI>Randomized, open label trial of primaquine against vivax malaria relapse in Indonesia</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>3</NO>
<PG>1128-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takeuchi-2010" MODIFIED="2013-10-03 10:05:24 +0100" MODIFIED_BY="[Empty name]" NAME="Takeuchi 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-10-03 10:05:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, et al</AU>
<TI>Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of <I>Plasmodium vivax </I>malaria on the Thai-Myanmar border</TI>
<SO>Malaria Journal</SO>
<YR>2010</YR>
<VL>9</VL>
<PG>308</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valibayov-2003" MODIFIED="2013-09-02 17:00:23 +0100" MODIFIED_BY="[Empty name]" NAME="Valibayov 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-02 17:00:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valibayov A, Abdullayev F, Mammadov S, Gasimov E, Sabatinelli G, Kondrachine AV, et al</AU>
<TI>Clinical efficacy of chloroquine followed by primaquine for <I>Plasmodium vivax</I> treatment in Azerbaijan</TI>
<SO>Acta Tropica</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>1</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-V_x00e1_squez-2009" MODIFIED="2013-10-03 10:05:39 +0100" MODIFIED_BY="[Empty name]" NAME="Vásquez 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-10-03 10:05:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vásquez AM, Sanín F, Álvarez LG, Tobón A, Ríos A, Blair S</AU>
<TI>Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for <I>Plasmodium falciparum </I>malaria and treatment effects on gametocytic development</TI>
<TO>Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato-mefloquina-primaquina para la malaria por <I>Plasmodium falciparum</I>
</TO>
<SO>Biomédica</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>2</NO>
<PG>307-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilairatana-1999" MODIFIED="2013-09-02 17:02:17 +0100" MODIFIED_BY="[Empty name]" NAME="Wilairatana 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-02 17:02:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilairatana P, Silachamroon U, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, et al</AU>
<TI>Efficacy of primaquine regimens for primaquine-resistant <I>Plasmodium vivax </I>malaria in Thailand</TI>
<SO>American Journal of Tropical Medical Hygiene</SO>
<YR>1999</YR>
<VL>61</VL>
<NO>6</NO>
<PG>973-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-07-22 12:29:16 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-10-17 16:54:32 +0100" MODIFIED_BY="Harriet MacLehose">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01178021" MODIFIED="2013-10-17 16:54:32 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01178021" YEAR="2010">
<REFERENCE MODIFIED="2013-10-17 16:54:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Awab GR, Cheah YP, Woodrow C</AU>
<TI>Estimating the risk of <I>Plasmodium vivax </I>relapses in Afghanistan (VRA)</TI>
<SO>http://clinicaltrials.gov/ct2/show/study/NCT01178021</SO>
<YR>(accessed November 28, 2010)</YR>
<IDENTIFIERS MODIFIED="2013-07-22 18:49:55 +0100" MODIFIED_BY="Prathap  Tharyan">
<IDENTIFIER MODIFIED="2013-07-22 18:49:55 +0100" MODIFIED_BY="Prathap  Tharyan" TYPE="CTG" VALUE="NCT01178021  "/>
<IDENTIFIER OTHERTYPE="Secondary ID" TYPE="OTHER" VALUE="BAKMAL0903"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01376167" MODIFIED="2013-10-17 14:30:34 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01376167" YEAR="2011">
<REFERENCE MODIFIED="2013-10-03 10:06:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hudson C</AU>
<TI>Ph 2B/3 tafenoquine (TFQ) study in prevention of vivax relapse</TI>
<SO>http://clinicaltrials.gov/show/NCT01376167</SO>
<YR>(accessed 13 April 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 14:30:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-17 14:30:34 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01376167"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01640574" MODIFIED="2013-10-17 16:18:20 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01640574" YEAR="2012">
<REFERENCE MODIFIED="2013-10-17 16:18:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Chu C</AU>
<TI>Randomised parallel open label comparison between 7 and 14 day primaquine combined with 3-day dihydroartemisinin-piperaquine or 3-day chloroquine regimens for radical cure of plasmodium vivax</TI>
<SO>http://clinicaltrials.gov/show/NCT01640574</SO>
<YR>(accessed 8 October 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT01640574"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01680406" MODIFIED="2013-10-17 14:30:09 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="NCT01680406" YEAR="2012">
<REFERENCE MODIFIED="2013-10-08 11:23:57 +0100" MODIFIED_BY="Prathap  Tharyan" PRIMARY="NO" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Ethiopia antimalarial in vivo efficacy study 2012: Evaluating the efficacy of artemether-lumefantrine alone compared to artemether-lumefantrine plus primaquine and chloroquine alone compared to chloroquine plus primaquine for <I>Plasmodium vivax</I> infection</TI>
<SO>http://clinicaltrials.gov/ct2/show/record/NCT01680406</SO>
<YR>(accessed 21 July 2013)</YR>
<IDENTIFIERS MODIFIED="2013-10-08 11:23:57 +0100" MODIFIED_BY="Prathap  Tharyan"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 14:30:09 +0100" MODIFIED_BY="Prathap  Tharyan">
<IDENTIFIER MODIFIED="2013-10-17 14:30:09 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01680406"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-10-21 09:32:29 +0100" MODIFIED_BY="Harriet MacLehose">
<ADDITIONAL_REFERENCES MODIFIED="2013-10-21 09:32:29 +0100" MODIFIED_BY="Harriet MacLehose">
<REFERENCE ID="REF-Adak-2001" MODIFIED="2013-09-02 10:10:22 +0100" MODIFIED_BY="[Empty name]" NAME="Adak 2001" TYPE="JOURNAL_ARTICLE">
<AU>Adak T, Valecha N, Sharma VP</AU>
<TI>
<I>Plasmodium vivax </I>polymorphism in a clinical drug trial</TI>
<SO>Clinical and Diagnostic Laboratory Immunology</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>5</NO>
<PG>891-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alves-2002" MODIFIED="2013-10-03 10:06:22 +0100" MODIFIED_BY="[Empty name]" NAME="Alves 2002" TYPE="JOURNAL_ARTICLE">
<AU>Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP</AU>
<TI>High prevalence of asymptomatic <I>Plasmodium vivax </I>and <I>Plasmodium falciparum</I> infections in native Amazonian populations</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>6</NO>
<PG>641-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alving-1955" MODIFIED="2013-09-02 10:11:14 +0100" MODIFIED_BY="[Empty name]" NAME="Alving 1955" TYPE="JOURNAL_ARTICLE">
<AU>Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, et al</AU>
<TI>Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine</TI>
<SO>Journal of Laboratory and Clinical Medicine</SO>
<YR>1955</YR>
<VL>46</VL>
<NO>2</NO>
<PG>301-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alving-1960" MODIFIED="2013-10-03 10:06:33 +0100" MODIFIED_BY="[Empty name]" NAME="Alving 1960" TYPE="JOURNAL_ARTICLE">
<AU>Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE</AU>
<TI>Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of <I>Plasmodium vivax</I> by intermittent regimens of drug administration: a preliminary report</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1960</YR>
<VL>22</VL>
<PG>621-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anstey-2007" MODIFIED="2013-10-03 10:23:19 +0100" MODIFIED_BY="[Empty name]" NAME="Anstey 2007" TYPE="JOURNAL_ARTICLE">
<AU>Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, et al</AU>
<TI>Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>195</VL>
<NO>4</NO>
<PG>589-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baird-1997" MODIFIED="2013-10-08 11:17:54 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 1997" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al</AU>
<TI>Diagnosis of resistance to chloroquine by <I>Plasmodium vivax</I>: Timing of recurrence and whole blood chloroquine levels</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>6</NO>
<PG>621-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baird-2003a" MODIFIED="2013-09-02 10:13:45 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK, Rieckmann KH</AU>
<TI>Can primaquine therapy for vivax malaria be improved?</TI>
<SO>Trends in Parasitology</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>3</NO>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baird-2004" MODIFIED="2013-09-02 10:14:04 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK, Hoffman SL</AU>
<TI>Primaquine therapy for malaria</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>9</NO>
<PG>1336-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baird-2009" MODIFIED="2013-09-02 10:14:50 +0100" MODIFIED_BY="[Empty name]" NAME="Baird 2009" TYPE="JOURNAL_ARTICLE">
<AU>Baird JK</AU>
<TI>Resistance to therapies for infection by <I>Plasmodium vivax</I>
</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>3</NO>
<PG>508-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barcus-2007" MODIFIED="2013-10-03 10:06:45 +0100" MODIFIED_BY="[Empty name]" NAME="Barcus 2007" TYPE="JOURNAL_ARTICLE">
<AU>Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti, Elyazar I, et al</AU>
<TI>Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua</TI>
<SO>American Journal of Tropical Medicine and Hygiene.</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>5</NO>
<PG>984-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beg-2008" MODIFIED="2013-10-03 10:06:52 +0100" MODIFIED_BY="[Empty name]" NAME="Beg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Beg MA, Sani N, Mehraj V, Jafri W, Khan MA, Malik A, et al</AU>
<TI>Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>1</NO>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beutler-1994" MODIFIED="2013-09-02 10:16:50 +0100" MODIFIED_BY="[Empty name]" NAME="Beutler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Beutler E</AU>
<TI>G6PD deficiency</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>11</NO>
<PG>3613-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beutler-2007" MODIFIED="2013-10-03 10:07:02 +0100" MODIFIED_BY="[Empty name]" NAME="Beutler 2007" TYPE="JOURNAL_ARTICLE">
<AU>Beutler E, Duparc S, G6PD Deficiency Working Group</AU>
<TI>Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>4</NO>
<PG>779-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bouma-1995" MODIFIED="2013-09-02 10:18:27 +0100" MODIFIED_BY="[Empty name]" NAME="Bouma 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bouma MJ, Goris M, Akhtar T, Khan N, Khan N, Kita E</AU>
<TI>Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and Afghan refugee communities in Pakistan; implications for the use of primaquine in regional malaria control programmes</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>1</NO>
<PG>62-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breman-2001" MODIFIED="2013-10-03 10:07:11 +0100" MODIFIED_BY="[Empty name]" NAME="Breman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Breman JG</AU>
<TI>The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden</TI>
<SO>American Journal of Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>64</VL>
<NO>Suppl 1-2</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2004" MODIFIED="2013-10-03 10:07:18 +0100" MODIFIED_BY="[Empty name]" NAME="Campbell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Campbell MK, Elbourne DR, Altman DG, CONSORT group</AU>
<TI>CONSORT statement: extension to cluster randomised trials</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7441</NO>
<PG>702-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cappellini-2008" MODIFIED="2013-10-03 10:07:31 +0100" MODIFIED_BY="[Empty name]" NAME="Cappellini 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cappellini MD, Fiorelli G</AU>
<TI>Glucose-6-phosphate dehydrogenase deficiency</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9606</NO>
<PG>64-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2005" MODIFIED="2013-10-03 10:07:39 +0100" MODIFIED_BY="[Empty name]" NAME="CDC 2005" TYPE="BOOK">
<AU>Centers for Disease Control and Prevention, Kozarsky PE, Arguin PM, Navin AW</AU>
<SO>Health information for international travel 2005&#8211;2006</SO>
<YR>2005</YR>
<PB>Elsevier</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2011" MODIFIED="2013-10-03 10:07:49 +0100" MODIFIED_BY="[Empty name]" NAME="CDC 2011" TYPE="BOOK">
<AU>Centres for Disease Control and Prevention</AU>
<SO>Treatment of malaria (guidelines for clinicians)</SO>
<YR>2011</YR>
<PB>Available at: www.cdc.gov/malaria/pdf/treatmenttable.pdf</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Charoenlarp-1973" MODIFIED="2013-10-03 10:08:08 +0100" MODIFIED_BY="[Empty name]" NAME="Charoenlarp 1973" TYPE="JOURNAL_ARTICLE">
<AU>Charoenlarp P, Harinasuta T</AU>
<TI>Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>1973</YR>
<VL>4</VL>
<NO>1</NO>
<PG>135-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2007" MODIFIED="2013-10-08 11:18:03 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q</AU>
<TI>Relapses of <I>Plasmodium vivax</I> infection result from clonal hypnozoites activated at predetermined intervals</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>195</VL>
<NO>7</NO>
<PG>934-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cogswell-1992" MODIFIED="2013-10-03 10:08:21 +0100" MODIFIED_BY="[Empty name]" NAME="Cogswell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Cogswell FB</AU>
<TI>The hypnozoite and relapse in primate malaria</TI>
<SO>Clinical Microbiology Review</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>1</NO>
<PG>26-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1996" MODIFIED="2013-09-02 10:27:29 +0100" MODIFIED_BY="[Empty name]" NAME="Collins 1996" TYPE="JOURNAL_ARTICLE">
<AU>Collins WE, Jeffery GM</AU>
<TI>Primaquine resistance in P. vivax</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>3</NO>
<PG>243-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Craig-1996" MODIFIED="2013-09-02 10:28:00 +0100" MODIFIED_BY="[Empty name]" NAME="Craig 1996" TYPE="JOURNAL_ARTICLE">
<AU>Craig AA, Kain KC</AU>
<TI>Molecular analysis of strains of <I>Plasmodium vivax</I> from paired primary and relapse infections</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>2</NO>
<PG>373-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2013-10-03 10:08:33 +0100" MODIFIED_BY="Harriet MacLehose" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2013-09-02 10:33:22 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doolan-2009" MODIFIED="2013-10-08 11:18:12 +0100" MODIFIED_BY="[Empty name]" NAME="Doolan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Doolan DL, Dobano C, Baird JK</AU>
<TI>Acquired immunity to malaria</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>1</NO>
<PG>13-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Douglas-2010" MODIFIED="2013-09-02 10:34:42 +0100" MODIFIED_BY="[Empty name]" NAME="Douglas 2010" TYPE="JOURNAL_ARTICLE">
<AU>Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN</AU>
<TI>Artemisinin combination therapy for vivax malaria</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>6</NO>
<PG>405-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duarte-2001" MODIFIED="2013-10-03 10:08:51 +0100" MODIFIED_BY="[Empty name]" NAME="Duarte 2001" TYPE="JOURNAL_ARTICLE">
<AU>Duarte EC, Pang LW, Ribeiro LC, Fontes CJ</AU>
<TI>Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>65</VL>
<NO>5</NO>
<PG>417-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebringer-2011" MODIFIED="2013-10-03 10:09:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ebringer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ebringer A, Heathcote G, Baker J, Waller M, Shanks GD, Edstein MD</AU>
<TI>Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2011</YR>
<VL>105</VL>
<NO>10</NO>
<PG>568-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fonseka-1987" MODIFIED="2013-09-02 10:36:05 +0100" MODIFIED_BY="[Empty name]" NAME="Fonseka 1987" TYPE="JOURNAL_ARTICLE">
<AU>Fonseka J, Mendis KN</AU>
<TI>A metropolitan hospital in a non-endemic area provides a sampling pool for epidemiological studies on vivax malaria in Sri Lanka</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1987</YR>
<VL>81</VL>
<NO>3</NO>
<PG>360-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gamble-2006" MODIFIED="2013-10-03 10:09:12 +0100" MODIFIED_BY="[Empty name]" NAME="Gamble 2006" TYPE="COCHRANE_REVIEW">
<AU>Gamble CL, Ekwaru JP, ter Kuile FO</AU>
<TI>Insecticide-treated nets for preventing malaria in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-08-28 16:20:45 +0100" MODIFIED_BY="Prathap  Tharyan">
<IDENTIFIER MODIFIED="2013-08-28 16:20:45 +0100" MODIFIED_BY="Prathap  Tharyan" TYPE="DOI" VALUE="10.1002/14651858.CD003755"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Genton-2008" MODIFIED="2013-10-03 10:22:33 +0100" MODIFIED_BY="[Empty name]" NAME="Genton 2008" TYPE="JOURNAL_ARTICLE">
<AU>Genton B, D&#8217;Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al</AU>
<TI>
<I>Plasmodium vivax </I>and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea</TI>
<SO>PLoS Med</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>6</NO>
<PG>e127</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:31:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gogtay-2000" MODIFIED="2013-09-02 10:37:31 +0100" MODIFIED_BY="[Empty name]" NAME="Gogtay 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gogtay NJ, Desai S, Kadam VS, Kamtekar KD, Dalvi SS, Kshirsagar NA</AU>
<TI>Relapse pattern of <I>Plasmodium vivax</I> in Mumbai: a study of 283 cases of vivax malaria</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>11</NO>
<PG>1085-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goller-2007" MODIFIED="2013-10-08 11:18:20 +0100" MODIFIED_BY="[Empty name]" NAME="Goller 2007" TYPE="JOURNAL_ARTICLE">
<AU>Goller JL, Jolley D, Ringwald P, Biggs BA</AU>
<TI>Rerional differences in the response of <I>Plasmodium vivax</I> malaria to primaquine as anti-relapse therapy</TI>
<SO>American Jourrnal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>2</NO>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2004" MODIFIED="2013-10-03 11:27:33 +0100" MODIFIED_BY="[Empty name]" NAME="GRADE 2004" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schunemann H</AU>
<TI>GRADEpro. Version 3.6 for Windows</TI>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grietens-2010" MODIFIED="2013-09-02 10:43:21 +0100" MODIFIED_BY="[Empty name]" NAME="Grietens 2010" TYPE="JOURNAL_ARTICLE">
<AU>Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al</AU>
<TI>Adherence to 7-day primaquine treatment for the radical cure of <I>P. vivax</I> in the Peruvian Amazon</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>6</NO>
<PG>1017-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guerra-2010" MODIFIED="2013-10-08 11:18:27 +0100" MODIFIED_BY="[Empty name]" NAME="Guerra 2010" TYPE="JOURNAL_ARTICLE">
<AU>Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, et al</AU>
<TI>The International limits and population at risk of <I>Plasmodium vivax </I>transmission in 2009</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>8</NO>
<PG>e774</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:32:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gunawardena-2010" MODIFIED="2013-10-03 10:22:10 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Gunawardena 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gunawardena S, Karunaweera ND, Ferreira MU, Phone-Kyaw M, Pollack RJ, Alifrangis M, et al</AU>
<TI>Geographic structure of <I>Plasmodium vivax</I>: microsatellite analysis of parasite populations from Sri Lanka, Myanmar, and Ethiopia</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>2</NO>
<PG>235-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Havryliuk-2009" MODIFIED="2013-09-02 17:05:55 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Havryliuk 2009" TYPE="JOURNAL_ARTICLE">
<AU>Havryliuk T, Ferreira MU</AU>
<TI>A closer look at multiple-clone <I>Plasmodium vivax </I>infections: detection methods, prevalence and consequences</TI>
<SO>Memórias do Instituto Oswaldo Cruz</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>1</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-2004" MODIFIED="2013-10-08 11:18:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hay 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW</AU>
<TI>The global distribution and population at risk of malaria: past, present, and future</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>6</NO>
<PG>327-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-2008" MODIFIED="2013-09-02 10:45:33 +0100" MODIFIED_BY="[Empty name]" NAME="Haynes 2008" TYPE="COCHRANE_REVIEW">
<AU>Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X</AU>
<TI>Interventions for enhancing medication adherence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-05-30 15:59:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-30 15:59:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000011"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-09-02 10:46:08 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2013-10-03 10:09:43 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions [4.2.5] updated [May 2005]; Appendix 5b</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2013-10-03 10:09:53 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2013-10-03 11:23:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-2006" MODIFIED="2013-10-03 10:10:23 +0100" MODIFIED_BY="[Empty name]" NAME="Hill 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ</AU>
<TI>Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis I</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>75</VL>
<NO>3</NO>
<PG>402-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imwong-2007a" MODIFIED="2013-09-02 10:52:08 +0100" MODIFIED_BY="[Empty name]" NAME="Imwong 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A</AU>
<TI>Relapses of <I>Plasmodium vivax</I> infection usually result from activation of heterologous hypnozoites</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>195</VL>
<NO>7</NO>
<PG>927-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imwong-2007b" MODIFIED="2013-10-03 10:21:37 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Imwong 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Imwong M, Nair S, Pukrittayakamee S, Sudimack D, Williams JT, Mayxay M, et al</AU>
<TI>Contrasting genetic structure in <I>Plasmodium vivax </I>populations from Asia and South America</TI>
<SO>International Journal of Parasitology</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>8-9</NO>
<PG>1013-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imwong-2012" MODIFIED="2013-10-08 11:18:50 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Imwong 2012" TYPE="JOURNAL_ARTICLE">
<AU>Imwong M, Boel ME, Pagornrat W, Pimanpanarak M, McGready R, Day NP, et al</AU>
<TI>The first <I>Plasmodium vivax</I> relapses of life are usually genetically homologous</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2012</YR>
<VL>205</VL>
<NO>4</NO>
<PG>680-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-John-2012" MODIFIED="2013-10-08 11:24:25 +0100" MODIFIED_BY="[Empty name]" NAME="John 2012" TYPE="JOURNAL_ARTICLE">
<AU>John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al</AU>
<TI>Primaquine radical cure of Plasmodium vivax: a critical review of the literature</TI>
<SO>Malaria Journal</SO>
<YR>2012</YR>
<VL>11</VL>
<PG>280</PG>
<IDENTIFIERS MODIFIED="2013-10-08 11:24:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Karunaweera-2008" MODIFIED="2013-09-02 11:02:38 +0100" MODIFIED_BY="[Empty name]" NAME="Karunaweera 2008" TYPE="JOURNAL_ARTICLE">
<AU>Karunaweera ND, Ferreira MU, Munasinghe A, Barnwell JW, Collins WE, King CL, et al</AU>
<TI>Extensive microsatellite diversity in the human malaria parasite <I>Plasmodium vivax</I>
</TI>
<SO>Gene</SO>
<YR>2008</YR>
<VL>410</VL>
<NO>1</NO>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kitchner-2007" MODIFIED="2013-10-08 11:19:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kitchner 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kitchener S, Nasveld P, Edstein MD</AU>
<TI>Tafenoquine for the treatment of recurrent <I>Plasmodium vivax</I> malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>3</NO>
<PG>494-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kochar-2010" MODIFIED="2013-10-03 10:10:48 +0100" MODIFIED_BY="[Empty name]" NAME="Kochar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, Gupta A, et al</AU>
<TI>Clinical features of children hospitalized with Malaria - a study from Bikaner, northwest India</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>83</VL>
<NO>5</NO>
<PG>981-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krotoski-1985" MODIFIED="2013-10-03 10:21:05 +0100" MODIFIED_BY="[Empty name]" NAME="Krotoski 1985" TYPE="JOURNAL_ARTICLE">
<AU>Krotoski WA</AU>
<TI>Discovery of the hypnozoite and a new theory of malarial relapse</TI>
<SO>Transactions of the Royal Society of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krudsood-2006" MODIFIED="2013-10-03 10:21:17 +0100" MODIFIED_BY="[Empty name]" NAME="Krudsood 2006" TYPE="JOURNAL_ARTICLE">
<AU>Krudsood S, Wilairatana P, Tangpukdee N, Chalermrut K, Srivilairit S, Thanachartwet V, et al</AU>
<TI>Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of <I>Plasmodium vivax</I> malaria in Thailand</TI>
<SO>Korean Journal of Parasitology</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>3</NO>
<PG>221-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krudsood-2008" MODIFIED="2013-10-03 10:11:00 +0100" MODIFIED_BY="[Empty name]" NAME="Krudsood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, et al</AU>
<TI>High-dose primaquine regimens against relapse of <I>Plasmodium vivax </I>malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2008</YR>
<VL>78</VL>
<NO>5</NO>
<PG>736-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kshirsagar-2006" MODIFIED="2013-09-02 11:05:34 +0100" MODIFIED_BY="[Empty name]" NAME="Kshirsagar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kshirsagar NA</AU>
<TI>Malaria: anti malarial resistance and policy ramifications and challenges</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>2006</YR>
<VL>52</VL>
<NO>4</NO>
<PG>291-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2007" MODIFIED="2013-10-03 10:11:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Valecha N, Jain T, Dash AP</AU>
<TI>Burden of malaria in India: retrospective and prospective view</TI>
<SO>American Journal of Tropical. Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>Suppl 6</NO>
<PG>69-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lalloo-2007" MODIFIED="2013-10-03 10:11:19 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Lalloo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, et al</AU>
<TI>UK malaria treatment guidelines</TI>
<SO>Journal of Infection</SO>
<YR>2007</YR>
<VL>54</VL>
<NO>2</NO>
<PG>111-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lengeler-2004" MODIFIED="2013-10-03 10:11:32 +0100" MODIFIED_BY="[Empty name]" NAME="Lengeler 2004" TYPE="COCHRANE_REVIEW">
<AU>Lengeler C</AU>
<TI>Insecticide-treated bed nets and curtains for preventing malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-08-28 16:21:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-28 16:21:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000363"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leslie-2010" MODIFIED="2013-10-03 10:11:44 +0100" MODIFIED_BY="[Empty name]" NAME="Leslie 2010" TYPE="JOURNAL_ARTICLE">
<AU>Leslie T, Briceño M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, et al</AU>
<TI>The impact of phenotypic and genotypic G6PD deficiency on risk of <I>Plasmodium vivax</I> infection: a case-control study amongst Afghan refugees in Pakistan</TI>
<SO>PLoS Med</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>5</NO>
<PG>e1000283</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:32:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lin-2010" MODIFIED="2013-10-08 11:19:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, et al</AU>
<TI>Differential patterns of infection and disease with <I>P. falciparum</I> and <I>P. vivax</I> in young Papua New Guinean children</TI>
<SO>PLoS ONE</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>2</NO>
<PG>e9047</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:31:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Looareesuwan-1997" MODIFIED="2013-09-02 11:09:41 +0100" MODIFIED_BY="[Empty name]" NAME="Looareesuwan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y, Amradee S, et al</AU>
<TI>Primaquine-tolerant vivax malaria in Thailand</TI>
<SO>Annals of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>8</NO>
<PG>939-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Louicharoen-2009" MODIFIED="2013-10-03 10:11:59 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Louicharoen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, et al</AU>
<TI>Positively selected G6PD-Mahidol mutation reduces <I>Plasmodium vivax </I>density in Southeast Asians</TI>
<SO>Science</SO>
<YR>2009</YR>
<VL>326</VL>
<NO>5959</NO>
<PG>1546-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maguire-2010" MODIFIED="2013-10-03 10:20:42 +0100" MODIFIED_BY="[Empty name]" NAME="Maguire 2010" TYPE="JOURNAL_ARTICLE">
<AU>Maguire JD, Baird JK</AU>
<TI>The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>4</NO>
<PG>283-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendis-2001" MODIFIED="2013-10-03 10:12:10 +0100" MODIFIED_BY="[Empty name]" NAME="Mendis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mendis K, Sina JB, Marchesini P, Carter R</AU>
<TI>The neglected burden of <I>P. vivax</I> malaria</TI>
<SO>American Journal of Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>64</VL>
<NO>Suppl 1-2</NO>
<PG>97-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michon-2007" MODIFIED="2013-10-03 10:20:15 +0100" MODIFIED_BY="[Empty name]" NAME="Michon 2007" TYPE="JOURNAL_ARTICLE">
<AU>Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, et al</AU>
<TI>The risk of malarial infections and disease in Papua New Guinean children</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>6</NO>
<PG>997-1008</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2013-10-03 10:12:18 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>63</VL>
<NO>8</NO>
<PG>e-1-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mueller-2009" MODIFIED="2013-10-03 10:20:26 +0100" MODIFIED_BY="[Empty name]" NAME="Mueller 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al</AU>
<TI>Key gaps in the knowledge of <I>Plasmodium vivax</I>, a neglected human malaria parasite</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>9</NO>
<PG>555-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naing-2010" MODIFIED="2013-09-02 11:18:15 +0100" MODIFIED_BY="[Empty name]" NAME="Naing 2010" TYPE="JOURNAL_ARTICLE">
<AU>Naing C, Aung K, Win DK, Wah MJ</AU>
<TI>Efficacy and safety of chloroquine for treatment in patients with uncomplicated <I>Plasmodium vivax</I> infections in endemic countries</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>11</NO>
<PG>695-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMR-2011" MODIFIED="2013-10-03 10:12:30 +0100" MODIFIED_BY="[Empty name]" NAME="NIMR 2011" TYPE="BOOK">
<AU>National Institute of Malaria Research, Indian Council of Medical Research</AU>
<SO>Diagnosis and treatment of Malaria in India</SO>
<YR>2011</YR>
<EN>2nd</EN>
<PB>National Insitute of Malaria Research</PB>
<CY>New Delhi</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orjuela_x002d_Sanchez-2009" MODIFIED="2013-10-03 10:12:37 +0100" MODIFIED_BY="[Empty name]" NAME="Orjuela-Sanchez 2009" TYPE="JOURNAL_ARTICLE">
<AU>Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU</AU>
<TI>Recurrent parasitemias and population dynamics of <I>Plasmodium vivax</I> polymorphisms in rural Amazonia</TI>
<SO>American Journal of Topical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>81</VL>
<NO>6</NO>
<PG>961-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orton-2005" MODIFIED="2013-09-02 11:22:14 +0100" MODIFIED_BY="Harriet MacLehose" NAME="Orton 2005" TYPE="COCHRANE_REVIEW">
<AU>Orton L, Barnish G</AU>
<TI>Unit-dose packaged drugs for treating malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-12 15:06:24 +0100" MODIFIED_BY="Harriet MacLehose">
<IDENTIFIER MODIFIED="2008-05-12 15:06:24 +0100" MODIFIED_BY="Harriet MacLehose" TYPE="DOI" VALUE="10.1002/14651858.CD004614.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parfitt-1999" NAME="Parfitt 1999" TYPE="BOOK">
<AU>Parfitt K, editor</AU>
<SO>Martindale: the complete drug reference</SO>
<YR>1999</YR>
<EN>32nd</EN>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piaggio-2006" MODIFIED="2013-10-03 10:12:52 +0100" MODIFIED_BY="[Empty name]" NAME="Piaggio 2006" TYPE="JOURNAL_ARTICLE">
<AU>Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, CONSORT group</AU>
<TI>Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>10</NO>
<PG>1152-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poespoprodjo-2008" MODIFIED="2013-10-08 11:19:15 +0100" MODIFIED_BY="[Empty name]" NAME="Poespoprodjo 2008" TYPE="JOURNAL_ARTICLE">
<AU>Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, et al</AU>
<TI>Adverse pregnancy outcomes in an area where multidrug-resistant <I>Plasmodium vivax</I> and <I>Plasmodium falciparum</I> infections are endemic</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>9</NO>
<PG>1374-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poespoprodjo-2009" MODIFIED="2013-10-03 10:13:03 +0100" MODIFIED_BY="[Empty name]" NAME="Poespoprodjo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al</AU>
<TI>Vivax malaria: a major cause of morbidity in early infancy</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>12</NO>
<PG>1704-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-2007" MODIFIED="2013-10-03 10:13:10 +0100" MODIFIED_BY="[Empty name]" NAME="Price 2007" TYPE="JOURNAL_ARTICLE">
<AU>Price RN, Tjitra E, Guerra CA, Yeung S, White N, Anstey NM</AU>
<TI>Vivax malaria: neglected and not benign</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>Suppl 6</NO>
<PG>79-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-2009" MODIFIED="2013-10-08 11:19:25 +0100" MODIFIED_BY="[Empty name]" NAME="Price 2009" TYPE="JOURNAL_ARTICLE">
<AU>Price RN, Douglas NM, Anstey NM</AU>
<TI>New developments in <I>Plasmodium vivax</I> malaria: severe disease and the rise of chloroquine resistance</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>5</NO>
<PG>430-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-2011" MODIFIED="2013-09-03 16:30:29 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="Price 2011" TYPE="JOURNAL_ARTICLE">
<AU>Price RN, Douglas NM, Anstey NM, von Seidlein L</AU>
<TI>
<I>Plasmodium vivax</I> treatments: what are we looking for?</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>6</NO>
<PG>578-85</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:30:29 +0100" MODIFIED_BY="Prathap  Tharyan"/>
</REFERENCE>
<REFERENCE ID="REF-Pukrittayakamee-2004" MODIFIED="2013-10-08 11:19:35 +0100" MODIFIED_BY="[Empty name]" NAME="Pukrittayakamee 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, et al</AU>
<TI>Therapeutic responses to different antimalarial drugs in vivax malaria</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>6</NO>
<PG>1680-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pukrittayakamee-2008" MODIFIED="2013-10-08 11:19:55 +0100" MODIFIED_BY="[Empty name]" NAME="Pukrittayakamee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pukrittayakamee S, Imwong M, Singhasivanon P, Stepniewska K, Day NJ, White NJ</AU>
<TI>Effects of different antimalarial drugs on gametocyte carriage in <I>P. vivax </I>malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2008</YR>
<VL>79</VL>
<NO>3</NO>
<PG>378-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qingjun-1998" MODIFIED="2013-10-03 10:13:28 +0100" MODIFIED_BY="[Empty name]" NAME="Qingjun 1998" TYPE="JOURNAL_ARTICLE">
<AU>Qingjun L, Jihui D, Laiyi T, Xiangjun Z, Jun L, Hay A, et al</AU>
<TI>The effect of drug packaging on patients' compliance with treatment for <I>Plasmodium vivax </I>malaria in China</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1998</YR>
<VL>76</VL>
<NO>Suppl 1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5.2" MODIFIED="2013-10-03 10:19:54 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 5.2" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowland-2001" MODIFIED="2013-10-21 09:31:06 +0100" MODIFIED_BY="[Empty name]" NAME="Rowland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rowland M, Nosten F</AU>
<TI>Malaria epidemiology and control in refugee camps and complex emergencies</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>8</NO>
<PG>741-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saravu-2011" MODIFIED="2013-10-21 09:31:51 +0100" MODIFIED_BY="[Empty name]" NAME="Saravu 2011" TYPE="JOURNAL_ARTICLE">
<AU>Saravu K, Docherla M, Vasudev A, Shastry BA</AU>
<TI>Thrombocytopenia in vivax and falciparum malaria: an observational study of 131 patients in Karnataka, India</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2011</YR>
<VL>105</VL>
<NO>8</NO>
<PG>593-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-1977" MODIFIED="2013-09-02 11:35:23 +0100" MODIFIED_BY="[Empty name]" NAME="Schmidt 1977" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt LH, Fradkin R, Vaughan D, Rasco J</AU>
<TI>Radical cure of infections with <I>Plasmodium cynomolgi</I>: a function of total 8-aminoquinoline dose</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1977</YR>
<VL>26</VL>
<NO>6 Pt 1</NO>
<PG>1116-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schunemann-2008" MODIFIED="2013-10-03 10:13:43 +0100" MODIFIED_BY="[Empty name]" NAME="Schunemann 2008" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH</AU>
<TI>Chapter 12: Interpreting results drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Review of Intervention Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sinclair-2011" MODIFIED="2013-09-10 16:46:11 +0100" MODIFIED_BY="[Empty name]" NAME="Sinclair 2011" TYPE="COCHRANE_REVIEW">
<AU>Sinclair D, Gogtay N, Brand F, Olliaro PL</AU>
<TI>Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2012-05-11 16:30:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-11 16:30:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008492"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2011" MODIFIED="2013-10-03 10:13:54 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 2011" TYPE="JOURNAL_ARTICLE">
<AU>Singh H, Parakh A, Basu S, Rath B</AU>
<TI>
<I>Plasmodium vivax</I> malaria: is it actually benign?</TI>
<SO>Journal of Infection and Public Health.</SO>
<YR>2011</YR>
<VL>4</VL>
<NO>2</NO>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srivastava-2011" MODIFIED="2013-09-02 11:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="Srivastava 2011" TYPE="JOURNAL_ARTICLE">
<AU>Srivastava S, Ahmad S, Shirazi N, Kumar Verma S, Puri P</AU>
<TI>Retrospective analysis of vivax malaria patients presenting to tertiary referral centre of Uttarakhand</TI>
<SO>Acta Tropica</SO>
<YR>2011</YR>
<VL>117</VL>
<NO>2</NO>
<PG>82-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanwar-2011" MODIFIED="2013-10-03 10:14:07 +0100" MODIFIED_BY="[Empty name]" NAME="Tanwar 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tanwar GS, Khatri PC, Sengar GS, Kochar A, Kochar SK, Middha S, et al</AU>
<TI>Clinical profiles of 13 children with <I>Plasmodium vivax</I> cerebral malaria</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>4</NO>
<PG>351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ter-Kuile-2008" MODIFIED="2013-10-03 10:14:15 +0100" MODIFIED_BY="[Empty name]" NAME="ter Kuile 2008" TYPE="JOURNAL_ARTICLE">
<AU>ter Kuile FO, Rogerson SJ</AU>
<TI>
<I>Plasmodium vivax</I> infection during pregnancy: an important problem in need of new solutions</TI>
<SO>Clinical Infectious Diseases </SO>
<YR>2008</YR>
<VL>46</VL>
<NO>9</NO>
<PG>1382-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tjitra-2008" MODIFIED="2013-10-21 09:31:28 +0100" MODIFIED_BY="[Empty name]" NAME="Tjitra 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al</AU>
<TI>Multidrug-resistant <I>Plasmodium vivax</I> associated with severe and fatal malaria: a prospective study in Papua, Indonesia</TI>
<SO>PLoS Med</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>6</NO>
<PG>e128</PG>
<IDENTIFIERS MODIFIED="2013-09-03 16:32:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Tripathy-2007" MODIFIED="2013-10-03 10:14:30 +0100" MODIFIED_BY="[Empty name]" NAME="Tripathy 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tripathy V, Reddy BM</AU>
<TI>Present status of understanding on the G6PD deficiency and natural selection</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>3</NO>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tusting-2013" MODIFIED="2013-10-21 09:32:29 +0100" MODIFIED_BY="[Empty name]" NAME="Tusting 2013" TYPE="COCHRANE_REVIEW">
<AU>Tusting LS, Thwing J, Sinclair D, Fillinger U, Gimnig J, Bonner KE, Bottomley C, Lindsay SW</AU>
<TI>Mosquito larval source management for controlling malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-10-21 09:32:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-21 09:32:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008923.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vale-2008" MODIFIED="2013-10-03 11:30:47 +0100" MODIFIED_BY="[Empty name]" NAME="Vale 2008" TYPE="JOURNAL_ARTICLE">
<AU>Vale N, Moreira R, Gomes P</AU>
<TI>Primaquine revisited six decades after its discovery</TI>
<SO>European Journal of Medicinal Chemistry</SO>
<YR>2008</YR>
<VL>44</VL>
<NO>3</NO>
<PG>937-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valecha-2006" MODIFIED="2013-09-02 11:47:07 +0100" MODIFIED_BY="[Empty name]" NAME="Valecha 2006" TYPE="JOURNAL_ARTICLE">
<AU>Valecha N, Joshi H, Eapen A, Ravinderan J, Kumar A, Prajapati SK, et al</AU>
<TI>Therapeutic efficacy of chloroquine in <I>Plasmodium vivax</I> from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>9</NO>
<PG>831-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valecha-2009" MODIFIED="2013-09-02 11:47:59 +0100" MODIFIED_BY="[Empty name]" NAME="Valecha 2009" TYPE="JOURNAL_ARTICLE">
<AU>Valecha N, Pinto RG, Turner GD, Kumar A, Rodrigues S, Dubhashi NG, et al</AU>
<TI>Histopathology of fatal respiratory distress caused by <I>Plasmodium vivax</I> malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>81</VL>
<NO>5</NO>
<PG>758-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Eede-2010a" MODIFIED="2013-10-03 10:14:42 +0100" MODIFIED_BY="[Empty name]" NAME="Van den Eede 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Van den Eede P, Van der Auwera G, Delgado C, Huyse T, Soto-Calle VE, Gamboa D, et al</AU>
<TI>Multilocus genotyping reveals high heterogeneity and strong local population structure of the <I>Plasmodium vivax</I> population in the Peruvian Amazon</TI>
<SO>Malaria Journal</SO>
<YR>2010</YR>
<VL>9</VL>
<PG>151</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Eede-2011" MODIFIED="2013-09-02 11:49:04 +0100" MODIFIED_BY="[Empty name]" NAME="Van den Eede 2011" TYPE="JOURNAL_ARTICLE">
<AU>Van den Eede P, Soto-Calle VE, Delgado C, Gamboa D, Grande T, Rodriguez H, et al</AU>
<TI>
<I>Plasmodium vivax </I>sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study</TI>
<SO>PLoS ONE</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>1</NO>
<PG>e16257</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2011" MODIFIED="2013-09-02 11:49:24 +0100" MODIFIED_BY="Prathap  Tharyan" NAME="White 2011" TYPE="JOURNAL_ARTICLE">
<AU>White NJ</AU>
<TI>Determinants of relapse periodicity in <I>Plasmodium vivax</I> malaria</TI>
<SO>Malaria Journal</SO>
<YR>2011</YR>
<VL>10</VL>
<PG>297</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2013-10-03 10:14:54 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2000" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Severe falciparum malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>Suppl 1</NO>
<PG>1-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2012-05-16 18:10:08 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2006" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Guidelines for the treatment of malaria</SO>
<YR>2006</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2013-02-07 10:08:57 +0000" MODIFIED_BY="Prathap  Tharyan" NAME="WHO 2009" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Methods for surveillance of antimalarial drug efficacy</SO>
<YR>2009</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010a" MODIFIED="2013-10-21 09:31:38 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010a" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Guidelines for the treatment of malaria -- 2nd edition</SO>
<YR>2010</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010b" MODIFIED="2012-05-15 11:55:30 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010b" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Global report on antimalarial drug efficacy and drug resistance: 2000-2010</SO>
<YR>2010</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2013-10-03 10:15:07 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>World Malaria Report 2011</SO>
<YR>2011</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-05-31 02:16:27 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Galappaththy-2007" MODIFIED="2012-05-31 02:16:27 +0100" MODIFIED_BY="[Empty name]" NAME="Galappaththy 2007" TYPE="COCHRANE_REVIEW">
<AU>Galappaththy GN, Omari AA, Tharyan P</AU>
<TI>Primaquine for preventing relapses in people with <I>Plasmodium vivax </I>malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-31 02:16:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-31 02:16:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004389"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-10-18 03:50:26 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-10-08 11:16:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-10-08 11:16:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-2006">
<CHAR_METHODS MODIFIED="2013-10-03 09:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, parallel-group, open-label, three armed, active controlled trial</P>
<P>
<B>Period of study:</B> September 2003 to September 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants:</B> 210</P>
<P>Patients that attended the local malaria clinics with acute symptomatic vivax<I> </I>malaria and a positive thick blood smear during period of study were eligible.<BR/>
</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Age 15 years or older</LI>
<LI>
<I>P. vivax </I>parasitaemia of 1,000 asexual forms/L</LI>
<LI>Permanent residency in the municipalities of the study</LI>
<LI>Willingness to give informed consent and agreement to attend follow-up for six months</LI>
<LI>Normal G6PD screening test result</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Pregnant women</LI>
<LI>Co-infection with associated infectious diseases</LI>
<LI>History of anti-malarial intake during the previous two weeks</LI>
<LI>Diarrhoea or vomiting (&gt; 5 episodes in 24 hours)</LI>
<LI>Hypersensitivity to anti-malarials</LI>
<LI>Intake of any anti-malarial different from those provided by the researchers</LI>
<LI>Travel to a different municipality</LI>
<LI>Severe undernourishment</LI>
<LI>Symptoms or signs of severe malaria (according to <LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>)</LI>
<LI>Consent withdrawal</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-08 11:16:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>CQ plus PQ 45 mg over three days (N = 71)</LI>
<LI>CQ plus PQ 105 mg over seven days) (N = 71)</LI>
</OL>
<P>
<B>Control:</B>
</P>
<P>CQ * plus PQ 210 mg over for fourteen days (N = 68)</P>
<P>CQ (600 mg): 250-mg tablets with 150 mg of CQ base, on day 0 and 450 mg on days 1 and 2 (total dose 1,500 mg)</P>
<P>PQ: 26.3 mg tablets with 15 mg base/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 11:14:50 +0100" MODIFIED_BY="[Empty name]">
<P>Recurrence (defined as any <I>P. vivax</I> parasitaemia observed (in 200 oil-immersion fields on microscopy) after day 28 in patients with adequate treatment response)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:29:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Local malaria clinics in two malaria endemic (El Bagre: gold-mining and Turbo: banana plantations) municipalities; malaria transmission perennial and unstable; tropical strains of <I>P. vivax </I>(from report); chloroquine-sensitive <I>P. vivax</I> accounted for 75% of the cases of malaria in the country (&gt; 100,000 per year).</P>
<P>
<B>Country: </B>Colombia</P>
<P>
<B>Funding: </B>Universidad de Antioquia and Dirección Seccional de Salud de Antioquia, Medellin, Colombia</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size estimated to detect a minimum 15% difference in therapeutic efficacy and corrected for 20 drop-outs per arm</LI>
<LI>Parasite clearance by day 28: confirmed in 97% by day 3 and in 100% by day 28</LI>
<LI>Primaquine was administered concurrently with chloroquine (mentioned in this report and stated in another report from the same study group (<LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>))</LI>
<LI>No children were included in this trial</LI>
<LI>Chloroquine and primaquine treatments were supervised</LI>
<LI>Duration of follow-up: six months</LI>
<LI>Patients were followed-up by active surveillance at the clinic or their homes for six months to identify relapses; microscopy of thick blood smears taken at 60, 120, and 180 days</LI>
<LI>Recurrences confirmed by microscopy were given the same course of treatment (for up to two more times) as at enrolment. If parasitaemia reappeared a third time, PQ (plus a standard dose of CQ), 15 mg/day for 28 days, was given</LI>
<LI>Trial not prospectively registered</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 09:31:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<CHAR_METHODS MODIFIED="2013-10-03 09:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, parallel-group, open-label, four-armed, active controlled trial</P>
<P>
<B>Period of study:</B> September 2003 to September 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants:</B> 188</P>
<P>Patients that attended the local health clinics with acute symptomatic vivax malaria and a positive<BR/>thick blood smear during the period of the study were eligible.</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Age &gt; 2 years</LI>
<LI>
<I>P. vivax</I> parasitaemia of &gt;1000 asexual forms/L</LI>
<LI>Wllingness to participate</LI>
<LI>A normal quantitative G6PD screening test</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Pregnant women</LI>
<LI>Associated acute infectious diseases</LI>
<LI>History of antimalarials intake during the previous two weeks</LI>
<LI>Presence of diarrhoea or vomiting (&gt; 5 episodes in 24 hours)</LI>
<LI>Symptoms or signs of severe malaria (according to <LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>),</LI>
<LI>Hypersensitivity to antimalarials</LI>
<LI>Severe under-nutrition</LI>
<LI>Intake of any antimalarial different from those provided by the researchers</LI>
<LI>Failure to attend follow-up appointments</LI>
<LI>Treatment failure during the primary episode (28 days of follow-up)</LI>
<LI>Consent withdrawal</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>CQ + PQ STD 3 days (equivalent of standard total dose of 3.5 mg/kg but administered over 3 days; 1.17 mg/kg day for 3 days) (N = 65)</LI>
</OL>
<P>
<B>Control: </B>
</P>
<OL>
<LI>CQ + PQ 14 days (standard total dose of 3.5 mg/kg administered over 14 days; 0.25 mg/kg day for 14 days) (N = 68)</LI>
</OL>
<P>All participants received chloroquine as recommended by the Colombian health authorities (10mg/kg day on day 1 and 7.5mg/kg day on days 2 and 3)</P>
<P>
<B>Not used for quantitative synthesis in the review</B>*<B>: </B>
</P>
<OL>
<LI>CQ + PQ 71% STD 3 days (2.5 mg/kg, which is lower than the total standard dose and given over 3 days, (i.e. 0.83 mg/kg day for 3 days) (N = 28)</LI>
<LI>CQ + PQ 50% STD 3 days (1.75 mg/kg, which is lower than the standard total dose and administered over 3 days; i.e. 0.58 mg/kg day for 3 days) (N = 27)</LI>
</OL>
<P>* Trial authors stopped recruitment to these arms early, after recruiting only around half the estimated sample, due to lack of efficacy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:31:06 +0100" MODIFIED_BY="[Empty name]">
<P>Recurrence (defined as any <I>P. vivax</I> parasitaemia (in 200 oil-immersion fields on microscopy) observed after day 28 on patients with adequate treatment response) and during follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:31:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Local malaria clinics in two malaria endemic (El Bagre; gold-mining and Turbo: banana plantations) municipalities; malaria transmission perennial and unstable; tropical strains of <I>P. vivax </I>(from report); chloroquine-sensitive <I>P. vivax</I> accounted for 70% to 80 % of the malaria cases in the country</P>
<P>
<B>Country: </B>Colombia</P>
<P>
<B>Funding: </B>Universidad de Antioquia and Dirección Seccional de Salud de Antioquia, Medellin, Colombia</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size estimated to detect a minimum 15% difference in therapeutic efficacy and increased by 30% to correct for drop-outs per arm</LI>
<LI>Parasite clearance by day 28: confirmed in 100% by day 28</LI>
<LI>Primaquine was administered concurrently with chloroquine</LI>
<LI>Children &gt; 2 years old were included in this trial</LI>
<LI>Chloroquine and primaquine treatments were supervised</LI>
<LI>Duration of follow-up: four months</LI>
<LI>Patients were followed up by active surveillance at the clinic or their homes for six months to identify relapses; microscopy of thick blood smears taken at 60 and 120 days</LI>
<LI>Recurrences confirmed by microscopy were given the same course of treatment (for up to two more times) as at enrolment. If parasitaemia reappeared a third time, PQ (plus a standard dose of CQ), 15 mg/day for 28 days, was given</LI>
<LI>Recruitments into the two low dose three days of primaquine arms were stopped after recruiting half the estimated sample (28 and 27 patients respectively), due to the high number of recurrences observed (we did not use data from these arms for meta-analysis)</LI>
<LI>Trial not prospectively registered</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 09:32:18 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-Ganguly-2013">
<CHAR_METHODS MODIFIED="2013-10-03 09:31:54 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>Randomized, parallel-group, open-label, two-armed trial</P>
<P>
<B>Period of study:</B> December 2011 to August 2012</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:31:54 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Participants:</B> 250</P>
<P>All patients attending the clinic who were screened for malaria parasite presence, by examining thick and thin smears of peripheral blood followed by Giemsa staining, were eligible.</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Age &gt; 6 months</LI>
<LI>Axillary temperature &gt; 37.5 °C, or history of fever during 48 hours before recruitment</LI>
<LI>
<I>P. vivax </I>mono-infection, confirmed by presence of negative HRP-II test, with parasitaemia of 1000&#8211;100000 parasites/&#956;L blood</LI>
<LI>No anti-malarial treatment during the preceding four weeks</LI>
<LI>Absence of severe malaria</LI>
<LI>Able to swallow oral medicine</LI>
<LI>No history of hepatic or kidney diseases</LI>
<LI>Ability and willingness to comply with study protocol and visit schedule</LI>
<LI>Written informed consent provided by patient or guardian</LI>
</OL>
<P>
<B>Exclusion criteria: </B>
</P>
<OL>
<LI>Patients who repeatedly vomited their study medicines</LI>
<LI>Severe malnutrition by WHO standards</LI>
<LI>Contraindication to study medication</LI>
<LI>Pregnancy</LI>
<LI>Other febrile conditions</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-26 19:48:11 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Intervention:</B>
</P>
<P>CQ (25 mg/kg base) over 3 days + PQ (0.25 mg/kg) for 14 days (N = 125)</P>
<P>
<B>Control:</B>
</P>
<P>CQ (25 mg/kg base) over 3 days (N = 125)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:31:54 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Outcomes used in this review:</B>
</P>
<OL>
<LI>Adequate clinical and parasitological response (APCR) at day 42 (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>)</LI>
<LI>Adverse events</LI>
</OL>
<P>
<B>Outcomes not used in quantitative synthesis in this review:</B>
</P>
<OL>
<LI>Early treatment failure (ETF)</LI>
<LI>Late clinical failure (LCF)</LI>
<LI>Late parasitological failure (LPF)</LI>
<LI>PCR-corrected APCR at day 42</LI>
<LI>Genus and species specific PCR for polymorphisms of pvmdr1 and 58 pvcrt-0 genes by DNA sequencing</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:32:18 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Setting: </B>Malaria clinic attached to the protozoology unit, Calcutta School of Tropical Medicine. <I>P. falciparum</I> and <I>P. vivax </I>infection are equally predominant; <I>P. vivax </I>is perennial; <I>P. falciparum</I> is seasonal with an annual peak from August to December</P>
<P>
<B>Country: </B>India</P>
<P>
<B>Funding: </B>Department of Health and Family Welfare, Government of West Bengal</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>This trial primarily aimed to evaluate the sensitivity of chloroquine in eliminating blood stage vivax infection</LI>
<LI>Sample size estimation not reported</LI>
<LI>Mixed infections were ruled out by<I> P. vivax</I> specific pLDH 169 and HRP-II (SD Bio Standard Diagnostics Pvt. Ltd., Gurgaon, India)</LI>
<LI>G6PD level of all recruited patients were determined qualitatively using G6PDH Hemopak kit; no G6PD deficiency identified</LI>
<LI>Parasite clearance by day 28: confirmed in 100% by day 28</LI>
<LI>Primaquine and chloroquine were administered sequentially</LI>
<LI>Children &gt; 6 months old were eligible, but age of included participants ranged from 5 years to 65%; approximately 20% were aged 5 to 15 years</LI>
<LI>Chloroquine treatments were supervised in all and primaquine was supervised for first 7 days and by checking empty blister packs till day 14</LI>
<LI>Duration of follow-up: 42 days</LI>
<LI>Patients were followed up by active surveillance at the clinic or their homes 1, 2, 3, 7, 14, 21, 28, 35 and 42 days after initiation of treatment and were examined both clinically and parasitologically</LI>
<LI>PCR-corrected APCR not used as an outcome for this update, due to doubtful validity of the PCR method used to reliably differentiate relapse and re-infection</LI>
<LI>Trial was prospectively registered in the Clinical Trials Registry- India: Registration No. <LINK REF="STD-CTRI_x002f_2011_x002f_09_x002f_002031" TYPE="STUDY">CTRI/2011/09/002031</LINK>
</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:11:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gogtay-1999">
<CHAR_METHODS MODIFIED="2013-10-08 11:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel group, randomized, open-label, active controlled, observer-blinded, trial with three intervention arms</P>
<P>
<B>Period of study: </B>October 1997 to September 1998</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 11:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants:</B> 244</P>
<P>Patients residing within 12 km of the hospital and referred for suspected malaria were eligible.</P>
<P>
<B>Inclusion criteria: </B>
</P>
<OL>
<LI>Smear positive for <I>P. vivax</I>
</LI>
<LI>Willing to be hospitalized, followed up and comply with study instructions</LI>
</OL>
<P>
<B>Exclusion criteria: </B>
</P>
<OL>
<LI>Mixed infections</LI>
<LI>G6PD deficiency participants</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 11:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Interventions:</B>
</P>
<OL>
<LI>CQ 25 mg/kg for 3 days (N = 83)</LI>
<LI>CQ 25 mg/kg for 3 days plus PQ 0.25 mg/kg for 14 days (N = 81)</LI>
</OL>
<P>
<B>Control:</B>
</P>
<OL>
<LI>CQ 25 mg/kg for 3 days plus PQ 0.25 mg/kg for 5 days (N = 80)</LI>
</OL>
<P>CQ 10mg/kg on day and 5 mg/kg on day 2 and day 3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 11:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes </B>
</P>
<P>1. Number of participants relapsing during the 6-month follow-up period<BR/>2. Adverse events</P>
<P>
<B>Outcomes not available in report:</B>
</P>
<P>Parasitemia between 6 months and one year follow-up (specified in methods)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 11:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setitng:</B> K.E.M. Hospital in Mumbai; Malaria endemicity: 80% of infections in Mumbai were due to vivax malaria at the time of the report. Tropical strains; low transmission setting. Chloroquine-sensitive parasite at the time of the report.</P>
<P>
<B>Country:</B> India</P>
<P>
<B>Funding: </B>Not stated. Drugs provided free of cost by municipal authorities</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>No sample size estimation reported</LI>
<LI>Parasite clearance by day 28: Confirmed in 100% by day 4 and remained smear negative till day 29</LI>
<LI>Primaquine was administered after chloroquine on day 4</LI>
<LI>No children &lt; 16 years were included in this trial</LI>
<LI>Chloroquine and primaquine treatments were supervised</LI>
<LI>Duration of follow-up: Six months; 60/83 (72%) in CQ only arm, 62/80 (78%) in the CQ + PQ 5 days arm, and 63/81 (78%) in the CQ + PQ 14-day arm completed six months of follow-up; data from period 6 months to one year not available in the report.</LI>
<LI>Patients were followed-up at the hospital monthly for a year or when they had fever; in some instances the smear technician visited their homes for six months to identify relapses; microscopy of thick blood smears taken monthly from all participants at monthly clinic visits</LI>
<LI>Recurrences confirmed by microscopy were given CQ + PQ for 14 days</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:11:31 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-Kim-2012">
<CHAR_METHODS MODIFIED="2013-07-25 19:33:18 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>Randomized, parallel group, open-label, three arm trial</P>
<P>
<B>Period of study: </B>
</P>
<P>April 2003 to September 2004 (recruitment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:33:12 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Participants: </B>151</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Acute uncomplicated vivax malaria, confirmed by positive blood smear with asexual forms of <I>P. vivax</I>
</LI>
<LI>Male or female, aged from 36 months to 65 years old, inclusive</LI>
<LI>Fever defined as <U>&gt;</U> 37.5°C tympanic temperature or a history of fever within the last 24 hours</LI>
<LI>Written informed consent (by legally acceptable representative in case of children)</LI>
<LI>Willingness and ability of the patients/guardians to comply with the study protocol for the duration of the study</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Signs of severe/complicated malaria (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>)</LI>
<LI>Haematocrit &lt; 25% or haemoglobin (Hb) &lt; 8 g/dL at enrolment</LI>
<LI>Acute illness other than malaria requiring treatment</LI>
<LI>For females: pregnancy, breast feeding</LI>
<LI>Patients who have received anti-malarial treatment within the previous 7 days</LI>
<LI>History of allergy or known contraindication to study drugs</LI>
<LI>G6PD deficiency: patients who are deficient on spot testing were not allocated to the two primaquine groups</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:33:21 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Interventions:</B>
</P>
<P>1. Chloroquine (25 mg base/kg total) only; 10 mg/kg on day 1, 10 mg/kg on day 2 then 5 mg/kg on day 3 (N = 50)</P>
<P>2. Chloroquine (25 mg base/kg total as above) followed by primaquine 0.25 mg base/kg/day for 5 days - total dose 1.25 mg base/kg (75 mg in an adult) (doses were unsupervised) (N = 59)</P>
<P>
<B>Control: </B>
</P>
<P>3. Chloroquine (25mg base/kg total) followed by primaquine 0.25mg base/kg/day for 14 days - total dose 3.5 mg base/kg (210 mg in an adult) (doses were unsupervised) (N = 42)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:33:21 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Outcomes used in quantitative synthesis</B>
</P>
<OL>
<LI>Recurrence rate of vivax malaria over 15 months</LI>
<LI>Serious adverse events</LI>
</OL>
<P>
<B>Outcomes reported but not used in quantitative synthesis</B>
</P>
<OL>
<LI>Parasite clearance time assessed by microscopy</LI>
<LI>Fever clearance time (the time taken for the tympanic temperature to fall below 37&#730;C and remain there for at least 24 hours)</LI>
<LI>Genotype assessments</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:11:31 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Setting: </B>Calcutta School of Tropical Medicine. Of around 6,000 malaria cases seen annually, approximately 65% are caused by <I>P. vivax.</I> Patients were mainly from urban, and a few were from peri-urban Kolkata.</P>
<P>
<B>Country: </B>India</P>
<P>
<B>Source of funding: </B>
</P>
<UL>
<LI>Wellcome Trust-Mahidol University, Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain- Wellcome Trust (UK) (reference No. 066439/2/01/2);</LI>
<LI>National Science and Technology Development Agency, the office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative, and Wellcome Trust Intermediate Fellow [grant 080867/Z/06/Z] to Mallika Imwong.</LI>
</UL>
<P>
<B>Comments: </B>
</P>
<UL>
<LI>Trial authors based sample size estimation on an assumption that relapse rates would be 30% in the chloroquine only group and 4% in the 14-day primaquine group, and allowed for 20% loss to follow-up or incomplete data; trial authors aimed for a total of 150 participants with 50 in each arm.</LI>
<LI>Trial authors generated computer generated randomization sequences in the ratio 1:1:1 and allocation was through sequentially numbered opaque envelopes containing the randomization codes; this does not explain the unequal numbers allocated (CQ n = 50; CQ plus PQ 5 days n = 59; CQ plus PQ 14 days n = 42)</LI>
<LI>Parasite clearance by day 28: confirmed in 100%</LI>
<LI>Primaquine was administered after chloroquine on day 4</LI>
<LI>Children &lt; 16 years were included in this trial</LI>
<LI>Although G6PD deficiency was an exclusion criterion, two people in the CQ only arm were reported to have this deficiency</LI>
<LI>Chloroquine treatment was supervised. Primaquine was supervised for the first dose only</LI>
<LI>Duration of follow-up: 15 months</LI>
<LI>Patients were seen daily until afebrile then weekly for one month and thereafter every one to two months for 15 months.</LI>
<LI>If vivax malaria recurred blood was taken for parasite genotyping and comparison with the original infection, and patients were treated with chloroquine followed by primaquine 0.25 mg base/kg daily for 21 days.</LI>
<LI>Study used eight microsatellite and three antigenic markers were initially genotyped in 90 samples and three polymorphic microsatellite and antigenic molecular markers found sensitive to PCR amplification at low parasite densities were used for subsequent analyses for 39 of 47 recurrences. Only three markers were used in the remaining eight recurrences due to insufficient DNA to use all six markers.</LI>
<LI>Trial protocol available as supplementary file with published report</LI>
<LI>Contact author named in trial registration document and in the trial report were contacted for additional information- no reply was obtained till submission of this review update.</LI>
</UL>
<P>
<B>Registration Number:</B> ISRCTN14027467</P>
<P>This trial was registered retrospectively: date applied: 12/11/2011; date registered: 16/11/2011</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 09:34:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leslie-2004">
<CHAR_METHODS MODIFIED="2013-10-03 09:34:28 +0100" MODIFIED_BY="[Empty name]">
<P>Cluster-randomized, placebo and active controlled, three armed trial: unit of allocation = family; unit of analysis = individuals</P>
<P>
<B>Period of study: </B>June 2000 to August 2001</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:34:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants: </B>595</P>
<P>
<B>Inclusion criteria: </B>
</P>
<OL>
<LI>Clinical malaria cases with blood smear positive for <I>P. vivax</I>
</LI>
<LI>Temperature &gt; 37.5 ºC or recent history of fever</LI>
</OL>
<P>
<B>Exclusion criteria: </B>
</P>
<OL>
<LI>G6PD deficiency</LI>
<LI>Age &lt; 3 years</LI>
<LI>Pregnancy</LI>
<LI>Severe anaemia</LI>
<LI>Mixed infections</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Interventions</B>
</P>
<OL>
<LI>CQ (3 days) plus PQ (14 days): unsupervised (N = 173; 87 families)</LI>
</OL>
<P>
<B>Control:</B>
</P>
<OL>
<LI>CQ (3 days) and placebo: (N = 212; 98 families)</LI>
</OL>
<P>
<B>Not used in quantitative synthesis in this review</B>
</P>
<OL>
<LI>CQ* (3 days) plus PQ# (14 days); supervised (N = 210; 105 families)</LI>
</OL>
<P>CQ dose: 25 mg/kg<BR/>PQ dose: 0.25 mg/kg</P>
<P>*data from unsupervised primaquine and placebo arms used as they were considered comparable since the placebo arm was not supervised; and since estimates did not differ significantly between supervised and unsupervised arms</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-15 10:28:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Number of participants relapsing (confirmed by microscopy) during the 9-month follow-up period</P>
<P>2. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:34:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Adizai (Afghan) refugee camp, North-West Frontier Province. Malaria endemicity: highly endemic for <I>P. vivax </I>and <I>P. falciparum </I>malaria with active transmission from June to November</P>
<P>
<B>Country:</B> Pakistan</P>
<P>
<B>Funding: </B>European Commission (DG1), UNHCR, and WHO/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases; Department for International Development (DFID); Gates Foundation</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Trial authors did not report any sample size estimation</LI>
<LI>They did not confirm parasitic clearance after intervention</LI>
<LI>Included children &gt; 3 years and 38% of sample were aged 3 to 5 years, and 55% below the age of 10 years</LI>
<LI>G6PD deficiency was an exclusion criterion but 10/474 individuals tested (2.1%) were G6PD deficient</LI>
<LI>Chloroquinne and primaquine were given sequentially</LI>
<LI>The trial compared outcomes in two arms CQ + PQ for 14 days given unsupervised treatment by direct observation, and one arm of PQ 14 days that was supervised. Unsupervised group and those on placebo may have been blinded; supervised group was not blinded</LI>
<LI>Duration of follow-up: nine months. Patients were followed up by passive case detection, but all healthcare was provided in-camp, and was free. Follow-up completed by &gt; 90% of 595 participants enrolled from 290 families</LI>
<LI>Data analyzed in report by random-effects logistic regression: unit of analysis was the participant and adjusted for clustering</LI>
<LI>Data used in meta-analysis were adjusted odds ratios and 95% CIs for relapse at 9 months for unsupervised primaquine group (n = 34/210; 19.7%) and in placebo group (n = 86/212; 40.6%). Data for supervised primaquine groups not used; results not notably different from unsupervised group compared to placebo</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:12:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leslie-2008">
<CHAR_METHODS MODIFIED="2013-10-08 11:12:16 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel-group, placebo and active controlled, cluster and individually randomized, open-label, clinical trial</P>
<P>
<B>Period of study: </B>13 July 2006 to 17th June 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants:</B> 200</P>
<P>
<B>Inclusion criteria</B>
</P>
<OL>
<LI>Patients diagnosed with <I>P. vivax</I> parasitaemia at study BHUs</LI>
<LI>Patients over 3 years of age</LI>
<LI>Patients with G6PD deficiency to a sub-study, safety trial</LI>
<LI>Patients without G6PD deficiency to all other groups.</LI>
</OL>
<P>
<B>Exclusion criteria</B>
</P>
<OL>
<LI>Children under the age of three</LI>
<LI>Pregnant / breast feeding women</LI>
<LI>Patients with severe clinical anaemia (&lt;7 g/dL)</LI>
<LI>Patients with <I>P. falciparum </I>or mixed infections</LI>
<LI>Patients unavailable for the duration of follow-up</LI>
<LI>Patients who have taken any antimalarial drugs in the 2 weeks prior to consultation</LI>
<LI>Patients with concomitant infections or whose general health is considered too poor</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>CQ 3 days followed by supervised 8 week PQ treatment (45 mg / week) (N = 74)</LI>
</OL>
<P>
<B>Controls:</B>
</P>
<OL>
<LI>CQ 3 days with supervised weekly placebo for 8 weeks (-ve control group) (N = 71)</LI>
<LI>CQ 3 days followed by supervised 14-day primaquine treatment (+ ve control group) &#8211; excluding G6PD deficient patients (N = 55)</LI>
</OL>
<P>CQ (600 mg) total dose in adults was 1200 mg over three days in adults</P>
<P>PQ total dose in adults was (22.5 mg base) 325 mg for 14-day PQ group; and (45 mg for 8 doses) 360 for 8-week PQ</P>
<P>Additional intervention: health education messages and strong advice to complete the course.</P>
<P>
<B>Safety arm:</B> Quote from study protocol: "In addition a safety arm will be used for G6PD deficient patients; this will be used to compare HB with group 3 (above). This will be an 8 week regimen, administered by direct observation, and will receive close monitoring for signs of haemolysis".</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome:</B>
</P>
<OL>
<LI>Treatment failure (defined as the occurrence of any episode of microscopically-confirmed vivax malaria over the 11 months)</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>Any notable adverse events</LI>
</OL>
<P>
<B>Outcomes not used for quantitative synthesis in this review:</B>
</P>
<OL>
<LI>Number of subsequent episodes during and up to 2 weeks post-treatment</LI>
<LI>Anaemia rates during and up to 2 weeks post-treatment</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Afghan refugee settlements in<B> </B>Adizai, Baghicha and Khagan villages, close to Peshawar, Northwest Frontier Province. Seasonal malaria transmission, predominantly vivax. Chloroquine and primaquine sensitive parasites; study conducted in a period with low transmission intensities (75% reduction compared to studies in the same camps five years previously). Relapse patterns are as with tropical strains, early, frequent relapses, mostly in the early months (but also later)</P>
<P>
<B>Country: </B>Pakistan</P>
<P>
<B>Funding: </B>UNDP/World Bank/WHO Special Program for Research in Tropical Diseases; Gates Malaria Partnership</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Trial authors revised the sample size estimation before the start of the trial following an unscheduled interim analysis conducted in June/July 2006 due to low transmission and slow recruitment. They reduced sample size from 212 to 66 per treatment arm and aimed for a 25% difference between treated and non-treated arms. The trial was not powered to show equivalence or non-inferiority between the 14-day or 8 weekly-dose primaquine arms.</LI>
<LI>Parasitic clearance after intervention was not confirmed</LI>
<LI>Included children &gt; 3 years of age</LI>
<LI>All treatments were supervised according to the regimen</LI>
<LI>Chloroquine and primaquine were given sequentially</LI>
<LI>Duration of follow-up nine months after the 8 week treatments (11 months from start): follow-up was by active surveillance (being visited in their homes every two weeks) and passively on presentation at the basic health centre.</LI>
<LI>Only people with fever suggestive of malaria had blood smears taken</LI>
<LI>Blood smears were read by two independent microscopists blind to other results (not clear if blind to allocation)</LI>
<LI>For practical reasons, trial authors used two randomization methods. In Baghicha and Khagan villages, they randomized patients by household, whereas in Adizai randomization was at the individual (since this site was added later, and was not in the protocol). In addition, those with G6PD deficiency were not randomized, but assigned to the 8-week PQ group in order to follow closely to assess safety.</LI>
<LI>Numbers enrolled to 8-week placebo and 8-week PQ were similar (N = 71 and N = 74) but were less in 14-day PQ (N = 55), due to exclusion of G6PD deficient persons from this arm</LI>
<LI>The numbers randomized to each arm of this three-armed trial were unequal with the majority recruited from Adizai (Adizai 100 (50.0%), Baghicha 79 (39.5%), and Khagan 21 (10.5%)</LI>
<LI>The numbers recruited to each of the three arms also differed by trial site with Adizai contributing 38% of those given 8 week placebo, 54.5% of those given 14-day primaquine, and 58% of those given 8 weeks of primaquine; and Khagan contributing the least to the three arms (14%, 3.6% and 10.8%, respectively).</LI>
<LI>The percentage of people who were anaemic at enrolment (haemoglobin &lt;10 g/dL) were also unequally distributed (14.1% of those on 8-week placebo; 3.6% of those given 14 days of primaquine and 9.5% of those treated with 8 weekly doses of primaquine).</LI>
<LI>People from Adizai village also had the largest proportion of treatment failures over 11 months of follow-up, particularly in those on placebo (67%, versus 3.3% on 14 days primaquine, and 9.3% on 8 weeks of primaquine). Baghicha also experienced treatment failures on 8-week placebo following chloroquine (12.1%), while none of the people in the other treatment arms relapsed. There were no treatment failures in Khagan for those on any of the three interventions.</LI>
<LI>Loss to follow-up and withdrawals were 5% of those enrolled and occurred by 8 weeks (3 with 8-week placebo (4.2%), 1 with 14-day PQ (1.8%), and 6 with 8-week PQ (8.1%)); no losses over nine months of follow-up</LI>
<LI>Results reported were odds ratios adjusted for clustering and for sites, age and sex</LI>
<LI>Trial registration number: ClinicalTrials.gov NCT00158587</LI>
<LI>Numbers enrolled to 8-week placebo and 8-week PQ were similar (N = 71 and 74) but were less in 14-day PQ (N = 55), due to exclusion of G6PD deficient persons from this arm</LI>
<LI>The numbers randomized to each arm of this three-armed trial were unequal with the majority recruited from Adizai (Adizai 100 (50.0%), Baghicha 79 (39.5%), and Khagan 21 (10.5%).</LI>
<LI>The numbers recruited to each of the three arms also differed by trial site with Adizai contributing 38% of those given 8 week placebo, 54.5% of those given 14-day primaquine, and 58% of those given 8 weeks of primaquine; and Khagan contributing the least to the three arms (14%, 3.6% and 10.8%, respectively).</LI>
<LI>The percentage of people who were anaemic at enrolment (haemoglobin &lt;10 g/dL) were also unequally distributed (14.1% of those on 8-week placebo; 3.6% of those given 14 days of primaquine and 9.5% of those treated with 8 weekly doses of primaquine).</LI>
<LI>People from Adizai village also had the largest proportion of treatment failures over 11 months follow-up, particularly in those on placebo (67%, versus 3.3% on 14 days primaquine, and 9.3% on 8 weeks of primaquine). Baghicha also experienced treatment failures on 8-week placebo following chloroquine (12.1%), while none of the people in the other treatment arms relapsed. There were no treatment failures in Khagan for those on any of the three interventions</LI>
<LI>Loss to follow-up and withdrawals were 5% of those enrolled and occurred by 8 weeks (3 with 8-week placebo (4.2%), 1 with 14-day PQ (1.8%), and 6 with 8-week PQ (8.1%)); no losses over nine months follow-up</LI>
<LI>Results reported were odds ratios adjusted for clustering and for sites, age and sex</LI>
<LI>Trial registration number: ClinicalTrials.gov NCT00158587</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:14:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pukrittayakamee-1994">
<CHAR_METHODS MODIFIED="2013-10-08 11:14:13 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel group, randomized controlled, open-label trial with three intervention arms</P>
<P>
<B>Period of study:</B> 1992 to 1993</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-08 11:14:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number randomized:</B> 85 males</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Confirmed<I> P. vivax</I> infection</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>History of taking any antimalarials within the past 48 h;</LI>
<LI>Urine positive for sulphonamides or 4-aminoquinoline;</LI>
<LI>G6PD deficiency</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:37:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>CQ (3 days): N = 30</LI>
</OL>
<P>
<B>Control: </B>
</P>
<OL>
<LI>CQ (3 days) plus PQ (14 days): N = 25</LI>
</OL>
<P>
<B>Not included in quantitative synthesis in this review</B>
</P>
<OL>
<LI>PQ only (not included in review): N = 30</LI>
</OL>
<P>CQ dose: 25 mg/kg<BR/>PQ dose: 0.25 mg/kg</P>
<P>
<B>Co-interventions:</B>
</P>
<P>Oral acetaminophen for fever<B> </B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-04 13:53:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Number of participants relapsing during the 2-month follow-up period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:14:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Location: </B>Bangkok Hospital for Tropical Diseases; Malaria endemicity: very high endemicity with multiple-drug resistant <I>P. falciparum </I>malaria; no local transmission in Bangkok</P>
<P>
<B>Country:</B> Thailand</P>
<P>
<B>Funding:</B> Welcome-Mahidol University-Oxford Tropical Medicine Research programme, via the Welcome Trust, UK</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size estimation not reported</LI>
<LI>All participants were hospitalised during treatment; 71/85 participants were hospitalised &gt; 30 days</LI>
<LI>Age range: 15 to 50 years</LI>
<LI>Parasitic clearance by day 28 was confirmed</LI>
<LI>Chloroquine and primaquine were given sequentially</LI>
<LI>Duration of follow-up: 2 months. Patients were asked to return for weekly check- up or if they developed fever.</LI>
<LI>Inclusion of all randomized participants in final analysis: 61 of the 85 (71%) enrolled participants returned for follow-up after 2 months (no significant difference between groups)</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:14:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rajgor-2003">
<CHAR_METHODS MODIFIED="2012-05-18 04:24:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, parallel group, single-blinded, trial</P>
<P>
<B>Period of study:</B> July 1998 to April 2000</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:38:09 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Participants:</B> 273</P>
<P>Eligible were 690 people smear positive for vivax malaria</P>
<P>
<B>Inclusion criteria: </B>
</P>
<OL>
<LI>Age &gt; 16 years</LI>
<LI>Smear-positive for asexual forms of <I>P. vivax</I>
</LI>
<LI>Normal G6PD status</LI>
<LI>Consented to trial and follow-up</LI>
<LI>Haemoglobin &gt; 10 g/dL</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>&lt; 16 years</LI>
<LI>G6PD deficiency</LI>
<LI>Pregnant and lactating women</LI>
<LI>Mixed infections</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:38:09 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Intervention:</B>
</P>
<P>1. CQ (3 days): N = 142</P>
<P>
<B>Control:</B>
<BR/>2. CQ (3 days) plus PQ (14 days): N =131</P>
<P>CQ dose: 25 mg/kg<BR/>PQ dose: 15 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:38:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Outcome used in this review</B>
</P>
<P>1. Number of participants relapsing during the 6-month follow-up period</P>
<P>
<B>Outcome reported but not used in this review</B>
</P>
<P>1. Number of participants relapsing corrected for new infections with PCR (in people given PQ)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:14:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Seth GS Medical College &amp; KEM Hospital, Mumbai, Malaria endemicity: 80% of infections are due to <I>P. vivax; </I>low transmission intensity</P>
<P>
<B>Country:</B> India</P>
<P>
<B>Funding:</B> Not stated</P>
<P>
<B>Comments: </B>
</P>
<UL>
<LI>Sample size estimation not reported</LI>
<LI>No children &lt; 16 were recruited</LI>
<LI>Interventions were supervised</LI>
<LI>Chloroquine and primaquine were given sequentially</LI>
<LI>Parasitic clearance after intervention was not confirmed</LI>
<LI>Duration if follow-up: six months. Participants were asked to return for follow-up every month or if they developed fever</LI>
<LI>PCR (single strand conformational polymorphism) data were not used as an outcome for this review update due to doubtful validity in differentiating relapse from re-infection</LI>
<LI>Inclusion of all randomized participants in final analysis: 41/142 (28.8%) in chloroquine group and 28/131 (21.4 %) in the chloroquine plus 14-day primaquine group dropped out before 6 months (not statistically significant)</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:14:45 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Rowland-1999a">
<CHAR_METHODS MODIFIED="2012-05-18 05:06:20 +0100" MODIFIED_BY="Harriet MacLehose">
<P>Randomized, parallel group, placebo-controlled, assessor-blinded, trial</P>
<P>
<B>Period of study:</B> August 1997 to June 1998</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:39:15 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Participants: </B>200</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Positive for <I>P. vivax </I>with temperature &gt; 37.5 ºC</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Mixed infections</LI>
<LI>Pregnant women</LI>
<LI>G6PD deficiency</LI>
<LI>Severe anaemia</LI>
<LI>&lt; 3 years</LI>
<LI>Very elderly</LI>
<LI>Recent antimalarial intake</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:39:28 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Intervention:</B>
</P>
<P>CQ (3 days) plus placebo: N = 100</P>
<P>
<B>Control:</B>
<BR/>CQ (3 days) plus PQ (14 days): N = 100</P>
<P>CQ dose: 25 mg/kg<BR/>PQ dose: 0.25 mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:39:40 +0100" MODIFIED_BY="Harriet MacLehose">
<OL>
<LI>Number of participants relapsing during 12-month follow-up period</LI>
<LI>Adverse events</LI>
</OL>
<P>
<B>Outcomes not used in quantitative synthesis in this review:</B>
</P>
<OL>
<LI>Parasitaemic episodes during the 12-month follow-up period</LI>
<LI>28-day <I>in-vivo</I> test on <I>P. vivax</I> infection</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:14:45 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Setting:</B> Adizai refugee camp; Malaria endemicity: predominant species is <I>P. vivax</I>; Tropical strains, seasonal with high transmission intensity</P>
<P>
<B>Country:</B> Afghanistan</P>
<P>
<B>Funding:</B> European Commission (DGI); UNHCR; Department for International Development, UK; (DFID); HealthNet International</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size estimation not reported</LI>
<LI>Children &gt; three years included: average age 11 years to 12 years</LI>
<LI>G6PD deficiency was an exclusion criterion, but the report states that G6PD deficient persons tolerated the 14-day treatment well</LI>
<LI>Parasitic clearance by day 28 was confirmed</LI>
<LI>Medications were supervised</LI>
<LI>Chloroquine and primaquine were administered sequentially</LI>
<LI>Follow-up: 12 months; data analyzed were number of participants relapsing over 12 months; inclusion of all randomized participants in final analysis: no losses (100%)</LI>
<LI>Relpases treated with same intervention as randomized</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:14:55 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Rowland-1999b">
<CHAR_METHODS MODIFIED="2012-05-18 05:07:49 +0100" MODIFIED_BY="Harriet MacLehose">
<P>Randomized, parallel group, placebo-controlled, assessor-blinded, trial</P>
<P>
<B>Period of study:</B> 1996 to 1997</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:40:45 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Participants:</B> 500</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Positive for <I>P. vivax </I>with temperature &gt; 37.5 ºC</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Mixed infections</LI>
<LI>Pregnant women</LI>
<LI>G6PD deficiency</LI>
<LI>Severe anaemia</LI>
<LI>&lt; 3 years</LI>
<LI>Very elderly</LI>
<LI>Recent antimalarial intake</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:40:53 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Intervention:</B>
</P>
<P>CQ (3 days) plus placebo: N = 250</P>
<P>
<B>Control:</B>
<BR/>CQ (3 days) plus PQ (5 days): N = 250</P>
<P>CQ dose: 25 mg/kg<BR/>PQ dose: 0.25 mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:40:53 +0100" MODIFIED_BY="Harriet MacLehose">
<OL>
<LI>Number of participants relapsing during 12-month follow-up period</LI>
<LI>Adverse events</LI>
</OL>
<P>
<B>Outcomes not used in quantitative synthesis in this review:</B>
</P>
<OL>
<LI>Parasitaemic episodes during the 12-month follow-up period</LI>
<LI>28-day i<I>n-vivo</I> test on <I>P. vivax</I> infection</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:14:55 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Setting:</B> Adizai refugee camp; Malaria endemicity: predominant species is <I>P. vivax</I>
</P>
<P>
<B>Country:</B> Afghanistan</P>
<P>
<B>Funding:</B> European Commission (DGI); UNHCR; Depratment for International Development, UK; (DFID); HealthNet International</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size estimation not reported</LI>
<LI>Children aged &gt; 3 years included: average age 10 years to 10.4 years</LI>
<LI>G6PD deficiency was an exclusion criterion, but the report states that G6PD deficient persons tolerated the five day treatment well.</LI>
<LI>Parasitic clearance by day 28 was confirmed</LI>
<LI>Medications were supervised</LI>
<LI>Chloroquine and primaquine were administered sequentially</LI>
<LI>Follow-up: 12 months; data analyzed were number of participants relapsing over 12 months; Inclusion of all randomized participants in final analysis: no losses (100%)</LI>
<LI>Relapses treated with same intervention as randomized</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:15:01 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Villalobos-2000">
<CHAR_METHODS MODIFIED="2012-05-18 05:18:29 +0100" MODIFIED_BY="Harriet MacLehose">
<P>Randomized, parallel-group, active-controlled trial</P>
<P>
<B>Period of study: </B>April to December 1998</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:42:42 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Participants:</B> 79</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>
<I>P. vivax</I> uncomplicated malaria;</LI>
<LI>&gt; 12 years;</LI>
<LI>No history of antimalarials for the last 15 days;</LI>
<LI>No history of haemolytic anaemia</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Pregnant women</LI>
<LI>Negroid</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:42:22 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Intervention:</B>
</P>
<P>CQ* (5 days) plus PQ (5 days): N = 40</P>
<P>
<B>Control:</B>
</P>
<P>CQ* (3 days) plus PQ (14 days): N = 39</P>
<P>
<BR/>
</P>
<P>CQ total dose: 25 mg/kg<BR/>PQ dose: 0.25 mg/kg</P>
<P>*Used different duration of CQ treatment. However, people in both arms had cleared parasites by day 28 and hence were comparable in terms of relapse-prevention evaluating primarily the effects of primaquine, after eradicating blood-stage infections.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-22 13:36:56 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Outcomes used in this review</B>
</P>
<OL>
<LI>Number of participants with parasitaemia between days 30 and 90</LI>
<LI>Adverse effects</LI>
</OL>
<P>
<B>Outcomes not used in this review</B>
</P>
<OL>
<LI>Genotyping of <I>P. vivax</I> infection with PCR to differentiate new infections from relapses (single locus PCR)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 11:15:01 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Setting</B>: People presenting to the Centreo de Pesquisa em Medicine Tropical, city of Porto Velho area of Rondonia, Western Amazon; malaria transmission is low and seasonal, and sporadic.</P>
<P>
<B>Country:</B> Brazil</P>
<P>
<B>Funding: </B>Ministry of Science and Technology and Public Health</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size calculation not reported.</LI>
<LI>Children excluded: Mean age: 30.7 years for PQ 14 days and 32.7 years for PQ 5 days</LI>
<LI>Chloroquine and primaquine were given simultaneously in the five-day regimen and sequentially in the 14-day regimen</LI>
<LI>Treatments were supervised.</LI>
<LI>Parasitic clearance confirmed in 100% within 72 hours and by 28 and 35 days</LI>
<LI>Follow-up duration: two months (90 days after initiation of interventions). Inclusion of all randomized participants in final analysis: treatment outcome was investigated for 73 of the 79 enrolled participants (92%); of the 73 participants, 61 (84%) were followed up for 90 days, while 12 were followed up for 35 days. 31/39 (80%) in the 14 -day PQ arm and 30/40 (75%) in the five-day PQ arm completed two months of follow-up.</LI>
<LI>Recurrrences (evaluated using single locus PCR) not used as an outcome in this review update.</LI>
<LI>Trial protocol not available.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-08 11:15:06 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Walsh-2004">
<CHAR_METHODS MODIFIED="2012-05-18 09:46:19 +0100" MODIFIED_BY="Harriet MacLehose">
<P>Randomized controlled, open-label, active controlled, six-armed, trial</P>
<P>
<B>Period of study: </B>August 1998 to June 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-08 11:15:06 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Participants</B>: 25 included (from two arms of a 6-arm trial that randomized 80 people)</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Smear positive for <I>P. vivax</I>
</LI>
<LI>Weight within 20% of population standards</LI>
<LI>Normal G6PD screening</LI>
<LI>No antimalarials in previous 14 days</LI>
<LI>Negative pregnancy test</LI>
<LI>Consent to participate</LI>
<LI>Ability to take oral medication</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Mixed infection with <I>P. vivax</I> and <I>P. falciparum</I>
</LI>
<LI>Hematocrit &lt; 25%</LI>
<LI>Protracted vomiting</LI>
<LI>Oliguria</LI>
<LI>Systolic blood pressure &lt; 90 mm mercury</LI>
<LI>Lactation</LI>
<LI>Concomitant systemic disease</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:43:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>
</P>
<P>1. CQ (1500 mg over 3 days): N = 13</P>
<P>
<B>Control: </B>
<BR/>2. CQ (1500 mg over 3 days) + PQ 15 mg/day for 14 days: N = 12</P>
<P>Not used in this review:</P>
<P>Different doses of tafenoquine N = 55</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-15 10:44:47 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Number of participants with parasitaemia between 8 to 24 weeks</LI>
<LI>Adverse effects</LI>
</OL>
<P>
<B>Outcomes not used for quantitative synthesis in review</B>
</P>
<OL>
<LI>Incidence (per person-year) of relapse</LI>
<LI>Cumulative risk of relapse</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:43:42 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Setting:</B> Bangkok Hospital for Tropical Diseases; Tropical strains; no local transmission of vivax malaria</P>
<P>
<B>Country:</B> Thailand</P>
<P>
<B>Funding</B>: US Army Medical and Materiel Development Activity; GlaxoSmithKline</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Sample size calculation</LI>
<LI>Children were not included</LI>
<LI>Interventions were supervised</LI>
<LI>Clearance of parasites after treatment with chloroquine was confirmed by 2 consecutive negative blood smears by day 28</LI>
<LI>Chloroquine and primaquine were given sequentially</LI>
<LI>Follow-up: two months; patients were admitted for treatment and remained in Bangkok for 90 days after treatment initiation</LI>
<LI>10/13 (77%) in CQ only arm and 13/13 in CQ + 14-day PQ arm completed treatment (not statistically significant)</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 09:45:26 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Yadav-2002">
<CHAR_METHODS MODIFIED="2012-05-18 14:39:45 +0100" MODIFIED_BY="Harriet MacLehose">
<P>Randomized, parallel-group, active-controlled trial</P>
<P>
<B>Period of study</B>: 1998 to 1999</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:45:19 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Participants:</B> 1482</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Smear positive for <I>P. vivax</I>
</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Mixed infections;</LI>
<LI>Pregnant women</LI>
<LI>Infants</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:45:19 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Intervention:</B>
</P>
<P>1. CQ (single dose of 600 mg): N = 723</P>
<P>
<B>Control:</B>
<BR/>2. CQ (single dose of 600 mg) plus PQ (5 days) plus : N = 759</P>
<P>CQ dose: single dose of 600 mg (1500 mg base)<BR/>PQ dose: 0.25 mg/kg (45 mg total dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:45:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Number of participants relapsing during the 1-year follow-up</LI>
</OL>
<P>
<B>Outcomes not used in quantitative synthesis:</B>
</P>
<OL>
<LI>Episodes of clinical- parasitaemia during the 1-year follow-up period</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:45:26 +0100" MODIFIED_BY="Harriet MacLehose">
<P>
<B>Setting</B>: Tribal villages in Bisra Block near the Sundarbhans, a hilly and forested area in eastern Orissa State; Predominatly <I>P. falciparum</I> malaria (77%); vivax malaria (19%); <I>P.malariae</I> (1%); mixed infections (3%); malaria meso-endemic and seasonal</P>
<P>
<B>Country:</B> India</P>
<P>
<B>Funding:</B> Not reported</P>
<UL>
<LI>Sample size estimation not reported</LI>
<LI>Children included: Age range- equal numbers in both groups from age 1 year to &gt; 49 years</LI>
<LI>Primaquine dose unsupervised</LI>
<LI>Chloroquine and primaquine given sequentially</LI>
<LI>Parasitic clearance after treatment not confirmed</LI>
<LI>Follow-up: one year: by field worker visiting homes: none lost to follow-up</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-03 09:46:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeshiwondim-2010">
<CHAR_METHODS MODIFIED="2013-10-03 09:46:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized (quasi-randomized), open-label, controlled trial</P>
<P>
<B>Period of study: </B>January to August 2003</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:46:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants: </B>290</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Aged one year and above</LI>
<LI>Positive for <I>P. vivax</I> mono-infection with asexual parasite density of &#8805; 250/L of blood</LI>
<LI>Fever or history of fever 48 h prior to the time of recruitment</LI>
<LI>Ability and willingness to participate for the stipulated follow-up visits,</LI>
<LI>Informed consent in adults or of guardian in children</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Clinical conditions requiring hospitalisation</LI>
<LI>Evidence of severe malnutrition</LI>
<LI>Pregnancy-based on history of last menstrual period</LI>
<LI>Signi&#64257;cant concomitant febrile illness which would interfere with follow-up</LI>
<LI>Chronic infectious diseases other than malaria (for example, tuberculosis, HIV/AIDS)</LI>
<LI>Known allergy, or intolerance to the drug being tested, or both</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-10 21:24:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention:</B>
</P>
<P>CQ 3 days followed by PQ 14 days (from day 29 to day 41) (N = 145)</P>
<P>
<B>Control:</B>
</P>
<P>CQ 3 days followed by PQ 14 days (from day 3 to day 16) (N = 145)</P>
<P>CQ was given at a dose of 25 mg base/kg; 10 mg base/kg on day 0 and day 1 and 5 mg base/kg on day 2</P>
<P>PQ was given at a dose of 0.25 mg base/kg daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-22 02:15:50 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Relapse (defined as recurrent parasitaemia with or without fever between day 29 and 157 after clearing their primary infection during the 28-day follow-up period)</LI>
</OL>
<P>
<B>Outcomes not used for quantitative synthesis in this review:</B>
</P>
<OL>
<LI>Therapeutic efficacy at day 28 (primary outcome in study)</LI>
<LI>Cumulative risk of treatment failure in the 28 day period</LI>
<LI>Cumulative risk of relapse</LI>
<LI>Fever clearance time</LI>
<LI>Parasite clearance time</LI>
<LI>Gametocyte clearance time</LI>
<LI>Proportions with parasitaemia and gametocytaemia in the 28 day period</LI>
<LI>PCR adjusted failure rates at day 28</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-03 09:46:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> outpatient settings of the Malaria Diagnosis and Treatment Centers in Debre Zeit and Nazareth East Shoa;Malaria transmission is seasonal and unstable; <I>P. vivax</I> accounts for 50% of malaria transmission</P>
<P>
<B>Country:</B> Ethiopia (central)</P>
<P>
<B>Funding:</B> Global Malaria Program, WHO, Geneva, Switzerland</P>
<P>
<B>Comments:</B>
</P>
<UL>
<LI>Trial authors performed sample size estimation based on an estimated 15% difference between arms but results showed only a 11 % difference between arms for the primary outcome of efficacy at day 28.</LI>
<LI>Children included: 68 (24%) were aged 5 to 14 years, and 3 (1%) were between 1 to 3 years old</LI>
<LI>G6PD deficiency screening not done as people in Ethiopia tolerate primaquine well</LI>
<LI>Trial used sequential administration of primaquine following chloroquine in both arms but at different dosing intervals</LI>
<LI>All CQ treatments were directly supervised; PQ treatments were not supervised</LI>
<LI>Follow-up: 157 days (four months follow-up after primaquine treatment ended). Parasitological and clinical assessments were performed at day 42 and at any day of reappearance until day 157. Only patients who cleared parasites by day 28 or were not protocol violators or had mixed infections were followed up to day 157 (136/145 in CQ + PQ arm and 141/145 in the CQ only plus late PQ arm (overall 96% follow-up)</LI>
<LI>Relapses differentiated from recurrences by PCR during the 28 day period, not used as this was not an outcome for this review update</LI>
<LI>Trial protocol not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CQ: chloroquine; G6PD deficiency: glucose-6-phosphate dehydrogenase enzyme deficiency; <I>P. vivax</I>: <I>Plasmodium vivax</I>; PCR: polymerase chain reaction; PQ: primaquine.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-10-18 03:50:26 +0100" MODIFIED_BY="Harriet MacLehose" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:15:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdon-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:15:09 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Different doses of chloroquine were given to control and experimental groups and the outcome was parasitic clearance. No follow-up to detect relapses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:15:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN1261000055406">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: ongoing single arm trial of chloroquine followed by primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 14:05:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12613000003774">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 14:05:48 +0100" MODIFIED_BY="[Empty name]">
<P>Ongoing RCT.</P>
<P>People with mixed vivax and falciparum infection are eligible for inclusion.</P>
<P>Comparisons are oral primaquine at a dose of 0.75 mg/kg given once per week for 8 weeks versus oral dihydroartemisinin-piperaquine given once per day for 3 days. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:15:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appavoo-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: participants were not randomly assigned.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:15:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arango-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:15:44 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:15:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baird-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:15:52 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: compared primaquine with chloroquine in healthy people.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baird-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Healthy participants randomized to 30 mg primaquine or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baird-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basavaraj-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:23 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Betuela-2012a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:30 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:38 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-Betuela-2012b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:38 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>RCT: No chloroquine or chloroquine plus primaquine arms.</P>
<P>Compared artesunate (seven days) plus primaquine (14 days), artesunate alone or no treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buchachart-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:16:56 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Bunnag-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:16:56 +0100" MODIFIED_BY="Harriet MacLehose">
<P>RCT.</P>
<P>Compared chloroquine + primaquine (15 mg/day for 14 days) with chloroquine + primaquine (22.5 mg/day for 14 days). Only 33/81 (40%) in 15 mg/day primaquine arm and 40/86 (47%) in 22.5 mg/day primaquine arm completed 6 months follow-up; only 19 in each arm completed 18 months follow up; no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:17:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carmona_x002d_Fonseca-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:17:09 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Comparisons: CQ (1500 mg, in 48 hours), followed by PQ 45, 105 and 210 mg. </P>
<P>Outcomes: Effect of CQ with different doses of PQ on blood stage parasites. No follow-up beyond 28 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:17:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carmona_x002d_Fonseca-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:17:15 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Comparisons: CQ (1500 mg in 48 hours) followed by total dose of PQ: 45, 105 and 210 mg. </P>
<P>Outcome: assessed only at 28 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:17:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carmona_x002d_Fonseca-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:17:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Comparisons and outcomes: MetHB levels in three different dosing regimens of primaquine (twice, three-fold daily and five-fold daily standard dose over three days) following chloroquine. No arm with standard 14 days of primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:17:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carmona_x002d_Fonseca-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Comparisons: children with vivax malaria given primaquine 0.50 mg/kg/day for 7 days versus 1.17 mg/kg/day for 3 days; no 14 day primaquine arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:17:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cedillos-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:17:51 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared two regimens of primaquine with amodiaquine versus amodiaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:17:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clyde-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: No comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:18:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Contacos-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: No comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:18:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTRI_x002f_2011_x002f_09_x002f_002031">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:18:32 +0100" MODIFIED_BY="[Empty name]">
<P>On-going RCT. </P>
<P>Compared chloroquine versus chloroquine plus primaquine for 14 days. </P>
<P>Outcomes: will be assessed only up to 28 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:18:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTRI_x002f_2012_x002f_03_x002f_002511">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:18:40 +0100" MODIFIED_BY="[Empty name]">
<P>On-going RCT. </P>
<P>Comparing tafenoquine versus chlorquine plus primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:18:47 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-da-Silva-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:18:47 +0100" MODIFIED_BY="Harriet MacLehose">
<P>RCT.</P>
<P>Compared artemesinin and primaquine with chloroquine and primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:18:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:18:54 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: No comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:19:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dua-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:19:22 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT. Controlled clinical trial </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:19:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elmes-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if RCT; compared three doses of tafenoquine versus primaquine for post-exposure prophylaxis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:19:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fryauff-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared one year of weekly chloroquine, daily primaquine, or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:19:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gogtay-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:19:54 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:20:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamedi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Compared three doses of artesunate followed by primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:20:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrera-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Randomized Duffy + and Duffy -ve human volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-18 03:50:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN82366390">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-18 03:50:26 +0100" MODIFIED_BY="[Empty name]">
<P>Ongoing RCT.</P>
<P>Comparisons of artesunate and artesunate plus primaquine ; no chloroquine in either arm. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:20:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolaczinski-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Falciparum malaria: compared artesunate or primaquine combined with chloroquine or SP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:20:34 +0100" MODIFIED_BY="Harriet MacLehose" STUDY_ID="STD-Looareesuwan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:20:34 +0100" MODIFIED_BY="Harriet MacLehose">
<P>RCT. </P>
<P>Randomized participants to chloroquine + primaquine for 14 days or chloroquine alone. </P>
<P>Followed participants for 28 days to assess failure of initial therapy. Further follow-up beyond 28 days only for four participants with reappearance of parasitaemia in first 28 days who were retreated with chloroquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:20:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luxemburger-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:20:43 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:20:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manneeboonyang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Compared DOT or self-administered therapy (SAT) in two groups given chloroquine plus primaquine for 14 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:21:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nasveld-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Compared tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:21:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01074905">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:21:10 +0100" MODIFIED_BY="[Empty name]">
<P>On-going RCT. </P>
<P>Compared chloroquine plus primaquine 14 days versus ACT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 13:52:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01288820">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 13:52:12 +0100" MODIFIED_BY="[Empty name]">
<P>On-going RCT.</P>
<P>Comparing two ACTs plus primaquine. No chloroquine treatment in either arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:12:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01290601">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:12:55 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared tafenoquine versus chloroquine and primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 15:44:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01716260">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 15:44:46 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 14:17:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01780753">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 14:17:29 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: Single arm study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 15:45:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01814683">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 15:45:06 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>People with mixed infections with <I>P. vivax </I>and <I>P. falciparum</I> are eligible for recruitment in countries which use an artemisinin combination therapy for treating blood-stage infection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:24:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01837992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>Ongoing RCT.</P>
<P>Comparisons: No chloroquine treatment arms; randomised primaquine (0.25mg/kg or 0. 5 mg/kg for 14 days) following three days of artemether-lumefantrine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:25:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pasaribu-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:25:20 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Compared dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:13:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinto-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Low dose of chloroquine and primaquine was given for two groups for five days and seven days respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:25:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prasad-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:25:35 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: no comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:25:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pukrittayakamee-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:25:50 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared 30 mg or 60 mg primaquine daily for seven days; no 14 day primaquine arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:25:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RBR_x002d_77q7t3">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: on-going single arm trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roy-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:06 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: no comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saint_x002d_Yves-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:15 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Presumptive treatment of 45 mg primaquine given to all participants before randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:27 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shekalaghe-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Children were randomized to receive SP plus AS plus PQ or placebo; those with a haemoglobin (Hb) level below 8 g/dL were excluded from receiving PQ and received SP plus AS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shekalaghe-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:46 +0100" MODIFIED_BY="[Empty name]">
<P>Cluster RCT.</P>
<P>Compared mass drug treatment with SP plus AS plus PQ versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:26:55 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-Shin-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:26:55 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>RCT. </P>
<P>Compared fixed dose formulation of pyronaridine: artesunate versus chloroquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:08 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:13 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-Sinha-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:13 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>Non-RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smithuis-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:18 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Falciparum malaria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soto-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:23 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared 30 mg primaquine for 16 weeks against placebo in healthy people.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soto-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared 30 mg primaquine for 16 weeks against placebo in healthy people.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:41 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-Sutanto-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:41 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>RCT.</P>
<P>Compared artesunate followed by quinine and primaquine versus dihydroartemisinin plus piperaquine followed by primaquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takeuchi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:48 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. </P>
<P>Compared DOT versus SAT in two groups given chloroquine plus primaquine 14 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:27:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valibayov-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:27:54 +0100" MODIFIED_BY="[Empty name]">
<P>Non-RCT: no comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 11:28:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-V_x00e1_squez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 11:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
<P>Falciparum malaria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-02 12:22:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilairatana-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-02 12:22:19 +0100" MODIFIED_BY="[Empty name]">
<P>Non-
RCT:
 sequential allocation. 
</P>
<P>No chloroquine.
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ACT = artemesinin combination therapy; CQ = chloroquine; PQ = primaquine; DOT = directly observed treatment; RCT= randomized controlled trial; SAT = self-administered treatment.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-07-22 12:29:16 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-10-17 16:53:09 +0100" MODIFIED_BY="Harriet MacLehose" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-10-17 16:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01178021">
<CHAR_STUDY_NAME MODIFIED="2013-10-17 16:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>"Estimating the risk of <I>Plasmodium vivax </I>relapses in Afghanistan (VRA)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-08 11:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Phase 4 randomized, parallel-group, open label trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:47:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Estimated enrolment: </B>600</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Adults and children &gt; 6 months of age</LI>
<LI>Negative pregnancy test in women at risk of pregnancy</LI>
<LI>Microscopic diagnosis of <I>P. vivax</I> mono-infection (&gt; 200/µL asexual forms)</LI>
<LI>Axillary temperature &#8805; 37.5°C, or an oral or rectal temperature &#8805; 38°C, or history of fever within the last 24 hours</LI>
<LI>Ability to swallow oral medication</LI>
<LI>Participant (or parent or guardian if &lt; 18 years old) is willing and able to give written informed consent</LI>
<LI>Ability (in the investigator's opinion) and willingness of patient, parent or guardian to comply with all study requirements</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Severe malaria (see WHO definition)</LI>
<LI>Patients with microscopic diagnosis of co-infection with <I>P. falciparum</I>
</LI>
<LI>Haemoglobin concentration &lt;8 g/dL</LI>
<LI>Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study, for example, other acute febrile conditions or chronic disease</LI>
<LI>Pregnancy or lactation</LI>
<LI>History or phenotypic test compatible with severe G6PD deficiency</LI>
<LI>History of hypersensitivity to any of the drugs being tested</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:47:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention:</B>
</P>
<OL>
<LI>Chloroquine/primaquine (chloroquine 10 mg/kg on day 0 and 1 and 5 mg/kg on day 2 primaquine (if given) 0.25 mg/kg/day for 14 days)</LI>
</OL>
<P>
<B>Control:</B>
</P>
<OL>
<LI>Chloroquine 10 mg/kg on day 0 and 1 and 5 mg/kg on day 2</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:47:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome:</B>
</P>
<OL>
<LI>Secondary <I>P. vivax</I> attack (completion of the one year (± one month) follow-up period without secondary <I>P. vivax</I> attack)</LI>
</OL>
<P>
<B>Secondary outcomes:</B>
</P>
<OL>
<LI>Secondary vivax attack (completion of six months (± one month) follow-up without secondary vivax attack)</LI>
<LI>G6PD prevalence at time of enrolment</LI>
<LI>Time to first recurrence (one year)</LI>
<LI>Median time between episodes of vivax infections</LI>
<LI>Total number of episodes in the follow-up period (one year)</LI>
<LI>Overall days of illness (one year)</LI>
<LI>Haematocrit below 30% over one year)</LI>
<LI>Chloroquine levels at Day 7; and any day of recurrence of <I>P. vivax</I> malaria</LI>
<LI>Adverse event profiles of chloroquine and primaquine</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-16 11:50:49 +0100" MODIFIED_BY="[Empty name]">
<P>January 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-03 09:47:28 +0100" MODIFIED_BY="[Empty name]">
<P>Principal Investigator: Ghulam Rahim Awab, MD; E-mail: <A HREF="mailto:awabgr%40yahoo.com?subject=NCT01178021,%20BAKMAL0903,%20Estimating%20the%20Risk%20of%20Plasmodium%20Vivax%20Relapses%20in%20Afghanistan">awabgr@yahoo.com</A>     </P>
<P>Mahidol Tropical Medicine Research Unit; Mahidol University, Bangkok, Thailand</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-17 14:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Provincial Malaria Control Centers (MRC)</P>
<P>
<B>Country:</B> Afganistan</P>
<P>
<B>Funding:</B> University of Oxford; National Malaria and Leishmaniasis Control Program, Afghanistan; Mahidol University</P>
<P>
<B>Comments:</B> <B>Estimated Study Completion Date:</B> December 2014 <B>Status:</B> Recruiting (last verified:August 2013; last checked 17 October 2013)</P>
<P>
<B>Registration Number:</B> Clinicaltrials.gov: <LINK REF="STD-NCT01178021" TYPE="STUDY">NCT01178021</LINK>  </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-10-17 16:52:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01376167">
<CHAR_STUDY_NAME MODIFIED="2013-10-03 09:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>"Ph 2B/3 Tafenoquine (TFQ) study in prevention of vivax relapse"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-03 09:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, parallel-group, double blind (subject, caregiver, investigator, outcomes assessor), double-dummy, active-controlled, multi-centre, trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:47:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Estimated enrolment: </B>924</P>
<P>
<B>Inclusion criteria</B>:</P>
<OL>
<LI>Positive Giemsa smear for <I>P. vivax</I>
</LI>
<LI>Parasite density &gt; 100 and &lt; 200,000/&#956;L</LI>
<LI>&#8805; 16 years</LI>
<LI>Non-pregnant, non-lactating females of non-child bearing potential, or has a negative serum pregnancy test at screening, and uses measures to prevent pregnancy (as defined in protocol)</LI>
<LI>A signed and dated informed consent is obtained from the subject or the subject's legal representative prior to screening (NB assent is obtained from subjects &lt; 18 years, where applicable and written or oral witnessed consent has been obtained from parent or guardian).</LI>
<LI>The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is likely to complete the study as planned.</LI>
<LI>Willing to be hospitalized for 3 days and return to clinic for all follow-up visits including Day 180.</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>QTc &lt; 450 msec at screening, based on a single QTcF value at screening or as an average of triplicate electrocardiogram obtained over a brief recording period by machine or manual over-read if first is &gt; 450 msec. Exclusion criteria: mixed malaria infections (for example, identified by Giemsa-stained smear or rapid diagnostic test)</LI>
<LI>Severe vivax malaria as defined by WHO criteria.</LI>
<LI>Severe vomiting (no food or inability to take food during previous 8 hours).</LI>
<LI>Screening haemoglobin concentration &lt; 7 g/dL.</LI>
<LI>G6PD deficiency, assessed by a quantitative spectrophotometric phenotype assay.</LI>
<LI>Males: any subject with an enzyme level &lt; 70% of the site median value for G6PD normals will be excluded.</LI>
<LI>Females: screening Hb &#8805; 10 g/dL will only be excluded if their enzyme level is &lt; 70% of the site median value for G6PD normals. Females with Hb &#8805; 7 but &lt; 10 g/dL will be excluded if an enzyme level is not &gt; 90% of the site median value for G6PD normals.</LI>
<LI>Liver function test alanine transaminase &gt; 2x upper limit of normal.</LI>
<LI>Any clinically significant concurrent illness (for example, pneumonia, septicaemia), pre-existing conditions (for example, renal disease, malignancy), conditions that may affect absorption of study medication (for example, vomiting or severe diarrhoea) or clinical signs and symptoms of severe cardiovascular disease (for example, uncontrolled congestive heart failure or severe coronary artery disease). These abnormalities may be identified on the screening history and physical or laboratory examination.</LI>
<LI>Subject has taken antimalarials (for example, ACT, mefloquine, primaquine, chloroquine) or drugs with anti-malarial activity within the past 30 days by history.</LI>
<LI>History of allergy to chloroquine, mefloquine, tafenoquine, primaquine or to any other 4- or 8-aminoquinolines.</LI>
<LI>Any contraindications to chloroquine or primaquine administration including a history of porphyria, psoriasis or epilepsy (please refer to chloroquine and primaquine locally approved prescribing information).</LI>
<LI>Subject who has previously received study medication for this protocol (all parts) or has received treatment with any other investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.</LI>
<LI>History of illicit drug abuse or heavy alcohol intake within 6 months of the study.</LI>
<LI>Subjects who have taken or will likely require the use of medications from the prohibited medication list which include the following classes: histamine-2 blockers and antacids.</LI>
<LI>Drugs with haemolytic potential.</LI>
<LI>Drugs known to prolong the QTc interval</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Interventions </B>(not relevant to this review)<B>:</B>
</P>
<OL>
<LI>Tafenoquine 50mg (on Day 1 and Day 2 600 mg chloroquine will be administered, on Day 3 300 mg chloroquine will be administered. 50 mg tafenoquine will be administered on either Day 1 or Day 2 depending on when eligibility is confirmed).</LI>
<LI>Tafenoquine 100mg (on Day 1 and Day 2 600 mg chloroquine will be administered, on Day 3 300 mg chloroquine will be administered. 100 mg tafenoquine will be administered on either Day 1 or Day 2 depending on when eligibility is confirmed).</LI>
<LI>Tafenoquine 300mg (on Day 1 and Day 2 600 mg chloroquine will be administered, on Day 3 300 mg chloroquine will be administered. 300 mg tafenoquine will be administered on either Day 1 or Day 2 depending on when eligibility is confirmed).</LI>
<LI>Tafenoquine 600 mg (on Day 1 and Day 2 600 mg chloroquine will be administered, on Day 3 300 mg chloroquine will be administered. 600 mg tafenoquine will be administered on either Day 1 or Day 2 depending on when eligibility is confirmed).</LI>
</OL>
<P>
<B>Controls </B>(to be included in quantitative synthesis in this review):</P>
<OL>
<LI>Active comparator: primaquine 15 mg (on Day 1 and Day 2 600 mg chloroquine will be administered, on Day 3 300 mg chloroquine will be administered. 15 mg primaquine once daily Days 2 to 15)</LI>
<LI>Placebo comparator: chloroquine only (on Day 1 and Day 2 600 mg chloroquine will be administered, on Day 3 300mg chloroquine will be administered.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome measures:</B>
</P>
<OL>
<LI>Relapse efficacy (180 days). Subjects for whom initial clearance of parasitaemia is confirmed (parasite numbers fall below the limit of detection in thick blood smear and remain undetectable at the second smear collected 6 to 12 hours later) and who do not present with <I>P. vivax</I> asexual stage parasites within six months will be considered treatment successes.</LI>
</OL>
<P>
<B>Secondary outcome measures:</B>
</P>
<OL>
<LI>Relapse efficacy (4 months post dosing). First confirmed presence of <I>P. vivax</I> asexual stage parasites after clearance of initial parasitaemia following treatment.</LI>
<LI>Time to relapse (80 days post dosing). Time from initial parasite clearance to time of relapse.</LI>
<LI>Parasite clearance time (from first dose until Day 180). Time needed to clear asexual parasites from blood, parasites fall below limit of detection in thick blood smear and remains undetectable for at least 48 hours.</LI>
<LI>Fever clearance time (from first dose until Day 180). Time from first dose of treatment to time when body temperature falls to normal and remains normal for at least 48 hours.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-17 14:35:48 +0100" MODIFIED_BY="[Empty name]">
<P>September 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-03 09:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>US GSK Clinical Call Center; 877-379-3718; <A HREF="mailto:GSKClinicalSupportHD%40gsk.com?subject=NCT01376167,%20112582,%20Ph%202B/3%20Tafenoquine%20(TFQ)%20Study%20in%20Prevention%20of%20Vivax%20Relapse">GSKClinicalSupportHD@gsk.com</A>; Cheri Hudson; Clinical Disclosure Advisor;</P>
<P>GlaxoSmithKline</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-17 16:52:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Not reported</P>
<P>
<B>Country: </B>Not reported</P>
<P>
<B>Funding: </B>GlaxoSmithKline; Medicines for Malaria Venture</P>
<P>
<B>Comments: Estimated study completion date</B>: September 2015 <B>Status: </B>Not yet recruiting (last updated on September 25, 2013; last checked 17 October 2013)</P>
<P>
<B>Registration number: </B>
<LINK REF="STD-NCT01376167" TYPE="STUDY">NCT01376167</LINK>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-10-17 16:52:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01640574">
<CHAR_STUDY_NAME MODIFIED="2013-10-17 16:41:08 +0100" MODIFIED_BY="[Empty name]">
<P>"Comparison between 7 and 14 day primaquine combined with dihydroartemisinin-piperaquine or 3 day chloroquine radical cure of P. Vivax (BPD)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-17 16:19:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, parallel group, open label, four-arm trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-17 16:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Estimated enrolment: </B>900</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>&#8805; 6 months old</LI>
<LI>Microscopic diagnosis of <I>P. vivax</I> malaria mono-infection</LI>
<LI>Participant or parent/guardian is willing and able to give informed consent for participation in the study</LI>
<LI>Able (in the Investigators opinion) and willing to comply with all study requirements.</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>Severe malariaHistory of allergy or adverse reaction to artesunate, piperaquine, chloroquine, or primaquine</LI>
<LI>Blood transfusion in the past 3 months</LI>
<LI>G6PD deficiency by rapid test</LI>
<LI>Hematocrit &#8804; 25%</LI>
<LI>Pregnancy at the time of screening</LI>
<LI>Breastfeeding an infant &lt; 6 months old</LI>
<LI>Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-17 16:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Interventions </B>(not relevant to this review)<B>:</B>
</P>
<OL>
<LI>Dihydroartemisinin-piperaquine plus primaquine daily for 3 days and primaquine 1 mg/kg once daily for 7 days</LI>
<LI>Dihydroartemisinin-piperaquine plus primaquine daily for 3 days and primaquine 0.5 mg/kg daily for 14 days</LI>
</OL>
<P>
<B>Controls </B>(to be included in quantitative synthesis in this review):</P>
<OL>
<LI>Chloroquine (10 mg, 10 mg, 5 mg) over 3 days and primaquine 1 mg/kg once daily for 7 days</LI>
<LI>Chloroquine (10 mg, 10 mg, 5 mg) over 3 days and primaquine 0.5 mg/kg daily for 14 days</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-17 16:34:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome measure:</B>
</P>
<OL>
<LI>Recurrence with <I>P.vivax</I> malaria within 52 weeks of first treatment dose</LI>
</OL>
<P>
<B>Secondary outcome measures:</B>
</P>
<OL>
<LI>Number of adverse events within 28 days of study medication</LI>
<LI>Recurrence with <I>P. vivax </I>malaria within 6 months of first treatment dose</LI>
<LI>Chloroquine, piperaquine and primaquine drug levels (not relevant to this review)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-17 16:34:37 +0100" MODIFIED_BY="[Empty name]">
<P>July 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-17 16:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>Cindy Chu: +66 55 545021; <A HREF="mailto:cindy%40shoklo-unit.com">cindy@shoklo-unit.com</A>
</P>
<P>Francois Nosten:+66 55 545021; <A HREF="mailto:francois%40tropmedres.ac">francois@tropmedres.ac</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-17 16:52:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Shoklo Malaria Research Unit</P>
<P>
<B>Country: </B>Thailand</P>
<P>
<B>Funding: </B>University of Oxford</P>
<P>
<B>Comments: Estimated study completion date</B>: December 2014 <B>Status: </B>recruiting (last updated on 28 August 2013; last checked 17 October 2013)</P>
<P>
<B>Registration Number: </B>NCT01640574 </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-10-17 16:53:09 +0100" MODIFIED_BY="Prathap  Tharyan" STUDY_ID="STD-NCT01680406">
<CHAR_STUDY_NAME MODIFIED="2013-10-03 09:47:52 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>"Ethiopia antimalarial in vivo efficacy study 2012: evaluating the efficacy of artemether-lumefantrine alone compared to artemether-lumefantrine plus primaquine and chloroquine alone compared to chloroquine plus primaquine for <I>Plasmodium Vivax</I> infection"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-22 19:03:39 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>Randomized, parallel group, open label, four-arm trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-03 09:47:51 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Estimated enrolment: </B>480</P>
<P>
<B>Inclusion criteria:</B>
</P>
<OL>
<LI>Slide-confirmed infection with <I>P. vivax</I>
</LI>
<LI>Age &gt; 1 year</LI>
<LI>Lives within 20 km of the enrolling health facility</LI>
<LI>Weight &#8805; 5.0 kg</LI>
<LI>Axillary temperature &#8805; 37.5º C or history of fever during the previous 48 hours</LI>
<LI>Patient or caregiver agrees to all finger pricks and return visits</LI>
</OL>
<P>
<B>Exclusion criteria:</B>
</P>
<OL>
<LI>General danger signs or symptoms of severe malaria</LI>
<LI>Signs or symptoms of severe malnutrition, defined as weight-for-age &#8804; 3 standard deviations below the mean (NCHS/WHO normalized reference values)</LI>
<LI>Slide confirmed infection with any other <I>Plasmodium</I> species. besides <I>P. vivax</I> mono-infection</LI>
<LI>Acute anaemia, defined as Hg &lt; 8 g/dL</LI>
<LI>Known hypersensitivity to any of the drugs being evaluated</LI>
<LI>Presence of febrile conditions caused by diseases other than malaria</LI>
<LI>Serious or chronic medical condition by history (cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS)</LI>
<LI>Pregnant or breastfeeding women</LI>
<LI>History or haemolysis or severe anaemia</LI>
<LI>Regular medication, which may interfere with antimalarial pharmacokinetics</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-03 09:48:00 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Interventions </B>(not relevant to this review)<B>:</B>
</P>
<OL>
<LI>Artemether-lumefantrine and primaquine: artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days. Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days.</LI>
<LI>Artemether-lumefantrine: weight-based dose to be administered as fixed-dose combination twice daily for three days.</LI>
</OL>
<P>
<B>Controls </B>(to be included in quantitative synthesis in this review):</P>
<OL>
<LI>Chloroquine given in a weight-based dose to be administered once daily for three days.</LI>
<LI>Chloroquine and primaquine: chloroquine will be given in a weight-based dose to be administered once daily for three days. Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-03 09:48:00 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Primary outcome measures:</B>
</P>
<OL>
<LI>
<I>P. vivax</I> treatment failures in the 4 weeks following treatment with AL compared to AL+PQ (time frame: day 28).</LI>
<LI>
<I>P. vivax</I> treatment failures in the 4 weeks following treatment with CQ compared to CQ+PQ (time frame: day 28).</LI>
</OL>
<P>
<B>Secondary outcome measures:</B>
</P>
<OL>
<LI>Number of episodes of <I>P. vivax</I> parasitaemia over one year following initial effective therapy against <I>P. vivax</I> (i.e. parasite clearance) (time frame: 1 year after day 0 of enrolment).</LI>
<LI>
<I>P. vivax</I> treatment failures in the 6 weeks following treatment (time frame: Day 42).</LI>
</OL>
<P>
<B>Other outcome measures:</B>
</P>
<OL>
<LI>Safety endpoint (time frame: baseline (day 0) and day 28).</LI>
<LI>Change in haemoglobin concentration.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-22 19:15:06 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>October 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-03 09:47:52 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>Keren Z Landman, MD, <A HREF="mailto:fea8%40cdc.gov?subject=NCT01680406,%20CDC-CGH-6338,%20Ethiopia%20Antimalarial%20in%20Vivo%20Efficacy%20Study%202012">fea8@cdc.gov</A>
</P>
<P>Jimee Hwang, MD, MPH, <A HREF="mailto:jhwang%40cdc.gov?subject=NCT01680406,%20CDC-CGH-6338,%20Ethiopia%20Antimalarial%20in%20Vivo%20Efficacy%20Study%202012">jhwang@cdc.gov</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-17 16:53:09 +0100" MODIFIED_BY="Prathap  Tharyan">
<P>
<B>Setting: </B>Bishoftu Malaria Center, Debre Zeit; Bulbula Health Center, Zeway</P>
<P>
<B>Country: </B>Ethiopia</P>
<P>
<B>Funding: </B>Centers for Disease Control and Prevention; Ethiopia Health and Nutrition Research InstituteFederal Ministry of Health, Ethiopia Columbia University Oromia Regional Health Bureau, Ethiopia United States Agency for International Development (USAID), Menzies School of Health Research</P>
<P>
<B>Comments: Estimated study completion date</B>: October 2013 <B>Status: </B>Not yet recruiting (last updated on 6 September 2012; last checked 17 October 2013)</P>
<P>
<B>Registration Number: </B>
<LINK REF="STD-NCT01680406" TYPE="STUDY">NCT01680406</LINK>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>G6PD: glucose-6-phosphate dehydrogenase</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-10-08 11:16:22 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-10-08 11:15:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:10:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>"We conducted a non-blind random clinical and controlled trial without placebo. A total of 210 patients with vivax malaria were recruited and allocated a treatment using an Excel (Microsoft, Redmond, WA) function".</P>
<P>Computer generated randomization sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>"After clinical evaluation and examination of thick and thin blood smears to establish the diagnosis, patients were randomly assigned, in an open fashion, to one of four treatment groups."</P>
<P>Method not mentioned, but trial due during the same period by the same group (<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>) used computer generated sequences.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 10:01:18 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>Quote from trials registration record, "Computer generated randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:11:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>Patients were "randomly assigned".</P>
<P>The first author clarified that randomization codes were generated from a list of random numbers by personnel not otherwise involved in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:11:36 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>Quotes from trial protocol: "Subjects who fulfil all the inclusion criteria and have none of the exclusion criteria will be randomized 1:1;1 to one of the three treatment arms." "The subjects will be assigned a study arm through a computer-generated randomisation schedule."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:12:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>"randomised by family".</P>
<P>Cluster randomization: method used for generating sequence not stated but likely to be adequate as baseline characteristics balanced across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:36:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>Quote from report: "Randomisation lists for each village were generated using a random number list (MS Excel, Microsoft Corp., Seattle, USA) by staff not involved in patient recruitment."</P>
<P>Quote from report: "Those with G6PD deficiency were not randomised, but assigned to the 8-week PQ group in order to follow closely to assess safety."</P>
<P>Quote from study protocol: "All patients will be randomly allocated into three groups using randomisation blocks of different sizes."</P>
<P>While the procedure to generate random sequences is adequate, the application of the random sequences appear to have been compromised by the exclusion of G6PD deficient persons from the 14-day primaquine arm leading to a 22% lower enrolment rate in this arm (55), compared to the CQ + placebo arm (71) and the 8-week supervised PQ arm (74). The 55 in the 14-day PQ arm is below the estimated 66 per treatment arm estimated in the unscheduled revised sample size calculation. Also see below under allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>"Patients were allocated at random".</P>
<P>Unclear if trial authors used adequate methods for sequence generation but there were no baseline imbalances for important prognostic variables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>"Patients were then allocated to the 2 groups using a simple, computer generated randomisation scheme".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>Quote from report: "..year-long randomised trials were conducted". Trial authors did not state methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>"..year-long randomised trials were conducted". Trial authors did not state the methods they used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>"randomly assigned".</P>
<P>No further details; however, baseline details well-matched (see below).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:43:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>"A computer-generated blocked randomisation list (block size, 5) was used to assign patients sequentially to treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:15:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>Stratified randomization by decades of age from 1 to 10 years, until &gt; 49 years; method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>"After enrolment, patients were randomly assigned to receive either CQ or CQ+ PQ treatment, using even or odd code numbers. First, the test drugs were coded either in even or odd number using a lottery method prior to the study. Then, patients registered in odd number at the outpatient settings of the two malaria laboratory and treatment enters were assigned into the CQ treatment group prior to pre-screening and recruitment while those patients registered in even number were assigned into CQ+ PQ treatment group in serial order. The same procedures were followed throughout the study period."</P>
<P>This suggests quasi-randomization with odd and even number registrations being predictably allocated to treatment arms; however baseline prognostic variables were equal in both intervention arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-10-08 11:14:04 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>"patients were randomly assigned, in an open fashion, to one of the three treatment groups."</P>
<P>Trial authors did not conceal allocation; however, there were no baseline imbalances between the three treatment groups with regards to age, sex, parasitaemia, weight, duration of symptoms, history of malaria, number of previous episodes, or ethnicity. Selection bias appears unlikely to have occurred.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:31:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>"...patients were randomly assigned, in an open fashion, to one of four treatment groups."</P>
<P>Trial authors did not conceal allocation, but as in <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>, there were no baseline imbalances in age, weight, duration of symptoms, and malaria history; and parasite density or G6PD activity. Unlikely to be at risk of selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>Quote from trials registration record, "An open list of random numbers."</P>
<P>Allocation can be predicted with the use of an open list, but participants had to have vivax mono-infection by smear and a rapid diagnostic test; and there were no baseline imbalances between treatment groups for age, sex, temperature, and baseline parasite count, making selection bias less likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>Trial authors did not state the method used for allocation concealment; however, the first author clarified that coded containers with the interventions were prepared by the pharmacists; person recruiting subjects did not have access to the code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:11:52 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="NO" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>Quotes from trial protocol: "Allocation will be done by drawing the next sequential numbered opaque envelope, which contains the study number of the patient referring to the study treatment" ".., the randomisation procedure allows for adequate drug allocation concealment before envelopes are opened."</P>
<P>The unequal numbers in the three arms (CQ alone n = 50; 5-day PQ n= 59, 14-day PQ n = 42) is unexplained for a planned total sample of 150 participants with 50 each in each arm (1:1:1 computer-generated randomization), and the stated method of allocation concealment. The estimated sample size was achieved, so even if simple, and not block randomization was used, unequal numbers, particularly the 59 in the 5-day PQ arm. is unlikely; unless method of allocation concealment was compromised during execution of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>Trial authors did not state the method they used, but there were no baseline imbalances for known confounders.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-08 11:14:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>Quote from report: "In Baghicha and Khagan villages, patients were randomized by household, whereas in Adizai randomization was at the individual level. Randomization lists for each village were generated using a random number list (MS Excel, Microsoft Corp., Seattle, USA) by staff not involved in patient recruitment. Patients were randomized on enrolment by study staff in the BHUs based on house number or sequential patient numbers, depending on the study site."</P>
<P>This appears to be a quasi-random allocation method where allocation was not unpredictable. The study protocol available from the online PLoS One publication does not list Adizai village; this village appears to have been added after the unscheduled interim analysis (that also resulted in a revised sample size estimate from 212 per treatment arm to 66 per treatment arm) due to low recruitment rates caused by lower than expected malaria transmission during the study period. The mixed randomization design and, in particular, the sequential allocation of participants to the Adizai site, which had the highest enrolment (50%) and was also associated in multivariate analysis to have the highest treatment failure rates in the placebo arm, indicates that there was a high risk of selection bias. In addition, the trial report states that only one G6PD deficiency participant was enrolled (see quote below under blinding for objective outcomes). This does not then explain the difference in enrolment in the three arms, considering that block-randomization was to have been used.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>Trial authors did not state methods, but there were no baseline imbalances in age, parasitaemia on admission, haematological or biochemical tests.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>Not stated; however a similar trial done earlier by the same group in the same hospital was allocation concealed (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>Not mentioned. Trial authors matched baseline variables for age and sex but did not provide any other details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>Trial authors did not mention this. Baseline variables were matched for age and sex but they did not provide any other details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>Trial authors did not state methods used but people in both arms did not differ significantly in age, sex, previous malaria history, parasitic density, duration of local residence, clinical signs and symptoms and biochemical tests; hence selection bias with respect to prognostic indicators appears unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:44:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>"The randomisation list was kept by an off-site investigator (D.S.W.) who was not directly involved with patient enrolment."</P>
<P>"To achieve these target sample sizes, some assignments were eliminated (6 group D, 4 group E) as the trial progressed (non-randomly). In each case, the patient was assigned the next treatment on the randomisation schedule. For 2 enrolled subjects, treatment substitutions were made (one subject was moved from group E to group B to replace a patient in group B who dropped out of the study on the day that prophylaxis began, and the other was moved from group E to group D because of an inability to remain hospitalised for 14 days). In all cases, elimination of a group D or E assignment or substitution was made without the knowledge of the next treatment assignment or the identity of the next patient to be randomised".</P>
<P>Since allocation was concealed, the risk of selection bias is low: Groups were similar at baseline for age, sex (mostly male), mean weight, and parasite load.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 11:11:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>Not stated; baseline variables not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>"Baseline characteristics were similar in all treatment groups"</P>
<P>Comment: Allocation not concealed but both groups were similar with regard to sex, age, weight, previous medication, fever, vomiting, parasitaemia and gametocytaemia.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-08 11:16:22 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Subjective outcomes:other adverse effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Objective outcomes: parasitaemia and serious adverse effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>The study was not blinded and trial authors actively followed up patients at home; the microscopist was probably aware of treatment allocation, but the definition of recurrence used was any parasitaemia detected during specified follow-up examinations during six months. We feel this was unlikely to have biased outcome reporting. No serious adverse events were presented in the trial report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-01 17:10:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>No adverse events or subjective outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>"We confirmed the absence of severe complications or adverse effects and therefore recommend the simultaneous administration of chloroquine and primaquine."</P>
<P>As with <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>, the study was not-blinded and patients were actively followed up at home; the microscopist was probably aware of treatment allocation, but the definition of recurrence used was any parasitaemia detected during specified follow-up examinations during six months. We felt it unlikely that the open-label design would bias outcome reporting of parasitaemia. No serious adverse events were observed in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>No participants reported adverse events; no subjective outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>The trial was open label and trial authors did not conceal allocation; but two microscopists independently read blood smears. We don't think this would be have biased detection of parasitaemia or serious adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="NO" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>The open label nature of the trial, lack of allocation concealment, and lack of placebo in the CQ only arm could have biased reporting of subjective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>The trial was unblinded with supervised treatment of 5 or 14 days of primaquine, and the third group receiving no treatment after CQ. The first author clarified that microscopist had no knowledge of treatment assignment. We judged this was unlikely to introduce bias for ascertainment of objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>The trial was unblinded with supervised treatment of 5 or 14 days of primaquine, with the third group receiving no treatment. This raised the possibility of bias, but as trial authors reported that no participants developed adverse effects, hence the risk of bias is unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-08 11:16:22 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="NO" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>Quotes from study protocol: "This is an open-label study so the blinding of investigators and patients is not applicable." "All laboratory investigations will be performed without knowledge of the treatment allocation.."</P>
<P>Quote from report: "All patients tolerated their medication well and recovered following antimalarial treatment. The treatments were generally well tolerated and (<I>there</I>) were no serious adverse effects."</P>
<P>Quote from report: "In this open randomised comparison neither primaquine regimen reduced the incidence of <I>P. vivax</I> recurrence. The most likely explanation for this lack of effectiveness is poor adherence to the 14-day primaquine regimen, and lack of efficacy of the shorter course regimen". </P>
<P>The method used (if any) to monitor adherence was not mentioned in the trial report and was not available from the authors. In this trial of unsupervised primaquine treatment, the expected benefit with 14-day primaquine (4% relapse was used for sample size estimations) was not seen, but without data to confirm the explanation offered by the authors, and to adjust for non-adherence, the results for efficacy and safety are unreliable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:33:58 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>The trial authors did not report any other adverse effects; we do not know if the trial authors systematically ascertained these. Evaluation of risk of bias is also confounded by possibility (raised by trial authors) that participants given primaquine did not take their drugs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>Trial authors did not state whether they performed blinding in report but the risk of bias for objective outcomes is unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>Trial authors did not state whether they performed blinding in report and the risk of bias for subjective outcomes is possible, though unlikely, as trial authors did not report adverse effects as different in treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:36:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>Quotes from report, "Patients were monitored during the eight weeks of treatment and for nine additional months by active surveillance (being visited in their homes every two weeks) and passively on presentation at the basic health centre. Patients presenting at the basic health unit with suspected treatment failure (febrile illness) were assessed by thick and thin "blood smear". "Blood slides were double read by two independent microscopists, blinded to the others result."</P>
<P>Although this was an open label study, the independent confirmation adds credibility to the results, but since study staff allocated participants (using quasi-random techniques), and home visits were made, detection bias is possible. However, the detection of parasitaemia is an objective outcome measure, and unlikely to introduce detection bias.</P>
<P>Quote from study protocol: "An adverse event is defined as any noxious, pathological or unintended change in anatomical, physiological or metabolic functions as indicated by physical signs, symptoms and/or laboratory changes occurring in any phase of the clinical study whether associated with the study drug or placebo and whether or not considered drug related. Adverse events will be classified as follows: ...Severe adverse event: For example, an adverse experience which prevents normal everyday activities e.g. haemolysis".</P>
<P>Quote from report: "The sole G6PD deficient patient showed a slight drop in haemoglobin which was not clinically significant. "</P>
<P>Trial authors monitored serious adverse events and none were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-01 17:12:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>No other adverse events were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>Not stated but likely to be unblinded as groups were treated for differing durations with no mention of dummy tablets used; however, the risk of bias for objective outcomes is unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>" All treatments were well tolerated. No patient developed serious adverse effects or had evidence of significant haemolysis."</P>
<P>Since all groups tolerated treatments well, the risk of bias appears low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>"The study was assessor blinded as the medical officer looking after the day to day care of patients and the technician analysing the peripheral smear were unaware of the study group to which the patient belonged".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>Participants were not blind to treatment but trial authors reported there were no adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>Quote from report: "Blood smears were taken at I to 3-day intervals for 28 days: 200 fields were examined before any blood film was classified as malaria-negative. The number of parasites were counted against 200 leucocytes". Trial authors did not mention</P>
<P>how they identified relapses, but the likelihood of risk of bias in detecting parasitaemia during follow-up is low. No serious adverse events were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>No adverse events were reported; they did not perform systematic screening but the report states G6PD patients tolerated treatments well.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:42:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>"Blood smears were taken at I to 3-day intervals for 28 days: 200 fields were examined before any blood film was classified as malaria-negative. The number of parasites were counted against 200 leucocytes".</P>
<P>The trial authors did not mention how relapses were identified, but the likelihood of risk of bias in detecting parasitaemia during follow-up is low. No serious adverse events were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>No adverse events were reported; trial authors did not perform systematic screening but the report states G6PD patients tolerated treatments well.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>Two independent microscopists detected parasitaemia on 200 microscopic fields. No serious adverse events were reported. PCR used only a single locus and may not have accurately differentiated relapses from recurrences but this may not have affect the differential detection of this outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-01 17:14:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>No other adverse events were reported, and though it is unclear if they were ascertained systematically, differential effects may be unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>"Microscopic examination of blood smears was conducted by a standard operating procedure whereby 200 oil-immersion eels (magnification, 1000) were read on Giemsa-stained thick blood smears by 2 independent readers who were blinded to the patient&#8217;s group assignment. The identification of 1 asexual <I>P. vivax</I> parasite was recorded as a positive smear result. For positive smear results, speciation was determined by examination of thin smears. Any discrepancies were resolved by a third senior study microscopist." (also see quote from report below for adverse events).</P>
<P>The trial was open-label but efficacy outcomes would not be at risk of detection bias according to the procedures adopted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:44:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>"evaluations were conducted at least every 2 weeks to week 8, and then every 2&#8211;4 weeks for up to 24 weeks. A complete blood cell count was determined and standard hepatic and renal function tests were conducted approximately every other day during treatment, and then every 2&#8211;4 weeks for up to 24 weeks. Methemoglobin levels were measured on a similar schedule using an OSM-3 Hemoximeter (Radiometer)". Trial authors</P>
<P>systematically ascertained adverse events. No significant differences were detected in subjectively reported adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:45:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>Blood smears were read centrally of all participants who were febrile on weekly home visits. Adverse events were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-03 09:45:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>Trial authors reported no adverse events in either intervention arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-03 09:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>"All the collected blood &#64257;lms were forwarded and cross-checked by an independent observer at the central level, Addis Ababa. Any discordant readings between the two observers were further cross-checked by a third independent laboratory technician. Mean parasite density was used if the<BR/>parasite count between the two observers show greater than 20%"</P>
<P>The study was open label but the determination of parasitaemia was objectively ascertained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-07-22 11:12:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>No patient is reported to have had other adverse effects though it is unclear if they were systematically ascertained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-10-08 11:12:03 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Subjective outcomes: Other adverse effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Objective outcomes: parasitaemia and serious adverse effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:30:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>"Between days 28 and 180 of the follow-up period, 19 patients were lost; these were equally distributed among the three groups of study and had no effect on the results observed." The total loss to follow-up was 9%, (9%, 13%, 6%).</P>
<P>"All patients were included in analysis of efficacy (to time of recurrence or loss to follow-up) and all outcomes were included for analysis, regardless of compliance with dosing regimens (intent-to-treat)."</P>
<P>"The number of lost patients during the follow-up period had no effect on the final results, as confirmed after per protocol, intend-to-treat, and worst-case scenario analysis."</P>
<P>Sensitivity analyses did not differ in direction of effect estimates.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>Not applicable as trial authors did not report any subjective outcomes or other adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>"Patients lost during the follow-up period represented &lt; 5% in all groups."</P>
<P>Trial authors did not report actual proportions in each arm, but at these rates of dropout, we thought differential effects were unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>Trial authors did not report any subjective outcomes or other adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-08 11:11:06 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>In the CQ arm 24/125 were lost to follow-up compared to 21/124 in the CQ plus 14-day PQ arm (plus one exclusion after randomization due to detection of mixed <I>P. vivax</I> and <I>P. falciparum</I> infection). There were 101/125 evaluable participants in the CQ arm and 103/125 in those randomized to CQ + 14-day PQ arm. Overall 18% were not included in the per-protocol analysis, but no differential drop-out rates were seen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>Trial authors actively followed up all participants with clinical assessments at regular intervals up to day 42.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-08 11:11:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>"One patient in Group A (CQ only) who came back with <I>P. vivax</I> parasitaemia on Day 14 (indicative of RI resistance to chloroquine) was excluded from analysis"</P>
<P>Unlikely to introduce bias in the intention to treat analysis used in this review.</P>
<P>Follow-up completed only by 72% to 77% of participants randomized but nearly equal numbers in each group completed follow-up at six months; follow-up data from 6 months to one year not reported but this was because the trial was terminated due to lack of efficacy in the 5 day PQ arm.</P>
<P>Relapse in India behave like temperate strains with few early relapses with most occurring between six months to a year. Unlikely to introduce bias in relative efficacy reported at 6 month follow-up.</P>
<P>Adverse events appear not to have been systematically ascertained nor reported; however, trial authors state that all participants tolerated drugs and none reported adverse events other than mild nausea and itching.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:32:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>Trial authors did not systematically report adverse events or numerical data on adverse events by treatment arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:34:14 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>The trial authors did not report any other adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-08 11:12:03 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>All randomized participants completed the trial and trial authors reported data for all participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>"All families were still residing in the camp after 9 months of follow up".</P>
<P>There appear to have been no drop outs or withdrawals and trial authors fully reported outcome data for primary outcomes, which were presented stratified by age group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>Trial authors did not report numerical data for adverse events by treatment group but stated that PQ was well-tolerated throughout.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>Attrition was 5% of those enrolled and occurred by 8 weeks; the difference in attrition between groups was not statistically significant. There were no serious adverse events reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>No other adverse events were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>Only 71% of participants completed follow-up but the proportion of drop outs in each group were similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>Numerical data for other adverse events were not reported but trial authors state there were none.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>Dropouts were greater in the CQ only arm (28.8%) than in the CQ + PQ 14 days arm (21.4%) and reasons for dropout are not available in the report; though difference in dropout rates were not significant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>Unclear whether trial authors systematically ascertained other adverse effects but since none were reported, the lack of participant blinding is unlikely to have introduced detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>Trial authors reported no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>Trial authors reported no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>Trial authors did not report any attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>Trial authors did not report any attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>In the 14-day PQ arm , 80%, and 75% in the five-day PQ arm completed two months of follow-up (not statistically significant).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>Trial authors did not report any other adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-22 11:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>77% in CQ only arm and 100% CQ + 14-day PQ arm completed treatment (not significantly different).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-07-22 11:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>As above; treatment arms did not differ in other adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-03 09:45:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>Trial authors reported there was no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:45:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>Trial authors reported there was no attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-22 11:13:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>Attrition was low and similar in both arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2013-10-03 09:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>Attrition was low and similar in both arms; trial authors did not report any other adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>Trial authors only pre-stated the outcome of recurrence in the methods and adequately reported this. They did not report any safety outcomes specifically.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:31:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>The stated outcome was recurrence only and trial authors adequately reported this. Trial authors did not report any safety outcomes specifically other than lack of severe adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>Trial authors prospectively registered the trial and we did not detect any evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>Apart from incomplete outcome reporting between 6 months to one year, trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:34:14 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>The trial was retrospectively registered, but from the trial protocol made available in a supplementary online file, no selective reporting was evident.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>The trial was not prospectively registered but trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>Trial authors reported all pre-stated outcomes in the protocol and the registration document in the published report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>Trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:38:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>Trial authors appear to have reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:39:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>Trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>The trial was not prospectively registered, but trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>Trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:44:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>The trial was not prospectively registered, but trial authors reported all pre-stated outcomes in the methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:46:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>The only outcome the trial authors reported was efficacy. We did not think the lack of reporting of adverse events was due to selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>Trial authors reported all pre-stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2006">
<DESCRIPTION>
<P>We did not detect any other potential sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:31:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmona_x002d_Fonseca-2009">
<DESCRIPTION>
<P>We did not detect any other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 11:04:05 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="NO" STUDY_ID="STD-Ganguly-2013">
<DESCRIPTION>
<P>Follow-up was for only 42 days (two weeks after the 28 day period where CQ alone would be effective against relapses). This is inadequate to detect future relapses over the next four to five months.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:32:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gogtay-1999">
<DESCRIPTION>
<P>"No attempt was made to distinguish relapses and re-infections in the present study"</P>
<P>Trial authors do not believe that re-infections were likely based on local epidemiology; and parasitic clearance was confirmed by day 28. We did not detect any other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:34:14 +0100" MODIFIED_BY="Prathap  Tharyan" RESULT="YES" STUDY_ID="STD-Kim-2012">
<DESCRIPTION>
<P>We did not detect any other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leslie-2004">
<DESCRIPTION>
<P>Trial authors did not differentiate relapses from re-infections and conducted the trial in an endemic area during a period of intense transmission; males had higher rates of infection at follow-up and trial authors surmised that this could be due to re-infection. However, it is unlikely that this would introduce bias for relative efficacy of treatments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leslie-2008">
<DESCRIPTION>
<P>The interim analysis was unscheduled. The sample size estimation initially was powered to detect differences between the 14-day PQ arm and the placebo arm but later changed to detect differences between the 8-week PQ (assuming a failure rate of 5%) and the placebo arm (assumed failure rate of 30%). However, it is unclear if this unscheduled interim analysis and downward revision introduced biases other than what was commented on under selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:37:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pukrittayakamee-1994">
<DESCRIPTION>
<P>Relapses were not differentiated from re-infections; though Bangkok is not known to have a high rate of re-infections due to low transmission, participants returned home after treatment to malaria endemic areas but this is unlikely to have affected outcomes differentially in the intervention arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:38:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rajgor-2003">
<DESCRIPTION>
<P>We did not detect any other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999a">
<DESCRIPTION>
<P>We did not detect any other potential sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:41:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rowland-1999b">
<DESCRIPTION>
<P>We did not detect any other potential sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:43:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Villalobos-2000">
<DESCRIPTION>
<P>We did not detect any other potential biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:44:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walsh-2004">
<DESCRIPTION>
<P>Partly industry funded; trial authors did not report the role of funding agency in the conduct and reporting of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:45:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yadav-2002">
<DESCRIPTION>
<P>We did not detect any other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-03 09:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeshiwondim-2010">
<DESCRIPTION>
<P>We did not detect any other biases.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-10-17 16:44:56 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-10-17 16:44:56 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-07-15 17:43:22 +0100" MODIFIED_BY="Grade Profiler">Primaquine five days compared to 14 days</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>What are the effects of five days of primaquine compared to 14 days of primaquine for preventing relapses in people with <I>P. vivax </I>malaria treated for blood stage infections with chloroquine?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>P. vivax</I> malaria<SUP>1</SUP>
<BR/>
<B>Intervention:</B> Chloroquine (25 mg/kg over three to five days) plus primaquine (0.25 mg/kg per day) for five days<BR/>
<B>Comparison: </B>Chloroquine (25 mg/kg over three days) plus primaquine (0.25 mg/kg per day) for 14 days</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine 14 days</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine 5 days </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>
<B>P. vivax </B>
</I>
<B>parasitaemia detected &gt; 30 days after starting primaquine</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>21 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>183 more per 1000</B>
<BR/>(from 49 more to 742 more)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 10.05 </B>
<BR/>(2.82 to 35.86)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>186<BR/>(2 studies)<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>186<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Other adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>none reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>186<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the average of the risk in the control groups of the two studies. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> was done in Mumbai, India, and <LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK> was done in Porto Velho, Brazil; treatments were supervised in both and follow-up was for three to six months. <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> was done in Kolkata, India; primaquine was not supervised; follow-up was for 15 months.</P>
<P>
<SUP>2 </SUP>Data from a third trial (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>) were not pooled due to substantial heterogeneity (I<SUP>2</SUP> = 87%). This trial was at risk of selection and detection bias, and the trial authors reported that the lack of significant difference in recurrences over 15 months (27%, 16/59 with 5-day primaquine; 38%, 16/42 with 14-day primaquine) was likely due to non-adherence to unsupervised primaquine.<BR/>
<SUP>3</SUP> No serious study limitations: the trials were at low risk bias in all domains we assessed. <BR/>
<SUP>4</SUP> No serious inconsistency: there was inconsistency in the magnitude of effect estimates (I<SUP>2 </SUP>= 53%), though not in the direction of effect. Using random effects did not change the estimates appreciably. <BR/>
<SUP>4</SUP> Serious indirectness: trials excluded children. Although other trials in this review that included children did not find five or 14 days of primaquine to differ in efficacy in children and adults, more direct evidence of the comparative effects in children are needed. Two trials in low transmission areas provided the data. We downgraded by 1.<BR/>
<SUP>5</SUP> No serious imprecision: the upper and lower limits of the 95% CI of the pooled estimate indicates appreciable benefit with 14 days of primaquine, and no inconsistency in the direction of effects. The combined sample size was greater than the optimal information size given the magnitude of the relative risk reduction. <BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-10-03 09:50:16 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-07-26 04:14:11 +0100" MODIFIED_BY="Grade Profiler">Primaquine three days compared to 14 days</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>What are the effects of primaquine (3 days) compared to primaquine (14 days) for preventing relapses in people with <I>P. vivax</I> malaria treated for blood-stage infections with chloroquine?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>P. vivax</I> malaria<SUP>1</SUP>
<BR/>
<B>Intervention:</B> Chloroquine (1500 mg over three days) with concurrently primaquine (3.5 mg/kg over three days; 45 mg over three days)<BR/>
<B>Comparison: </B>Chloroquine (1500 mg over three days) with concurrent primaquine (0.25 mg/kg for 14 days)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine 14 days</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine three days </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<I>
<B>P. vivax</B>
</I>
<B> parasitaemia detected &gt; 30 days after starting primaquine</B>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>363 more per 1000</B>
<BR/>(from 183 more to 635 more)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 3.18 </B>
<BR/>(2.10 to 4.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>262<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>262<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Other adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>262<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the average of the risk in the control group in the two trials. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK> and <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK> conducted the trials in the same semi-rural areas of Columbia, South America.<BR/>
<SUP>2</SUP> No study limitations: both trials were free of the risk of bias. <BR/>
<SUP>3</SUP> No serious inconsistency: the effect estimates in both trials were consistent (I<SUP>2</SUP> = 5%). <BR/>
<SUP>4</SUP> Serious indirectness: <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK> included children and both trials were done in endemic settings with unstable and high malaria transmission. Trial authors confirmed parasitic clearance by day 28. The possibility of new infections being mistaken for relapses was minimized by the duration of follow-up and the lack of heterogeneity in results for follow-up before and after three months. However, the two trials were done in the same area in Columbia and more data from other regions with differing transmission intensities would add to our confidence in the comparative effects of shorter courses of primaquine. We downgraded by 1.<BR/>
<SUP>5</SUP> No imprecision: the upper and lower limits of the 95% CI indicated appreciable benefit with 14 days of primaquine. Although the total number of events was &lt; 300, the sample size of the trials exceeded the optimal information size, given the magnitude of benefit.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-10-03 09:50:37 +0100" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-07-26 04:14:19 +0100" MODIFIED_BY="Grade Profiler">Primaquine seven days compared to 14 days</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>What are the effects of primaquine (seven days) compared to primaquine (14 days) for preventing relapses in people with <I>P. vivax</I> malaria treated for blood stage infections with chloroquine?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>P. vivax</I> malaria<SUP>1</SUP>
<BR/>
<B>Intervention:</B> Chloroquine (600 mg per day over three days) with concurrent primaquine (15 mg base per day for seven days; total dose 105 mg)<BR/>
<B>Comparison: </B>Chloroquine (600 mg per day over three days) with concurrent primaquine (15 mg base per day for 14 days; total dose 210 mg)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>14 days primaquine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>7 days primaquine </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<I>
<B>P. vivax</B>
</I>
<B> parasitaemia detected &gt; 30 days after starting primaquine</B>
<BR/>Follow-up: 2 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>188 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>233 more per 1000</B>
<BR/>(from 45 more to 568 more)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.24 </B>
<BR/>(1.24 to 4.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>126<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B> <SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Severe adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>126<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Other adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>126<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the risk in the control group. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK> was conducted in Columbia, South America.<BR/>
<SUP>2</SUP> Serious indirectness: trial authors did not include children &lt; 15 years in this trial. However, another trial done in the same area by the same group of investigators (<LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>) immediately after this trial included children as well, and results for three days of primaquine versus 14 days of primaquine did not differ in children from that in adults. Duration of follow-up was two months. While this ensures the detection of early relapses, it does not cover relapses after two months. The relapse rates at six months in <LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK> also showed that most relapses occur by two months. However, the data for the effects of seven days of primaquine come from only one trial. We downgraded by 1.<BR/>
<SUP>3</SUP> Serious imprecision:<I> </I>though the upper and lower limits of the 95% CI of the risk ratio in this trial showed statistically significant and clinically appreciable benefit with 14 days of primaquine over seven days of primaquine, the total number of events was 38 and the sample size of the trial was 104. This is lower than the optimal information size. We downgraded by 1.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-10-08 11:15:29 +0100" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-07-04 14:24:35 +0100" MODIFIED_BY="Grade Profiler">Primaquine (weekly for eight weeks) compared to daily primaquine for 14 days</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>What are the effects of supervised primaquine (weekly for 8 weeks) versus primaquine (daily for 14 days) for preventing relapses in people with <I>P. vivax</I> malaria treated for blood stage infections with chloroquine?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Children and adults with blood smear positive <I>P. vivax</I> malaria<SUP>1</SUP>
<BR/>
<B>Intervention:</B> Chloqoquine (600 mg over three days) plus primaquine (45 mg weekly for eight weeks; total dose 360 mg)<SUP>2</SUP>
<BR/>
<B>Comparison: </B>Chloroquine (600 mg per day over three days) plus primaquine (22.5 mg base daily for 14 days; total dose 315 mg)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine for 14 days</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine weekly for eight weeks </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<I>
<B>P. vivax</B>
</I>
<B> parasitaemia detected &gt; 30 days after starting primaquine</B>
<BR/>Follow-up: 6 to 11 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 more per 1000</B>
<BR/>(from 12 fewer to 452 more)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.97 </B>
<BR/>(0.34 to 25.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>129<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8861;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>Follow-up: 9 to 11 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>129<BR/>(1 study)<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
<BR/>Follow-up: 9 to 11 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>129<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the risk in the control group. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK> was conducted in three Afghan refugee camps in North West Frontier Province in Pakistan during a period of low transmission.<BR/>
<SUP>2</SUP> These were doses used in adults; doses for children were proportionately lower.<BR/>
<SUP>3</SUP> Very serious study limitations: mixed randomization and allocation procedures resulted in high risk of selection bias and imbalanced numbers of participants and unequal distribution of prognostic indicators. The occurrence of selection bias was demonstrated by significant differences in outcome estimates that varied by site, and by intervention. The sample size was not powered to detect significant differences between interventions, and recruitment did not achieve the estimated sample size in the 14-day primaquine arm. We downgraded by 2.<BR/>
<SUP>4</SUP> Serious indirectness: this trial included children and adults and was done in displaced persons in refugee camps. However, trial authors did not confirm parasitic clearance after chloroquine by day 28, though it is unclear if recrudescence or relapses would be differentially distributed in the intervention arms. The estimates for recurrences for periods greater than 3 to 6 months is likely to differ if applied to high transmission settings (transmission was unusually low during the period of recruitment of this trial); and the supervision options for 8 weeks of primaquine may also differ in populations that are not restricted to refugee settlements with limited geographical mobility. We downgraded by 1.<BR/>
<SUP>5</SUP> Very serious imprecision: sample size was under-powered to detect important differences between interventions; the number of events were very low and the total sample size was much lower than the optimal information size. The 95% CI of the risk ratio indicates appreciable benefit for the 8-week, intermittent primaquine and for 14 daily doses of primaquine that do not rule out random error. We downgraded by 2.</P>
<P>
<SUP>6 </SUP>Trial authors allocated insufficient numbers of people with G6PD deficiency (only one in the report) to the 8-week arm to be sure that intermittent primaquine is a safer alternative than 14 days of primaquine; none given the 14-day regimen had this deficiency.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-10-03 11:37:48 +0100" MODIFIED_BY="Grade Profiler" NO="5" READONLY="YES">
<TITLE MODIFIED="2013-07-26 04:14:29 +0100" MODIFIED_BY="Grade Profiler">Primaquine for five days</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>What are the effects of primaquine (five days) compared to no intervention or placebo for preventing relapses in people with <I>P. vivax</I> malaria treated for blood stage infections with chloroquine?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>P. vivax</I> malaria<SUP>1</SUP>
</P>
<P>
<B>Intervention:</B> Chloroquine (25 mg/kg for three days) plus primaquine (0.25 mg/kg) for five days<SUP>2</SUP>
<BR/>
<B>Comparison: </B>Chloroquine (25 mg/kg for three days)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No primaquine </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>5 days primaquine </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<I>
<B>P. vivax</B>
</I>
<B> parasitaemia detected &gt; 30 days after starting primaquine</B>
<BR/>Follow-up: 6 to 15 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>193 per 1000</B>
<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 fewer per 1000</B>
<BR/>(from 53 fewer to 59 more)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.73 to 1.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2213<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>3,4,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2213<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Other adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2213<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across the four studies. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Trial authors performed trials in outpatients in Mumbai, India (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>) and Kolkota, India (<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>), and in the Adizai Afghan refugee camp in the North West Frontier Province of Pakistan (<LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>).<BR/>
<SUP>2</SUP> Chloroquine and primaquine were given sequentially in the four trials.<BR/>
<SUP>3</SUP> No serious study limitations: three trials were free of the risk of bias in all domains assessed. <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> was at risk of selection and detection bias, but the results were consistent with that seen in two other trials with follow-up beyond six months; and this trial contributed only 16% weight to the pooled results. Removal of <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> in sensitivity analysis did not alter the results appreciably. <BR/>
<SUP>4</SUP> No serious inconsistency: the pooled effect estimates of <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK> and <LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK> that evaluated parasitaemia after 6 months were inconsistent in their direction of effect from <LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK> that assessed this at six months (I<SUP>2</SUP> = 50%). However, inconsistency was not evident within subgroups based on the duration of follow-up &gt; than or &lt; than six months, irrespective of whether treatments were supervised. <BR/>
<SUP>5</SUP> No serious indirectness: <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> and <LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK> included children &gt; 1 to 3 years of age; all four trials were conducted in low income countries and the transmission patterns were representative of the patterns seen with tropical strains and seasonality in other parts of the region. Though the outcome used is a proxy measure for relapse, the absence of widely available tests using valid molecular genetic marker makes clinical diagnoses based on recurrence timings the best available outcome to asses relapses in vivax malaria. <BR/>
<SUP>6</SUP> No serious imprecision: the 95% CI of the risk ratio indicates appreciable benefit with both interventions; however the total number of events was more than 300 and the total sample size exceeded the optimal information size. </P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2013-10-03 11:38:29 +0100" MODIFIED_BY="Grade Profiler" NO="6" READONLY="YES">
<TITLE MODIFIED="2013-07-04 14:24:19 +0100" MODIFIED_BY="Grade Profiler">Primaquine for 14 days</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>What are the effects of primaquine (14 days) compared to no intervention or placebo for preventing relapses in people with <I>P. vivax</I> malaria treated for blood stage infection with chloroquine?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with <I>P. vivax</I> malaria<SUP>1</SUP>
<BR/>
<B>Intervention:</B> Chloroquine (25 mg/kg for three days) plus primaquine (0.25 mg/kg) for 14 days<BR/>
<B>Comparison: </B>Chloroquine (25 mg/kg for three days)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No primaquine </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Primaquine 14 days </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<I>
<B>P. vivax </B>
</I>
<B>parasitaemia detected &gt; 30 days after starting primaquine</B>
<BR/>Follow-up: 7 weeks to 15 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>84 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 fewer per 1000</B>
<BR/>(from 21 fewer to 44 fewer)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.60 </B>
<BR/>(0.48 to 0.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1740<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2,3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1740<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Other adverse events</B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>None reported</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1740<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median risk in the control group. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Trial authors conducted the studies in Ethiopia (<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>), India (<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>; <LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>; <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>; <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>), Pakistan (<LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>; <LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>; <LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>; <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>) and Thailand (<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>).<BR/>
<SUP>2</SUP> No serious study limitations: <LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>, <LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>, and <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> were at high risk of bias. However, these studies contributed only 15.5% weight to the pooled effect estimates and their removal from the sensitivity analysis did not alter the results appreciably. <BR/>
<SUP>3</SUP> No serious inconsistency: results were consistent within subgroups of trials based on duration of follow-up &lt; than or &gt; than six months, and whether treatments were supervised or not; the I<SUP>2</SUP> value for the pooled effect estimates from the 10 trials was 30%. <BR/>
<SUP>4</SUP> No serious indirectness: trials included children and were also done in transmission settings and countries representative of vivax malaria burden. The outcome used was the best estimate currently available in the absence of widely available validated molecular techniques to differentiate relapse from new infections. <BR/>
<SUP>5</SUP> No serious imprecision: upper and lower limits of the 95% CI of the pooled relative risk indicated appreciable benefit with chloroquine plus primaquine for 14 days. The total number of events was less than 300 but the total sample size was larger than the optimal information size, given the magnitude of risk reduction.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-10-08 11:16:24 +0100" MODIFIED_BY="Harriet MacLehose">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-05-13 15:32:13 +0100" MODIFIED_BY="Harriet MacLehose" NO="1">
<TITLE>Detailed search strategies</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Plasmodium vivax</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>primaquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
<P/>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>primaquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>primaquine</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vivax malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRIMAQUINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRIMAQUINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PRIMAQUINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>primaquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Plasmodium vivax</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Plasmodium vivax</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MALARIA, VIVAX</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria vivax</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vivax malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Plasmodium vivax</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PLASMODIUM VIVAX</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 or 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 or 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 or 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 and 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-10-08 11:16:24 +0100" MODIFIED_BY="Prathap  Tharyan" NO="2">
<TITLE MODIFIED="2013-06-17 10:49:55 +0100" MODIFIED_BY="Prathap  Tharyan">Relapse rates and total dose of primaquine used in the intervention arms</TITLE>
<TABLE COLS="5" ROWS="33">
<TR>
<TH>
<P>
<B>Total dose of primaquine in intervention arms</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Duration of primaquine treatment</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Relapse (%)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Mean relapse rate (95% CI);</B>
</P>
<P>
<B>Median relapse rate</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="12">
<P>No primaquine</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>
</P>
</TD>
<TD ROWSPAN="12">
<P>Nil</P>
</TD>
<TD>
<P>4/30 (13)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="12">
<P>22% (19% to 26%);</P>
<P>12%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>
</P>
</TD>
<TD>
<P>7/60 (12)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>
</P>
</TD>
<TD>
<P>49/100 (49)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rowland-1999b" TYPE="STUDY">Rowland 1999b</LINK>
</P>
</TD>
<TD>
<P>129/250 (5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>
</P>
</TD>
<TD>
<P>62/723 (9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>
</P>
</TD>
<TD>
<P>13/142 (9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>
</P>
</TD>
<TD>
<P>88/212 (42)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>
</P>
</TD>
<TD>
<P>8/10 (80)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>
</P>
</TD>
<TD>
<P>2/71 (3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>**</P>
</TD>
<TD>
<P>9/128 (7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>
</P>
</TD>
<TD>
<P>1/100 (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK>
</P>
</TD>
<TD>
<P>5/50 (15)</P>
</TD>
</TR>
<TR>
<TD>
<P>45 mg</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>*</P>
</TD>
<TD>
<P>3 days</P>
</TD>
<TD>
<P>32/65 (49)</P>
</TD>
<TD ALIGN="CENTER">
<P>49% (38% to 61%)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>75 mg*</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>
</P>
</TD>
<TD ROWSPAN="4">
<P>5 days</P>
</TD>
<TD>
<P>16/62 (26)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4">
<P>28% (27% to 30%);</P>
<P>27%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>
</P>
<P/>
</TD>
<TD>
<P>128/250 (51)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>*</P>
<P/>
</TD>
<TD>
<P>8/30 (27)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yadav-2002" TYPE="STUDY">Yadav 2002</LINK>
</P>
</TD>
<TD>
<P>49/759 (7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>105 mg</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>
</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>26/62 (42)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>42% (31% to 54%)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="12">
<P>210 mg*</P>
</TD>
<TD>
<P>
<LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>*</P>
</TD>
<TD>
<P>3 days</P>
</TD>
<TD>
<P>37/65 (57)</P>
</TD>
<TD ALIGN="CENTER">
<P>57% (45% to 68%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pukrittayakamee-1994" TYPE="STUDY">Pukrittayakamee 1994</LINK>
</P>
</TD>
<TD ROWSPAN="11">
<P>14 days</P>
</TD>
<TD>
<P>2/25 (8)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="11">
<P>12% (11% to 13%);</P>
<P>8%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gogtay-1999" TYPE="STUDY">Gogtay 1999</LINK>
</P>
</TD>
<TD>
<P>0/63 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rowland-1999a" TYPE="STUDY">Rowland 1999a</LINK>
</P>
</TD>
<TD>
<P>32/100 (32)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Villalobos-2000" TYPE="STUDY">Villalobos 2000</LINK>
</P>
</TD>
<TD>
<P>2/31 (7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rajgor-2003" TYPE="STUDY">Rajgor 2003</LINK>
</P>
</TD>
<TD>
<P>6/131 (5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Leslie-2004" TYPE="STUDY">Leslie 2004</LINK>
</P>
</TD>
<TD>
<P>27/173 (16)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Walsh-2004" TYPE="STUDY">Walsh 2004</LINK>
</P>
</TD>
<TD>
<P>3/12 (25)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Alvarez-2006" TYPE="STUDY">Alvarez 2006</LINK>*</P>
</TD>
<TD>
<P>12/64 (19)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carmona_x002d_Fonseca-2009" TYPE="STUDY">Carmona-Fonseca 2009</LINK>
</P>
</TD>
<TD>
<P>10/68 (15)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yeshiwondim-2010" TYPE="STUDY">Yeshiwondim 2010</LINK>
</P>
</TD>
<TD>
<P>4/132 (3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ganguly-2013" TYPE="STUDY">Ganguly 2013</LINK>
</P>
</TD>
<TD>
<P>1/103 (1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>315 mg</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>
</P>
</TD>
<TD>
<P>14 days</P>
</TD>
<TD>
<P>0/55 (0)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>360 mg</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Leslie-2008" TYPE="STUDY">Leslie 2008</LINK>
</P>
</TD>
<TD>
<P>Weekly over 8 weeks</P>
</TD>
<TD>
<P>3/74 (4)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4% (1% to 11%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* We did not show data for 5 days primaquine (75 mg) and 14 days primaquine (210 mg) from <LINK REF="STD-Kim-2012" TYPE="STUDY">Kim 2012</LINK> due to high risk of selection and detection bias. Also, the trial authors expressed doubts regarding patient adherence to primaquine in this unsupervised trial, raising concerns about the reliability of relapse estimates with primaquine.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-10-08 11:22:49 +0100" MODIFIED_BY="Harriet MacLehose">
<COMPARISON ID="CMP-001" MODIFIED="2013-10-08 11:22:49 +0100" MODIFIED_BY="Harriet MacLehose" NO="1">
<NAME>Primaquine: 5 days versus 14 days</NAME>
<DICH_OUTCOME CHI2="15.659760850390697" CI_END="2.8837809537181522" CI_START="1.1227331413980945" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7993655685468626" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="18" I2="87.22841287866729" I2_Q="92.79049213093256" ID="CMP-001.01" LOG_CI_END="0.4599622691526751" LOG_CI_START="0.050276542556619015" LOG_EFFECT_SIZE="0.25511940585464704" METHOD="MH" MODIFIED="2013-10-08 11:22:49 +0100" MODIFIED_BY="Harriet MacLehose" NO="1" P_CHI2="3.9767432771931066E-4" P_Q="1.9584405830608276E-4" P_Z="0.014645978052926728" Q="13.87057227984346" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="151" TOTAL_2="136" WEIGHT="200.0" Z="2.4410166855794917">
<NAME>
<I>P. vivax</I> parasitaemia &gt; 30 days after starting primaquine</NAME>
<GROUP_LABEL_1>CQ + PQ (5 days)</GROUP_LABEL_1>
<GROUP_LABEL_2>CQ + PQ (14 days)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CQ + PQ (5 days)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CQ + PQ (14 days)</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.126788996029461" CI_END="35.86339752529737" CI_START="2.817482031248243" DF="1" EFFECT_SIZE="10.052088246082903" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="2" I2="52.980761050253825" ID="CMP-001.01.01" LOG_CI_END="1.5546514301395615" LOG_CI_START="0.449861154973825" LOG_EFFECT_SIZE="1.0022562925566934" MODIFIED="2013-10-08 11:22:39 +0100" MODIFIED_BY="Prathap  Tharyan" NO="1" P_CHI2="0.14474375221614888" P_Z="3.763648554118194E-4" STUDIES="2" TAU2="0.0" TOTAL_1="92" TOTAL_2="94" WEIGHT="100.0" Z="3.5561251412990016">
<NAME>Follow-up &#8804; 6 months (supervised treatment)</NAME>
<DICH_DATA CI_END="546.842693846703" CI_START="2.0551537354976728" EFFECT_SIZE="33.523809523809526" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7378624140490566" LOG_CI_START="0.3128443147673294" LOG_EFFECT_SIZE="1.525353364408193" MODIFIED="2013-07-25 21:32:46 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="203" O_E="0.0" SE="1.4244676355512766" STUDY_ID="STD-Gogtay-1999" TOTAL_1="62" TOTAL_2="63" VAR="2.0291080447330447" WEIGHT="20.138343027825815"/>
<DICH_DATA CI_END="17.903787002582337" CI_START="0.9542363546874351" EFFECT_SIZE="4.133333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2529449025090404" LOG_CI_START="-0.020344041623895085" LOG_EFFECT_SIZE="0.6163004304425727" MODIFIED="2013-07-25 21:32:51 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="204" O_E="0.0" SE="0.7479362286656114" STUDY_ID="STD-Villalobos-2000" TOTAL_1="30" TOTAL_2="31" VAR="0.5594086021505377" WEIGHT="79.86165697217419"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2573409037864585" CI_START="0.40303384079344573" DF="0" EFFECT_SIZE="0.711864406779661" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.09945304424179995" LOG_CI_START="-0.3946584867302874" LOG_EFFECT_SIZE="-0.14760272124424373" MODIFIED="2013-10-08 11:22:49 +0100" MODIFIED_BY="Prathap  Tharyan" NO="2" P_CHI2="1.0" P_Z="0.2416090213042006" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="42" WEIGHT="100.0" Z="1.1709745655588246">
<NAME>Follow-up &gt; 6 months (unsupervised treatment)</NAME>
<DICH_DATA CI_END="1.2573409037864582" CI_START="0.4030338407934458" EFFECT_SIZE="0.711864406779661" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.09945304424179988" LOG_CI_START="-0.39465848673028736" LOG_EFFECT_SIZE="-0.14760272124424373" MODIFIED="2013-07-25 21:31:52 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="24" O_E="0.0" SE="0.2902435591845292" STUDY_ID="STD-Kim-2012" TOTAL_1="59" TOTAL_2="42" VAR="0.08424132364810331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-10-03 10:15:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Primaquine: 3 days versus 14 days</NAME>
<DICH_OUTCOME CHI2="0.8380510366127926" CI_END="4.814869816237821" CI_START="2.103144375630539" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1821952129644435" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.6825845492271421" LOG_CI_START="0.3228690869456947" LOG_EFFECT_SIZE="0.5027268180864184" METHOD="MH" MODIFIED="2013-05-29 17:24:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3599548431973587" P_Q="1.0" P_Z="4.2927178381594274E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="5.478365879867928">
<NAME>
<I>P. vivax </I>parasitaemia &gt; 30 days after starting primaquine</NAME>
<GROUP_LABEL_1>CQ + PQ (3 days)</GROUP_LABEL_1>
<GROUP_LABEL_2>CQ + PQ (14 days)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CQ +PQ (3 days)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CQ + PQ (14 days)</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.627114211246435" CI_START="1.4899115260161646" EFFECT_SIZE="2.6256410256410256" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="12" LOG_CI_END="0.6653102193403849" LOG_CI_START="0.17316047988624061" LOG_EFFECT_SIZE="0.41923534961331277" MODIFIED="2012-05-21 11:59:34 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.2890911931358649" STUDY_ID="STD-Alvarez-2006" TOTAL_1="65" TOTAL_2="64" VAR="0.08357371794871794" WEIGHT="55.3014553014553"/>
<DICH_DATA CI_END="7.125506586852936" CI_START="2.1027072609145083" EFFECT_SIZE="3.870769230769231" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="10" LOG_CI_END="0.8528157458811002" LOG_CI_START="0.32277881437965134" LOG_EFFECT_SIZE="0.5877972801303758" MODIFIED="2012-05-21 11:59:49 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3113463172890768" STUDY_ID="STD-Carmona_x002d_Fonseca-2009" TOTAL_1="65" TOTAL_2="68" VAR="0.09693652928947047" WEIGHT="44.698544698544694"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-10-03 10:15:42 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Primaquine: 7 days versus 14 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.02715903586285" CI_START="1.2421155313733017" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.236559139784946" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.6049987805967184" LOG_CI_START="0.09416199222093428" LOG_EFFECT_SIZE="0.3495803864088264" METHOD="MH" MODIFIED="2013-05-29 17:28:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0073069768599330455" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="2.682520063762013">
<NAME>
<I>P. vivax </I>parasitaemia &gt; 30 days after starting primaquine</NAME>
<GROUP_LABEL_1>CQ + PQ (7 days)</GROUP_LABEL_1>
<GROUP_LABEL_2>CQ + PQ (14 days)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CQ + PQ (7 days)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CQ + PQ (14 days)</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.02715903586285" CI_START="1.2421155313733017" EFFECT_SIZE="2.236559139784946" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" LOG_CI_END="0.6049987805967184" LOG_CI_START="0.09416199222093428" LOG_EFFECT_SIZE="0.3495803864088264" MODIFIED="2012-05-21 11:49:50 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.3000680581748202" STUDY_ID="STD-Alvarez-2006" TOTAL_1="62" TOTAL_2="64" VAR="0.09004083953680728" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-10-03 10:15:54 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Primaquine: weekly for 8 weeks versus daily for 14 days</NAME>
<DICH_OUTCOME CHI2="0.09259256084328628" CI_END="21.107786325600372" CI_START="0.6567425685866864" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7232219660737016" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="1.3244426891585646" LOG_CI_START="-0.18260483280158726" LOG_EFFECT_SIZE="0.5709189281784885" METHOD="MH" MODIFIED="2013-05-29 17:28:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7609067849999421" P_Q="0.7620719385087703" P_Z="0.13754461429147155" Q="0.09166429114832056" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="110" WEIGHT="200.0" Z="1.4849970170371771">
<NAME>
<I>P. vivax </I>parasitaemia &gt; 30 days after starting primaquine</NAME>
<GROUP_LABEL_1>CQ + PQ (8 weeks)</GROUP_LABEL_1>
<GROUP_LABEL_2>CQ + PQ (14 days)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CQ + PQ (8 weeks)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CQ + PQ (14 days)</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.15395272002087" CI_START="0.27551140115999095" DF="0" EFFECT_SIZE="5.226666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="1.9963100318068439" LOG_CI_START="-0.5598604245493295" LOG_EFFECT_SIZE="0.7182248036287572" MODIFIED="2012-05-22 22:15:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2707186480456091" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="55" WEIGHT="100.0" Z="1.101409136793161">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="99.15395272002087" CI_START="0.27551140115999095" EFFECT_SIZE="5.226666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9963100318068439" LOG_CI_START="-0.5598604245493295" LOG_EFFECT_SIZE="0.7182248036287572" MODIFIED="2012-05-22 22:15:09 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="1.5015071793114443" STUDY_ID="STD-Leslie-2008" TOTAL_1="74" TOTAL_2="55" VAR="2.2545238095238096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.865466863270274" CI_START="0.3417130780878649" DF="0" EFFECT_SIZE="2.972972972972973" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="1.4127203216900939" LOG_CI_START="-0.46633839950763384" LOG_EFFECT_SIZE="0.47319096109123004" MODIFIED="2012-05-22 22:15:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3235791216765177" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="55" WEIGHT="100.0" Z="0.9871295996088391">
<NAME>At 11 months</NAME>
<DICH_DATA CI_END="25.865466863270274" CI_START="0.3417130780878649" EFFECT_SIZE="2.972972972972973" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4127203216900939" LOG_CI_START="-0.46633839950763384" LOG_EFFECT_SIZE="0.47319096109123004" MODIFIED="2012-05-22 22:15:28 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="1.1037683943222276" STUDY_ID="STD-Leslie-2008" TOTAL_1="74" TOTAL_2="55" VAR="1.2183046683046683" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-10-08 11:22:16 +0100" MODIFIED_BY="Harriet MacLehose" NO="5">
<NAME>Primaquine 5 days versus no primaquine</NAME>
<DICH_OUTCOME CHI2="5.984922686207572" CI_END="1.302329348649508" CI_START="0.7345503251973682" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9780728227307887" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="213" I2="49.874039193295054" I2_Q="75.64168969433335" ID="CMP-005.01" LOG_CI_END="0.11472082771409703" LOG_CI_START="-0.13397844465683204" LOG_EFFECT_SIZE="-0.009628808471367517" METHOD="MH" MODIFIED="2013-10-08 11:22:16 +0100" MODIFIED_BY="Harriet MacLehose" NO="1" P_CHI2="0.11234612819478906" P_Q="0.04274721517592839" P_Z="0.8793710496345839" Q="4.105375075082129" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0399691086671798" TOTALS="YES" TOTAL_1="1130" TOTAL_2="1083" WEIGHT="100.0" Z="0.15176657042861932">
<NAME>
<I>P. vivax </I>parasitaemia &gt; 30 days after starting primaquine</NAME>
<GROUP_LABEL_1>CQ plus PQ (5 days)</GROUP_LABEL_1>
<GROUP_LABEL_2>CQ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CQ + PQ (5 days)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CQ</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.993154607170506" CI_START="0.9799140697398403" DF="0" EFFECT_SIZE="2.2119815668202762" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.6983750136820813" LOG_CI_START="-0.008812006627965994" LOG_EFFECT_SIZE="0.34478150352705766" MODIFIED="2013-10-08 11:22:10 +0100" MODIFIED_BY="Harriet MacLehose" NO="1" P_CHI2="1.0" P_Z="0.055989270406356685" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="10.041598712353398" Z="1.9111191524763393">
<NAME>Follow-up &#8804; 6 months</NAME>
<DICH_DATA CI_END="4.993154607170508" CI_START="0.9799140697398404" EFFECT_SIZE="2.2119815668202767" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.6983750136820814" LOG_CI_START="-0.008812006627965946" LOG_EFFECT_SIZE="0.3447815035270577" MODIFIED="2013-07-25 22:33:59 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="194" O_E="0.0" SE="0.41540515636232983" STUDY_ID="STD-Gogtay-1999" TOTAL_1="62" TOTAL_2="60" VAR="0.17256144393241168" WEIGHT="10.041598712353398">
<FOOTNOTE>Supervised treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0217980455025177" CI_END="1.0936296850347509" CI_START="0.8072690229825508" DF="2" EFFECT_SIZE="0.9396027710382288" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="206" I2="1.078151477641766" ID="CMP-005.01.02" LOG_CI_END="0.038870290030703705" LOG_CI_START="-0.09298171220858961" LOG_EFFECT_SIZE="-0.027055711088942936" MODIFIED="2013-10-08 11:22:16 +0100" MODIFIED_BY="Prathap  Tharyan" NO="2" P_CHI2="0.36389180853545056" P_Z="0.4211892685135079" STUDIES="3" TAU2="3.322967101206534E-4" TOTAL_1="1068" TOTAL_2="1023" WEIGHT="89.95840128764661" Z="0.8043597125542353">
<NAME>Follow-up &gt; 6 months</NAME>
<DICH_DATA CI_END="1.6392075863448685" CI_START="0.4984934741247572" EFFECT_SIZE="0.903954802259887" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.21463395533706864" LOG_CI_START="-0.30234052274883233" LOG_EFFECT_SIZE="-0.043853283705881846" MODIFIED="2013-07-26 04:30:54 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="25" O_E="0.0" SE="0.3036733674925968" STUDY_ID="STD-Kim-2012" TOTAL_1="59" TOTAL_2="50" VAR="0.09221751412429377" WEIGHT="16.14495081462564">
<FOOTNOTE>Primaquine treatment was unsupervised</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1766640178918701" CI_START="0.8367352120934823" EFFECT_SIZE="0.9922480620155039" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="129" LOG_CI_END="0.07065247303396237" LOG_CI_START="-0.07741195433672363" LOG_EFFECT_SIZE="-0.003379740651380603" MODIFIED="2013-07-25 22:34:30 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="195" O_E="0.0" SE="0.086973777568277" STUDY_ID="STD-Rowland-1999b" TOTAL_1="250" TOTAL_2="250" VAR="0.007564437984496124" WEIGHT="44.89769170726437">
<FOOTNOTE>Supervised treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0796350933470793" CI_START="0.524958329534883" EFFECT_SIZE="0.7528369246461813" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="62" LOG_CI_END="0.03327699277896296" LOG_CI_START="-0.27987516892034237" LOG_EFFECT_SIZE="-0.12329908807068972" MODIFIED="2013-07-25 22:34:41 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="196" O_E="0.0" SE="0.18394712991037254" STUDY_ID="STD-Yadav-2002" TOTAL_1="759" TOTAL_2="723" VAR="0.03383654660226348" WEIGHT="28.9157587657566">
<FOOTNOTE>Unsupervised treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-10-08 11:21:52 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Primaquine 14 days versus no primaquine</NAME>
<IV_OUTCOME CHI2="12.848074661356131" CI_END="0.74853649989406" CI_START="0.48422257756583476" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.6020450758712423" ESTIMABLE="YES" I2="29.950593865477757" I2_Q="77.71264988168825" ID="CMP-006.01" LOG_CI_END="-0.1257870178779145" LOG_CI_START="-0.31495496482476926" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.22037099135134186" MODIFIED="2013-10-08 11:21:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16960225268801354" P_Q="0.011256056530181135" P_Z="4.958977514301476E-6" Q="8.973700280127776" RANDOM="NO" SCALE="228.61473749283954" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="836" TOTAL_2="904" WEIGHT="100.0" Z="4.566515768206357">
<NAME>
<I>P. vivax</I> parasitaemia detected &gt; 30 days after starting primaquine</NAME>
<GROUP_LABEL_1>CQ + PQ (14 days)</GROUP_LABEL_1>
<GROUP_LABEL_2>CQ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CQ + PQ (14 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CQ</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.3253543499878604" CI_END="0.6826600356672076" CI_START="0.23235792559528673" DF="5" EFFECT_SIZE="0.3982731095296753" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-0.16579552090287272" LOG_CI_START="-0.6338425093973137" LOG_EFFECT_SIZE="-0.39981901515009327" MODIFIED="2013-10-08 11:21:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8025360627892453" P_Z="8.124627209779199E-4" STUDIES="6" TAU2="0.0" TOTAL_1="466" TOTAL_2="471" WEIGHT="16.334889101719792" Z="3.3485136718821735">
<NAME>Follow-up &#8804; 6 months (supervised treatment)</NAME>
<IV_DATA CI_END="7.931652524055222" CI_START="0.01347577832958968" EFFECT_SIZE="0.3269330072071321" ESTIMABLE="YES" ESTIMATE="-1.118" LOG_CI_END="0.8993636800427349" LOG_CI_START="-1.8704461415784062" LOG_EFFECT_SIZE="-0.4855412307678356" MODIFIED="2013-07-25 23:21:17 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="29" SE="1.627" STUDY_ID="STD-Ganguly-2013" TOTAL_1="103" TOTAL_2="101" WEIGHT="0.4664393688647796"/>
<IV_DATA CI_END="1.088786520341097" CI_START="0.0037079956960870955" EFFECT_SIZE="0.06353908821648634" ESTIMABLE="YES" ESTIMATE="-2.7561" LOG_CI_END="0.03694273547070275" LOG_CI_START="-2.4308607786178076" LOG_EFFECT_SIZE="-1.1969590215735524" MODIFIED="2012-05-22 21:22:56 +0100" MODIFIED_BY="[Empty name]" ORDER="197" SE="1.4496" STUDY_ID="STD-Gogtay-1999" TOTAL_1="63" TOTAL_2="60" WEIGHT="0.5875893886992838"/>
<IV_DATA CI_END="3.008574485378226" CI_START="0.11966413041590263" EFFECT_SIZE="0.6000153744565693" ESTIMABLE="YES" ESTIMATE="-0.5108" LOG_CI_END="0.4783607680923595" LOG_CI_START="-0.9220360108047214" LOG_EFFECT_SIZE="-0.22183762135618107" MODIFIED="2013-02-11 13:28:53 +0000" MODIFIED_BY="Prathap  Tharyan" ORDER="198" SE="0.8226" STUDY_ID="STD-Pukrittayakamee-1994" TOTAL_1="25" TOTAL_2="30" WEIGHT="1.8247059767495424"/>
<IV_DATA CI_END="1.2776810692116807" CI_START="0.19588123051106715" EFFECT_SIZE="0.5002736651452683" ESTIMABLE="YES" ESTIMATE="-0.6926" LOG_CI_END="0.10642246010779484" LOG_CI_START="-0.7080071764401793" LOG_EFFECT_SIZE="-0.3007923581661922" MODIFIED="2012-05-22 21:28:14 +0100" MODIFIED_BY="[Empty name]" ORDER="199" SE="0.4784" STUDY_ID="STD-Rajgor-2003" TOTAL_1="131" TOTAL_2="142" WEIGHT="5.394956694694303"/>
<IV_DATA CI_END="0.8733709611760205" CI_START="0.11180431609641017" EFFECT_SIZE="0.3124846284423433" ESTIMABLE="YES" ESTIMATE="-1.1632" LOG_CI_END="-0.058801252087992154" LOG_CI_START="-0.9515414306117328" LOG_EFFECT_SIZE="-0.5051713413498625" MODIFIED="2013-02-11 13:29:01 +0000" MODIFIED_BY="Prathap  Tharyan" ORDER="200" SE="0.5244" STUDY_ID="STD-Walsh-2004" TOTAL_1="12" TOTAL_2="10" WEIGHT="4.489985503986887"/>
<IV_DATA CI_END="1.3644601049819602" CI_START="0.13612811387041357" EFFECT_SIZE="0.4309772390076078" ESTIMABLE="YES" ESTIMATE="-0.8417" LOG_CI_END="0.13496084199236819" LOG_CI_START="-0.8660521728283023" LOG_EFFECT_SIZE="-0.36554566541796707" MODIFIED="2012-09-04 15:01:45 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.588" STUDY_ID="STD-Yeshiwondim-2010" TOTAL_1="132" TOTAL_2="128" WEIGHT="3.571212168724997">
<FOOTNOTE>Both arms received primaquine. Primaquine was given immediately after chloroquine in one arm and after 28 days in the other arm</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.5490200312404947" CI_END="0.7378233530787401" CI_START="0.43707543882572536" DF="2" EFFECT_SIZE="0.5678771573348926" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="-0.13204760290058837" LOG_CI_START="-0.35944359772484624" LOG_EFFECT_SIZE="-0.24574560031271733" MODIFIED="2013-10-08 11:21:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4609297119606931" P_Z="2.2728919193880818E-5" STUDIES="3" TAU2="0.0" TOTAL_1="328" TOTAL_2="383" WEIGHT="69.20372611846713" Z="4.236244585964183">
<NAME>Follow-up &gt; 6 months (supervised treatment)</NAME>
<IV_DATA CI_END="0.7133669461662172" CI_START="0.32089520926095644" EFFECT_SIZE="0.4784517065178655" ESTIMABLE="YES" ESTIMATE="-0.7372" LOG_CI_END="-0.14668701755188956" LOG_CI_START="-0.49363676656626493" LOG_EFFECT_SIZE="-0.32016189205907725" MODIFIED="2012-05-30 03:03:40 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SE="0.2038" STUDY_ID="STD-Leslie-2004" TOTAL_1="173" TOTAL_2="212" WEIGHT="29.72774353196179">
<FOOTNOTE>Risk ratios adjusted for clustering (ICC = 0.32; design effect = 1.34)</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="6.438921986673316" CI_START="0.010622709830913053" EFFECT_SIZE="0.26153164223152203" ESTIMABLE="YES" ESTIMATE="-1.3412" LOG_CI_END="0.8088131632560409" LOG_CI_START="-1.9737646815133236" LOG_EFFECT_SIZE="-0.5824757591286414" MODIFIED="2013-07-25 23:21:19 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SE="1.6345" STUDY_ID="STD-Leslie-2008" TOTAL_1="55" TOTAL_2="71" WEIGHT="0.4621686203801855">
<FOOTNOTE>Total variance calculated as 0.12, between-site variance: 0.01; Risk ratios adjusted for clustering (ICC 0.13; design effect = 9.21)</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9254988337025349" CI_START="0.46080625620922877" EFFECT_SIZE="0.6530510337519364" ESTIMABLE="YES" ESTIMATE="-0.4261" LOG_CI_END="-0.03362412420105275" LOG_CI_START="-0.3364816332768985" LOG_EFFECT_SIZE="-0.18505287873897558" MODIFIED="2012-05-22 21:36:42 +0100" MODIFIED_BY="[Empty name]" ORDER="202" SE="0.1779" STUDY_ID="STD-Rowland-1999a" TOTAL_1="100" TOTAL_2="100" WEIGHT="39.013813966125156"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.251510842176398" CI_START="0.7161959499972819" DF="0" EFFECT_SIZE="1.269851545079859" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.35247404265406784" LOG_CI_START="-0.14496813920069412" LOG_EFFECT_SIZE="0.10375295172668683" MODIFIED="2013-10-08 11:21:40 +0100" MODIFIED_BY="Prathap  Tharyan" NO="3" P_CHI2="1.0" P_Z="0.41359095230528975" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="50" WEIGHT="14.46138477981307" Z="0.8175906913073238">
<NAME>Follow-up &gt; 6 months (unsupervised treatment)</NAME>
<IV_DATA CI_END="2.251510842176398" CI_START="0.7161959499972819" EFFECT_SIZE="1.269851545079859" ESTIMABLE="YES" ESTIMATE="0.2389" LOG_CI_END="0.35247404265406784" LOG_CI_START="-0.14496813920069412" LOG_EFFECT_SIZE="0.10375295172668683" MODIFIED="2013-07-25 23:21:21 +0100" MODIFIED_BY="Prathap  Tharyan" ORDER="26" SE="0.2922" STUDY_ID="STD-Kim-2012" TOTAL_1="42" TOTAL_2="50" WEIGHT="14.46138477981307"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-10-18 03:28:15 +0100" MODIFIED_BY="Harriet MacLehose">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-10-18 03:28:15 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: 2013 review update</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwgAAAQhCAYAAACJAahnAACAAElEQVR42uydD2RW7///vySZJDGT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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-10-08 11:16:23 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA38AAAEZCAMAAAAQW2zTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-10-08 11:16:23 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZAAAAQ4CAIAAACoqh2/AAA5gklEQVR42u3dwY4TSbq3cUtIiIUX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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-10-08 11:22:50 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Primaquine: 5 days versus 14 days, outcome: 1.1 <I>P. vivax</I> parasitaemia &gt; 30 days after starting primaquine.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA14AAAFACAMAAACbRV0CAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-10-08 11:22:17 +0100" MODIFIED_BY="Harriet MacLehose" NO="5" REF_ID="CMP-005.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Primaquine (5 days) plus chloroquine versus chloroquine: <I>P. vivax </I>parasitaemia detected &gt; 30 days after starting primaquine.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwAAAAHACAMAAAAiKP8hAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAABJrElEQVR42u29f3gkR3kn/o5G0z09MyupRhJeLTbsrhTIA8SHtevV
SlpBGBkcx8njhDMkD5x9xn/YBHz47sFfHvDlYhySEJPwPciXgO3kuY3jkDtyhrMBgw2WzrY0sne8
XvMYwh0grbRrvFpWUrek1Wg005LmW9W/e7pnpuf3SHo/trZ7uqreqq5636q3qt+3ykcAgdi7aMEq
QKAAIBAoAAgECkDD0CVw3D0yQHeI4yLd1pBYzBk7FotxXDgBMBHmuJCsPiQ3gBhjKJSSIniy1MJN
hDg+QnPpCnN8uLtxlUTfjedCXeD2inqYXp+hvO/fqKIHeKE7X9GVML22w3UserMIQPeq/+LKmQ6Q
VyCZ3Lo8XzTBeEYYeA/MX7d18Vw2okiAmIpDL5waHx8vkpT/qFiicF7nuxg+1gbdl7cvtm3/vtzA
ehpPtx1PgvsrqmEarj4OULQm6lt0+ZnBtXxFV8I03DdQx6I3iwCkTgSjwngSyIlgIPCDobeqHQMJ
CrLeWdC/boHnwoZszIIM+4d/GO0Rh5WlrN6hX8E2cFqoKNzAnsq0zxYmgrFu6I4JWnr/8OHSCrcx
vBwVx1NwaTgcXRCmG7twtghbRl0onWaCD8qWsG46Jga7aDXElGpr4/i2ZhGBEdo+tExdoQCvjtry
DbxsCZPpOwlR3ig6z7XvGQGQ4efadRrg7ZBRn24Jg1+1RFodnG8fsDDvbXAnjQsp2GS/MtBKb5Jc
SOnfHx18cYte2r+fWRt8lIcHKGVOSz8NJfbhH4LL6tDBCjmt5tYwTNDXpPj9wbX2AdZpyu/yzQYs
YWt85tzQZVqBSh/acTQsHG1vll5OZbe1479qO76P3iztG18LWMLaxHRycD2tFb396JPhIx17RQCG
IWpeo7Q3UDA3A9+2RXuj/JcpvYs/BA9RbjSjHwdamfHJ8PGr2K9vw8wcvay3tLXBI9+Fj1P5CBjp
SxSAaa1wJ2yFa5Aqfd+pFXYzA23qu+wbCvaYYWFItbTdDlmT52bOwtEmmQXceGqV3WzDGzcf26A3
HxwKBaxhqava7jJrNw1tM5DaKwIQB9G8Gip6NEo7NROh+GD/iFYlsf2psU2YVKP72JPn6V8yfWxG
7aGzLDGdGP/J9lkYHpnckjfji1r6aIWF8zVSkX5yclsZjs5MaXWR7ZPNsK2fAbl6+yUqqpCnDhtY
9Psn1ZtIfPCaHqZHTk5t2MI6rv7ct8yib8GxaO1L1SwCEIC3aNc+CAugdQyyxm0TqlBI8/cnhtv1
SXDGF6C9hACRPvUtWkC0My37mYTzPOtNTnSc+A96erH0wu3Trv/KcvM3sqKE0OBBdpUu3KLWxfK/
DOhLP4IwdJC98c+tCWg1NEkjj4QGPqOUaP6VseF1evMMNzhhDVuHW35mRr+OFd23VwRA6NsQU7Ew
SJPr8v93oz6V7eyFL7GrH7pZqws3//55O/tdjHfIre+kUkDxBcqmAj8vQFBl1t5Dyvu99QzrBmEA
/sFMz5VWuF9MdojPx0Lwi/h75cffqdJvGJanNuaVuvh/1HcRFiaNpZ8VGtYC+9gbT6pyHoTew6W+
bu2K/sLfsNEqdLNfhH/PuH5p8resYbfBW3rNATcOZ3prX9d+oTnqZv1c+q+ClyS/fyPk/87Fc99n
S/WH4OL6hXv/7hDMXl7MPP2/YXbqz1N/PR9eV4JmlWRfJFm//PqbXmYjxqme+59ICf+VvzT3AGOA
z2UCPTDbdnbjmwdg9sJ/ePPUKmjp/27/pY2SCvfFZ//xC3Njlx74YnTL/88XznGpRtWS8tqRgU+/
UamLv7oYXqdP/MHj/3jSDAvOBDrnYfbvv/olmT6an548fnq1CRpYK97SlTC7Lq5/8fVJv1L0gcvr
ZtidXzv2r4dZm6lF/9Q/ZhZWal0uX1Maw3X/8d1MzQePi8ETJ9hIKR7g8rW0uK9t8NVF/Vd7+kIl
ymWqew0QuwW+JrYG5fTVUI+Ibqzno+TzhUzNXxAFbHhE8wsAArFnVoEQCBQABAIFAIFAAUAg6i4A
YoTnRsMJ6LKvkRSwzE5kRzk+LHuIWQZiNtN+G5itewW0mL25W5EL5SgUpxrKQ1UGkYtxIsixGxzh
2t1EKIcubQWdtHIxUiiOEDd0u5YmfztFFF8LWS1vR+AhgLD2CXbiBm40kqhG0xUptdVXwVupxTDP
tRmlJlwHQCSl17Xin1ENhrMIwKPH9mW+O/AuuHrQa+L3jP5TZnng47USzvF8pv3M1r1ESlYLc2Zv
XmqOg8Wp5ivUc/CvJ+DEv9LrhCWhDY601+c3OR3PtKWTJfLmsZXImU5Kcoy93wfXPwHz2yNKyPx1
z1985dhvVqnBrof/kbfUVl8Fb3h0YDlytIuWOsFKvZ78IMhbaj+k+2dUeQT4FM1LGN8I6ObY9E8O
BwmAEOumcqh8lL6HZ9blsVhEKYkMb6MpHtZjA7TfIMiQCAU7YoxEKKTbdGsRYrGTfKgkS8yuGOut
w7FuSucekRKIhviTiq27aQ9fArK0TwHF3lz1E3DNMUL/jcS6WFyWIwnzKS1Hjgu7lV55RzUKs8XP
pfp++B2I07/3Q0C8h+OzolqzPFGqrEu4IaqktWJqCzbjed9ikVa8Vv5YLCUEo1o7ae9HH3aE+Y6O
IK9/sc6AMA1p2A9KpEcCWfh1Xg3ZPxyKiuPr1eH/KRFGpwqUekuvH8oHAi2wHOKJUX+spkNcRwd/
x4TBj0qpr1ANw7KBR6BTK7Xun1FlAWiBfsYSMpgfYFsH2Pcjjj57lPENtJ8JPalYly+8zoL9cI2d
ibIvDn4Vrj3+XbX7WnrNYdN9d/h4aynFW3xhgDb2wAvpo09GzjDbnq2Z4Y8qtu6GPXwJaB99Mny0
XbE3V/0EXHM8RnM89kJmNLRylOW4LQzfreR4mXkTuJjWq++oRFlbzJwbui4n/FbFEjtD//vpoTOR
H44eZA87B7Se4L9E0usZyPnm3ZqBDwXy9wqUnFH+KyJD61o7ae/H2mF5uH973/DdWoLbVOOaTUgp
EizfJqbPqiFB+Fn1RuzUnRDMz5WKr4JeP/8xMpSC1uOhLbDY/W/NnOjfnpvW6y/LSp2lYrN+By31
bVST1Eut+2dUWQBWp2DwPuZna4KH6ZcALtK2u0uxqNqAmTYqlPRdFVuC53JTKPb7QWiT1ArpdNh0
z00DX5LmzkMn/Y/PQNs0MAOe2R7N1t2why8BR6F/BlQzINVPwC3HoJrjtTCTUl51dlGLNwz/bvMx
l87S8o6pq6y2+CriP5W3J89PbstDkz0bMP0O9fM2rcnzSvAtCy7+BYGhrumAtVS2Ml6dWDHL/wxL
r7aT+X7MQ2ZpwXi/IPT1sWL51iIDnwQhfOQwf4jvUN+pihbH0enuYZK31MyPwaifWbXUisuGUX9z
PbTUPUb9cfCEwOomvjZIS30kLBwKHuaUUk9XsdQWAQhcODMFA++2hp6A6DGqAsU35zenFhShpL+Z
1KoFOHbhZXsKxfZ8G46pjRd12nTTCN4NXJlGfjaeltPxs1vw6Zt1mqrBuGEPXwImVB8BBtVPwC3H
mT6aY9/ZCbj5ZoU1o6DFOxNPX/Npl5q3vGOuLb7K6q3DgSg33ElbNMuIbhlVYXshKy7RVJespbKW
8Ufxrctm+Y+x9Go7me/H/g2A8X5fTFxOx32QHAtMw4OwnPnAxmK6TekIJku3Dc+PS/S/hXylVvwY
jPqJaqWOWutPK7VeHVLizq7JFkimAzfB1+DOzNnM4sY5pdTxKpbaugwaXb7witY8cdVralI1qg+c
+LUTnDaWimAZ4qMrF85QLpnUfVgUA24/iIam7FcfTegREqWWPBoc7hgORv3w2Ph42hpg2MOX9LKi
nr/mJ+CW47/QHL8RbWE52myRpPknb5p2mchZ7NbXcmzxFaGgPV2ADv9p+udjRJXK8YGYyF/QwFRm
KuDoRfXVEWGQ5JRfayfL+9nJrcnJrGZGzgra1xoYWthSe9m3Vk8AAnEuf6kVPwZ7/WguG/ns/gNr
maTPb7LpE+uBoR5ltNT9M6osAMFYNPpt2kp9itPTfJcyOvUxjfV7tJ9RdMVvQO8ZmLKkSEW/Q1Pc
Bl2KYguHemnhUnDG0PM51aZbs+enL9tXggqk6uTxAW6R0emOhS3tbdrDlwCtNKwD0fwE3LDADUye
pXEPyzFjdbJPyXH5Y24NFTep+l2oBmiXtkD/G6Z3QeidV4ny0HutjRXsiR448UBuL2py1fIU320v
v9ZOnMOCXk0k8N3RE0EI3dGlVn9KgKl5peWD8T8Wo7FQlZipdcRfqNQb8/b6oXVwENzs/vVSz0eH
l0DgTvUqpf7YJsS7lVLr/hlVFoDLp5LcZxPPwmOTV4EUv53J8uaLa19m1TQJU4rf6ezp5I2nTRPt
5xO/E7gusQyD8TXV58K/PjUO0gtfJKB5v82dvjF5ehmkqcvfU7NbO7VU0hwAAhswEYC5sRtXTi3r
AQ9NXgnPnVq94lSktJedO/355MsrEIpfCaGplffny3ESuE4a90g4Ybwqq5PVUwfDL0bcqN6YfHkZ
wpNvpJRXnnLI0yTwAQjwMPkzVn8HVZfepVMpAsZCD0trXxd18QSZNHvTE+v28mvtpL2fXetj5FtW
kreIEPr66jVjVOue8C9A8KCyjre4/Jn9Sdrm1cH/CwGX7sHoLk/8mr1+lvik36w/x6uGfQfXXxEg
EhhZP81K3RIAYUWplp6x7SvuH/tlVcrsxRpUhANDpjV98X42dHb606fcFn09G/jvfvDB2fSHXyxl
/bH78kbp2cwfTjX2PcsqdVeyfqX2IgB8tiVUgu4+8b4tCIQWXFWQDLK+NtNIbbb4VwIlpAiFF0rP
JvL9kca+Z1hYLCPRotBUAoBAIBCIWuHfNjDvVhwBEA1HA5kQzaERexooAIg9DYtpmqgYG2gLlaHj
+opleEC5i1kC2XpmuUuaJ/9ouyVScGWALYLhgimi7gLQe42xeC+3HzfuDOP5qrBk6lFp+WDh5e+r
kfkRjVCBzL314Xpw3qmw7dmu7j1P/9pjBLKqjYNh+k94wfLxQCQxxQama1LoSa+rEU37b92Ondne
B9TRhtnJK+e/CAlsJUQ9BGATknxYs1kzPjMnXrNFt9n3K3vPt4F/kyaVIZxjmLMVMu3tJyI3f+DH
ylefzdtCXFizhjDsvw079u3Q8N2aPwKzk4f3Dlw8N/hubCVEXSbB8cnQgLK3PqwZVr9rnUYws5Ox
2fcre89fCy1yQp7KJDZz5tNzM/ApVYtqi933/fGH1e+Yw9NLKwP3azF0+2/Tjt20YVfs5LfhwFOP
pbCVEDWD/UuweHM8bUxzwXanXgIj4xCLp9VJMD9Mf0xmsqNjoy8fOX10zKfH0+bINEyh0H1pFHRb
ohg8Bjcrz7WI7I87oVM1kqp/qfYTMCVI2Ey7G7EGTvpKXAb12223lb3nOyE4MTuZplc2Rhi+AbIR
ccH32P0bMXWKoBgH+hyFcLdjB+Hij8aG1pFDEPUQAIGfZ+biBU8ZtVmcK3vP8/A6DPNRbphemSG4
D7oOKaGdvfAFPVl0ZO1p1Xybh17BfO5GVbG91xC6mU4wfNhKiHoIQMR/cI0ZXheCZt+vYrY/eeT0
CltJ9bN/1BXVB+PauWctyRfVvUTalI1drr9G2RZm9eVke2LQQdVqx85s7zWsvGMl8uI+bCVEneYA
VVTrcDEfsRPmAK01ojuJzYrYCaiVAKDnC2KnzQEQCBQABAIFAIFAAUAgUAAQCBQABGLXwr4MKrn5
J0su38rUZ1p0+0UP1v9qAFvuZRFwlNhjqoIJClPNLbQRu/R6chAxCDBqLlnYCiS5hEpAUABK4FnJ
Gt1+MQIUbqmJBEilFdadF+0l9gRi5F0G1dxCm7GlUmvJQcRSKuKahbVAkltxSXNZ3K7Sv7b6C4BS
S0SrUK13oq2jVJOtaqXi9SXVrkotpCsQL1JW6mKsSupRHyT3TiI72mI8BrlWl48DgMsO0+M1FgCj
Ui29kyoROZ0IKc4lWpRaDAHE7MvKJl5m0iJvU4AqqUCqSpCIkrqPZsG4qy1QneyDWvOqlxoDW2qY
OAdrye1SJ2iCWVHSqspnOQUibJQtXR7NfArnKGltSArokrCnHY5aHZ2JVKCq3Bov51I/kIYkrTZV
UpkoFxcu+/Bt5tOoZvOCtsYJQIFpV94WJ7XkqloPIjWMXjulxOMAQNy7Mi3Nzm22aqIlV9+x16iU
M5iSZtF/GsH/TVjugm/g1iKEEI3lUf9xjgC6tqhd9dFRWSVz6abMaJaLXU5qyGKk/O8AWlKpkk8J
UKQ6CudMzGjqfWnfI/RFObc3cGRhPrCJkJfi7gH4iNfOpgR+rosAIEob04rMlhvZUM3qESblaohe
a8kYApD/d4hWt3cVodZS5lCeK5fUdLUFUdK010tbNFdDdWfWgZcCDRcABKL+kLvS6lnCH5parIMM
oDUoookgdtzFz82r9/88txZsF+soAGKE50bDxl7M2rZYXeZ5xBNhyAmMCpCIcNw9MsjK5j/QwT0E
8OUJLf4N3GgkweIGo01VzSeDXLCLvhnPfUKuovrB80IXrY9RVh9uCNFKk+/huIhSx3KW4yMiEK4D
IOJ9/9PuECWgbrRtlD8S0xolZqUf4fg2ERJhPb7av46qcWnuo9kEiGGea5Pdz3ZvRLt0z37Oeo70
/FxXOFpbGfCbB1IeWFu+/NP3/Omm9vMQzLLL8Stn9QjnzFs1UDz1evq/HxMDsJzOvGVsbnYWbo2P
bc3/7sNq6ft/+fq9R/5MpnHDH/zhA83D/9FLr/7qS1vy9nab2CZWbfuK1LtEYWNz8+GRex+n9eEy
tEcGaaURn/j42c+wze7IiaXA0Xsy2eRHXpY579lsb5872b8kK3dq+ecfHFCb6hCMW+lfe/KxI3f6
/un4j9+gxlffvUeN2zK6/OXX/zL9twM/7upfTs9qjd0gHGKZd2Xhv/Ea93em9GtqVXpZXK2hKmQZ
AT4FmyCMb+g7/AN0BIUEp5jlKfv38+xWDnO8oPXw0Jt+EjIgztB/9qvzqEcCWfh1dRdQ2D8sRMVx
ZWdP//ThJhoANtQzCjbSC5eruH1LZ1xcSKdAYDtdu1G9XtniMQPT/SCodzMzMALZwCPQyZdQ+HTP
z0BW79Tyf3jbEmzST8HIDPw2bIGwaJYnoUsmD4v99LEMwnQzbGHTHfH/Ir0AS2wvcvpnu77wyw3/
Pak6CEAL9BusrXY2PxiMZZhZnrp/f1q5/X5mzdj3Pw1vg9vYTp5ZKjspZd9/+TYxfVYNDcLPdErT
IDeRAGxBiPukUqBeGK0e1X8fviMsw60QjdL6cCKh7P2YZcG3GndjcJsMRo15xGGj1ZTy3/S6Jcyk
38IaZgz+Cia6TBa/VldofSz0Vhpdab0Gc/9zgZ+/tgis98/zt/ifN94T6aq1AKxOweB9Yct5LHNB
UM9HMvbvB1hvaWsz9vDfYjtDg9DHqtC3Fhl4MwjhI4f5Q7xyhMYwWDT/ZhKA4RPByCufZKNuEl6s
HtVpfnCgg8o6uLOUumXqsDJOGncAR8LCoeBhrsN7RhProOmtavnvtk6wTPoB6HuCXgan7rvat2lM
IERj9a9PoPE4eEKA7Qa3x7e6PYjgTI02SbYIQODCmSkYsJzHEj0Gz6tVzroVbab3J9tn9bZT2vmL
ibZ03AfJsQAbS5czH9hYTLcpwjJp7vIcbbItnqen4UHKP5dP3FvNL0DTN9EamFT713yIG/IRVx/c
mTmbWdw4t+G9vxw9cUYttVv5TfrnTyU/Tn+9Z+jJV7P6Mv+60SKvnUpGaaiUuLN7stErgSNv2zx8
VZem9bj+df/jT86vLdR8GTS6fOEV2qvH9f5a2f1fG031mkvCeVNhZeNoYE1OZlv03wB9rYGhhS32
i4O3GgtMTcX+2r6licvwo+uqTLVFPUGhUH2LCbVWfSwi08CeWA8M9XjuhcXVlieX85ffpB9Npte3
OablL4Ku+Q/cGNNcrWhoKttKWy+z5vM3vkmktYW2KztVjacT7Nd/88bgpbtH6jAHCMai0W/TsdEH
86q6dfAnVO9h/bi2f38cmES89YyRopX2NQLfHT0hQOiOLna4AJ17STA1r1AVuD8WozFF6dwHgSYS
AIGdUcDBdb45sbpU+2h9BdRLPtDg6+EBtsjAQ98Z+B599LFNiHd77oW/AfsEZcnTvfwm/RAnPz/C
UYFMddGn6jonO8CBnb1DQ++QyQmOnQkRHV5qiqW55eTiywdA0/uNa+eB3h+tCzVcRbdU/OVTSe6z
iWdBit+usqv/fS+8BA9NXqnv3x+KXwmhqZX3Gym+AiEIt6wkbxEh/PXVa8bmqLbkDwB/UNFRF/7X
U/uTlB6w8/ea6YvzCjujYBzSQx+u5vr3yulkMiHBM4nkWv9m3lhL/TSWcj7C4tjajTQ+TLQEQFgJ
es3mPw3/hlZq1/Kb9J/2hz7/igjPJdpX2fw7bo/39GvhFNWkwr6D668ITdIu0etS2YP7rQtr+w+m
U2JtvyFVdD6AeIBb9RSxIzXfXJ/CdiUKncnQfXmj3KR1KLg1c5EEL3ay3v8KoR6mEJUdkBHd8HaA
V/BrH0H+rDm4ArvSh4XFQil92UyzCACF3LG5FVyoz8DkQ4NNRMOHrp1zSiQCsbuAAoBAAUAgUAAQ
CBQABAIFAIHYM7B8odXsqpyb6EklbZ1SB1R8PkCZ2VqrB7HrBIDslG1MKj4foEwUOR8AsVtUIEmS
tO3HlLucx2AG0DiuMevR/0NDumPc6GgXjwDWRma7IRLnvsLWDa+MQwRIGYetVNoRayMBQf5H1HAS
7NLc6oExrhHqz40EFRJE9UcAh7bt8kNyykXdBQB7Y0SNBSD3/LUCzEf2gn6AGtAeU4EcXb1k3fgW
CowICMSOHQF0dSbnWACrlpOj8ajaeJ27x72+sT2iKkB/AETDgf4ACAQKAAKBAoBAoAAgECgACAQK
AAJRPwGQLP/a7zxCcvlw5pWi5AzFo5wRO2sEIG5sXUlyBKIhApDrEWA1+Zck1SnA4hFgjWbGV3ha
clDMTauT0HwNLOTACKmnuwFiT8HVGM7pEWDesv8hxyPAdAegaSS33tyk6EirX/R4zlwb4f2F2IsC
IHnTTqxm+E6uZDJArL/yEiOuJAies41okAAQQxEpLhOSR13fTQKKqjNSRXMJBKIyFQg8eN2S8uev
djcDTxFwLEDUcxJceBCQCg8COX2+q9+iZEkhuVGXHCE4CCDqNQLYPAIMVV291XwE7Nb4ll8a90s5
gQZFMEgoV/OixyWOCGj7j6gZyvIHKLIg43G9xikqiL2JRvoDlHx2l1RUI0eORuz0SXABkCrEsMVD
cUE04yQYgUABQCBQABAIFAAEYrdPgiXXSam+WFnSZNVq36Ynz6Fg2r+5ToWtwcT2ADR7O0d5LN8i
jK3MCa5JIbwKQCGLywrZSCrAiMSNvGTN2G4ZIRH3NKbFqM3SlKAEIEpUgSSLUb5m/J/jGgB5Tgtw
Gu7rRHI8ClTXgbziVfyBRyDzIzyPADldqbUDzXENgAKnBdiZ1eZZYPUfYI+IW69PXPmW5BEFqSCb
a3YVKAWIUgSgSAdq2yTabvvvucclbt17fjZ2fUSK9vASzgAQ5QiA1q16N0CT8nOrB4POgkxq25+3
RM0GmR9RlgCQ4pPiQgqKlJcJiQcxIiVxsYScjqiFCuRVeyASye3GpYI9vERyH0kFHSCLlAJZH1F1
ATAN/23LjXk9AMDuNGDTWGyJLB4FCl1JXayXCnG/QxHLO6fVYpppzAcIRD7svPMBSmVoFICmB54P
UApKPBoS+R+xuwSgRL0f+R+xywQAgUABQCBQABAIFAAEAgUAgUABQCBQABAIFAAEAgUAgUABQCBQ
ABAIFAAEAgUAgUABQCBQABAIFAAECgBWAQIFAIHYo/ALxq340iGKWfVHaES56YIW/8cn/fQuZgmk
P2Zjxg/vOPl0S6BjvVCMruwmlEMZsZPRyAa3jAC9cGp8XPXPl0PH1WdrW23Jn2hutXpgiQhH9bvo
o9K5bEH+h6sHkR0QDRKAbeD02+v1m430wmXIWOK38Vy7+YPj2wDoX3uMQJZXB4eY8heLEV4Q2YOB
dwaJqBKbFHrS62okEuI6Onh+Amg6rk15EuZTtAAxNg4IN0RhIsxxQgJbCFEvAdiEJB9WWTXxS+vA
YInTfvTJ8JEO7UfH0bBwtA38mzSpDGG/nfJWaPBRdn36Zd81BxSh2YIQ90lZk7aZE/3bc8PvhbbR
J8NHWfC2MHw3FTU2ymysUjl578DFc4PvxhZC1G0SHJ8MDVylaj5RUytPgjZNiNGOPQ1tM5DSglIw
cxauhRY5IU9lEps58+m5GfgUuwZWUrfAEXY3fCIYeeWTauhsD8BSDx11roX+GdhgTxbhES3p+QAN
2IYDTz2WwhZC1GsSLG/93YV/ObelzUtAnZh0XT5x78Pqg/HZWfC9+d4HDr22RUPp/61v+ugDhya3
0r/5md+8dPwvj/9fn55QCaZh5xkx8b2Pia9dSitBk5/4l29tKXcfpX/n4dCbZl9/kxJRefKmWTW1
cvv3Xx1+9T/u28AmwklwvUYAFyQuw5PXWeUFRBF85sKRSAl0QnBidjJNr2yMmKRPVXnSIl7xF9uv
XFhhd5PuBbBRNPGRiz8aG1pH7kDUSwAEfr4PeGUWq+s8cK1vTrBG5+BMLwS1H0HoPUwTvA7DfJQb
ple2TuSDrkNKaGcvfEFRgZ7ckFSNSoBewZxou1GEPk16KEI3f99dMhCImghAxH9w7fScPTg49OGY
KRFUsT99Y/L0svZjtj955PQK22Daz/5RN5p+ML4WUCknX1TWNNcNCVp5OdmeyF1KnTv9+eTLK/qv
xyavMmK/Y+TAi/uwhRA1Ra12h47BOFYuwiOzNJBXWmtEdxKbFbETUCsByGDVInbYHACBQAFAIFAA
EAgUAAQCBQCBQAFAIHYtrMug+iHWzoMV9SODtTPntIjmCXTsXG32q05HMjryL5kAqEcIe6Zg5Fgo
QWGqbpWmPCj9LGOTSE7DKNRsoc4CGXmZiYhaikZgtZkEQK8N4tZ22tnxEtHPgpfMhjPCSF0kwJF/
6SClUZCsycqj6qw0s+pK5X9idla2hgG9EzION3cWSHJQUcREgj2K1ny8rvYlxKXdJeJytnsdOxDJ
bC1SLoWyciySrGCwo9BS7XnOrUD2bBvS7dveW/Gi+iY0rkyteepMGxbd6pAUqOh6DAGWzqwCFYiU
kWORZIWCHYUm5ctjJa9JbMGkPpJYgH8UFejfNo0tkNkUJLeySNEupt5nskvlzzmIVasvI1lZwa6F
ZiOtVIkKLpVdXonUvcmaXQWSyE6qEVJpSpX5qpYhKYsGqYQVC7+Bp/I2uMXbGs1FLfYqyVedTTgA
VEOEmqLIlVRcFd5AkmDPzoDB+R3AXQJ2Gf9LxbWHUrWNMshVez5ZXoEIIbCXFaFW56jqtoQn6cMD
yX2oJZHq+iFAF1VSUdJSKRSJ74WqFijZp8BEKqccEnHNMl+olDOlq6D+dhOq4hFmWWXGKm1Wdapw
0zS04RrpEVYVUwhDb0L+bxLtrk7JdqMKVMmyCg6pDZ/WlxW0lxsOjeEQexooAAicBCMQDYJhDdqo
L2I4AiD2NFodSwGuJoSQ/6HNzt12yVntrsKHAre8SiNgJPXoD+ApR29UJbvtgZGopv4ATnuH3DVr
tVn27DS41bEWUHpjQK5hutMkvjoeA255lSxAEgHv/gCecvRGNefzs0mzZv4ANov/nGLkvNve9Qdw
V4EkSVIrSDIrSlLvJdU03tvKvyTlSFdFkEilhIiXQpecY6lUGwn8ZlloBHB2MY5Heqel9yTFPi9K
uaNKBUNA9VpMKtd2s3yqhlON5E3DrCrTSy5vhPzvFAC7pxeRtP+sT20mJwWGeBensSoqmhIp2xZI
11XKUDsg/xfTsqhqvohV8QdwK5inGtrrJkG5c4C8LSgVq0alJm0XZ39azb6uAp/g8m3oCunKXmxt
JJJLrBr+AHkKZpkh1KQad6UKlE9DMZ3hC7Y+qcvwWkGDlZnUPgyWQ1Uy6jB3YlGJT6Kn+pZQ4S91
EmwKA3HZTyD/r9yVDu9DSF35X6pyMg9UNbN70/q+KtXhybGhqS3+2xh+j/41zSSYuJuK20dZx5hr
Nz3X0xt27hailfdFrt4J5ST1TKFIjqVTtdZxzf0B3LoNieAcQIWvnltZ1WPJY28D/QGqqQJVEegx
UC8JqGuyXTgJrpkEVLYAgyitmksLQn8ABAIFAIFAAUAgcA6AQNQcmitMW/MIgOS0hnbf5pvkuxhJ
ar3tpFSmP4BuoVTq+QCF/QEsVPPHcgRWwx8g533KOh8A/QGMlQAvZiGuhv/2owJ0K6/aValkKUlJ
IGA10/NMoYg/gEa1YCxHYFX8Aezvo96UeD7AXvcHaC3U31k8hmw+H24csFNQrvEXKXw4DClil0Ma
8D5u3gxSM7C6UgS/ef/NBnKQVQA022dL31Qyw0jmjvO1GwIqacQyT1eSoIbfUStykiv0PkXOB2gY
iGUOwO5jzXI+AMnp5E07EWIZpz3slFvPnqTMFijJLM7Ns6cQO+b1CbZZ3lTFH8D+PvleMz959Aco
xldlmk7WeAZc+u7+zm7QOwVSIvn8XhWm+l4Nf4DCxSNeaxP9AZxVkueXpwGg1vbnkk3nrkA4SZVk
W/LiFZwbWBV/AIk0Q5dUFtqaoxgthXQLyTpUE6/8X2v7c42+VJEE1WJsK6hVSaRK6pt3VRANEMsb
AQq6N7ravtuPCqhTtdfxfADHa+bhtwJeA/bAavkDuFWFIwu3oxskUu4hCbsN1fYHQMP/hgL9Aaqj
AlXWLyP/N1AC6ppsF6DqxnBo+N9IFDg0j5SZrtZIPbO7BACBKAXivtvF3TQHQCBKQts5OHikOeYA
YoTnRsMJY2YSUy5dISPCRBhyAqMCJCIcd48McowBOriHAL48ocW/gRuNJFjcYLThFR2hJU5ERllZ
4WSQC3aBHOK5sFwZ1XBMrbesDF1hjqe1J4c4LtztjKnX0z0cF1HqWM5yfEQEwnXQwqU856i/A803
zHNt7E4ejWmNErPSV8tDEYrl1AMLVeNpNGKxWIOaRabsdXm6gXzhF4zbA2vLl3/6nj/d1H4egll2
OX7lrB7hnHmrBoqnXk//92NiAJbTmbeMzc3Owq3xsa35331YiTPf/8vX7z3yZzKNG/7gDx9oKPvP
PzhAS/zwyL1PZJfT0Uuv/upLW3Jk8OTjRxYrkYDuFkb1wNoiP7SczsodHH3btq1zf/7uNzmbVKsn
4hMfP/sZH1O7TywFjt6TySY/8rLMec+TvsPjlI7SXj/u6l+hd9EetakOwTiY9NsGTt76i89tAn1P
mLXXA8tdjfe3A5TGcnr2kBmlvmifobOArWxTjACfgk0QxjeU3l3pETqCQoI2Db3N0n4CeHbL+hVB
6+GhN/0kZECcof/sVydZjwSy8Ou8Grp/WIiK4+uKmE0fbmz//+Ft9q8A/dOQho1JoSe9Dtswsgib
lVD9DSX1U3B2mtZASl74OWxBMt1zBTzrjKvVUwam+0FQH8zMwAhkA49AJ+89T/oOjI7SXgJ7G0ik
bdmY9EdG6DvC9T5HPZjxZEYj07h2kV8D6ITFiaYQgBboF2wl2f7BYIxWzji0jz4ZPtqeVm6/n1kb
fFSLkIa3wW1A5zBZykgpLrxE3+g2MX1WDQ3Cz3RK0yA3VgBuep39eytEmS62BSHukzIEIDUB6Uqo
nrrA/r2KUVX6sDPAmC34zr7XnXG1esqyyLeyB8rdGNwmg1FjXnCrkVtWpQixkCXYpM9D1wR9R0is
OOrBjKfTaBT20T/KNe9tCgFYnYLB+8w5AMBcEAaUm6Os19lQbtdb2trgES3CFpXeIAh9rAp9a5GB
N4MQPnKYP8R3sNBhsGj+DRaAu6OqHCpNP3wiGHnlk3B+6sb74hWNAEkrVTqU3wiMFy+cmX6TM65W
T8PKOKlWj4IjYeFQ8DDX4TVPIzfg4AmBdvHdW9ZVFJP++amr74ufB1gLOOrBjKfRaDSaQwUKXDgz
BQPvNh9Ej8Hz6mxW7TkV3fFPts/qbaeU+4uJtnTcB8mxABtLlzMf2FhMtynCMglGy0TB1wwrDpPK
uhfjoml4EB4duv/VYVI9qvMdw6+wN46edRN3rZ7iRnvH1ed3Zs5mFjfObZT8DiAl7uyabIGUbRXR
pE+GXr1/+Kp8ZLR4lEb3ZAOXwmc7aR/aUMM468tHly+8Qnv1uN5fi6IW3MJutU4PzpsKq4+yeGBN
TmZb9N8Afa2BoYUttYd6q7HA1BxLbn72Hj6Vh5gOTecAVdB/R0GUKVU62b+/wAdVrZ5oVSbUWvWx
wozSmyfWA0M92yW9g0Yxk/T54diNMWWeprenTp+DxZH8UxwtHqWx5vM3rkV6BFjqhK6FphCAYCwa
/Ta00paZ71IeHPwJ1XtYP87BmV46hseBScRbzxgpWmkfIvDd0RMChO7o6mPTZEhJMDWvUBW4Pxaj
qoK6DwLNIAAB6O2jLyNAr0AvLWwOUIVyxeHMGyi5zuzaCP11F08rIugyeVXriRbheniALTLw0HcG
vkdDPrYJ8e6Wkt5BWakQ+Pno8BKMj4+zyZkZrNEPwEQKDN62rXMqoUo8jUbj8NrvwFJXI9UDS8Vf
PpXkPpt4FqT47Spb+N/3wkvw0OSVMHf688mXVyAUvxJCUyvvN1J8heq84ZaV5C0ihL++es3YHNWW
/AHgDyrLEAv/66n9yYSyILLZHNuvPJNIrvUvwcrLyfbEOKye6hg9tVw51bnEjcmxJUgPX8+W02/1
r671rzhjafW01J9MJgbZg8WxtRsTdMiYaAmAsBIs6R2Ujj3sO7j+ipATbNJfSYx2nHrWrvM44rnS
qCeiP6Hc8a4GFqCiL8HiAW7VU8SO1HwUEDVGDPJ/Ue2+vFFu0tpC3L++evP4DhUAiG6se4oX/NpH
kD9rDg7yT2nCwmKhlL5swz4GPPNBMbZjBQCBqMbQtfvPB0AgmhMoAAgUAAQCBQCBQAFAIFAAEIg9
A+v5AOrFuQWoly3T6wPbVrD12NAm7zEIiN0nAM2/SaRkSEGB3fqrLXCuxyAgdrMKJEmStp+Ycpfz
GMwAGsc1Zk37f4u81hzEwxPEbhkB7N0eye3yrD9sxwiQenWOjWc+CQVgT02C3bacl6yMThrEn5ou
VA99RLIdr7V3jxLaQyOAg9FcfkhOuaibABjb9ZJ6a+TY/e8xAbCfDUAKsUI954f15EOc9O5lFQhc
TosxDwqAAiNC7fWf+mSJ/L8HRwBdnVE0XlPptWo5JPfo2TqrQPXa2N71NATEbgL6AyAaDvQHQCBQ
ABAIFAAEAgUAgUABQCBQABCI2sL6HUAi5r/2O4+QiOPIeAY7GcnxxGJn72p4b3yX0DIpnYL+UZvk
SaSf1u54YXe6lpd0LY3ht4D20ztKACoGcf6WXI0mnOxiCp/DtjTH0pSUTsFdni1x2IUUjGKjS6zx
XA6tl8zuAPl/R6pAuR4BVpN/SVKdAiweAdZoZvxceqYvgUemMP1ftA/SUj4KpLAoupaptI+6xHEr
mdSLSBpip40ATo8Am1uUBDkeAWZPSTRdwkX/ICZbm0Z2xOuAQiwalncKpmamGzG5JrJzbGG6kmoU
QSD/+xCUhR0qAJI35cZqFO/iM+Uc993cBsrgDFKIguSuh+cWOX8iyYV/HZzvmOYUeB/Vkgp9aHaQ
AOgu5xZJkArrJ8VFx0twU4AUDddnCqVQlAiOAjtwEkyKswUpgXukvBNFz7zhwkU2CoUHAK+JyilZ
oVQSepDt2FWgAquhkrvqbNpKk7xjgFT6FJTk8zcmnhUgS76kuIwQjwJYwZQa0dwCYPMIMJRcwyhe
ubMttFt+WRYWc7RhsLkXOLOTcg3vNRoezPAlY31eT2pdsM+Tr2Ss8uddrCxUMg+ajZoORaOZUZY/
gEQqCa5WNlWkUGpOuENQVdFIf4CSP4RJnjT+HYYSv1ch7++BOUD5um7VuIPUjwIpnSwKwa4AGsMh
UAAQCBQABAIFAIHYs5NgV+t9Y12/pEmfwwBAciyIW43joCT7/uK2+2AYzaEhAsKzABRa266QjQpZ
xJRgh2+EFU6jCZWL7T4C4UEFkiw2/prxf45rAOQ5LcB5ToBOJMejQHUdqJJ4FZAsBMLzCJDTlVo7
0BzXAChwWkDuhuIWzwKr/4DVor6QLlRkLHJPY7NBwyEAUZoAFOlE7UY+xH5agEdec7XKd03rbghU
zHa/tkMLYpcLgFSA9dz5zPXW+VsqnUulfH7FyPaIWgkAKT4pzsePDsv/Es6QKccOP48KpC8DoSQg
ylOBvDoyEcnhWyIV7JBzt16x+hFUa6JLkP8RFQhAzm74EnHTxvOcFpBrem9LZPEoUGeq6mK9y6p+
Pjt88GS7b0gifghAFMPOOx+gHNt9RFMDzwcoSeuRkP8Re1gAyrHdRyB2jwAgECgACAQKAAKBAoBA
oAAgECgACAQKAAKBAoBAoAAgECgACAQKAAKBAoBAoAAgECgACAQKAAKBAoBoAkSyjczdL2ALIBqJ
cEpaaKAI4AiAaGz//8slWIw0hQDEFOi/ukKWAOUSDYIc4fisCAk1ZjvfAZBNafEFjrtHZnGDTemF
GFFfIkQvXWGOE2QQIzyXlSvsvig5jY4c5vhwAuQQx4W7nXknIqOsfuR7OC6SYA/lLMdHRCAcrcRI
ynOOGh0KMcxzbUa+agNa6GvNmVserR7sdWBp93o3y2vs39caNwRYVKDZ2UMwPqv/On6lcXsI2K14
4f+mybUnHxu60/fN/Td9bXYWfG3rm3LYp8TpXg28/l/2Lck0bih96YFmY//5BwfYS8j7jtNLi9z+
88Svtg6sLfJDy+kKqHa3MKoanbaBk7f+4nObbVvn/vzdb5p25P3wyL2Pw3Ka+MTHz36G1Rk5sRQ4
ek8mm/zIyzLnPU+NDr07sPbjrv4VPV+lncbBpD87O/vTt7wo28uj1QPodfCXI0rZZ9UmbhT/Q6fU
nWkeFegenm8D2iS09xB4Tohqjw9P+2EDRmbgt2ELPsuebC9sQWdQDU2dCEaF8SS7fXKot+n6/w9v
K5frlX/XMgvT4Ien4Ow0VFTvv8HYTqeTgZER2IZkuucKeNaZtwD9M0qs6X5QOp0MzMzACGQDj0An
7z1PjQ7Fp0CYhrSerwaTPu2yyMSzOeX5sB5Rq4PfrrgOKhtA1xn3Ayx1NmwMcApA+5nQk0fbaaWM
Q5uYTg6ua89lmAYfiABj8KfwAT4kQst8i5g5q4f+XCfwNkg3nQDc9LqqP/xS/Rm8b2oFroJoFCqq
91MX2L8aHR66JiDAiL+z73Vn3reqsbLscit7oNyNwW1UD0mf9Z7nrUaps6wxLPmCQfVWrcsaCh3L
Kc9NZsmUOhiruA4q1f8p9yt/y5FmEYA0zLRpLJy6qu0uo3ORIUrrue8Jevuf438bOn4VBA8Kh7n/
yXRYgGHQRwoqJVtNJwB3q6Vb0wp54Q+GPgnTKsNUgKRCTqNzfurq++LnGfEz029y5q3FGmaXR9Qa
U3AkLBwKHlYr0QvMUnPwhEBbx8gXDKqPqANAakrRa6zludtoJbUOTlRcBzt9BcZZBtqHHNNYuOPq
z31LrSOFrwHO35T8eJzyUTowA5tUEz2bmvtE8oMsNM66IxUN7FK8IvoBeBAm9beqEBodMvTq/cNX
MeJnQc4bK25wXFx9fmfmbGZx49xGiblRSIk7uyZbzHzBoKrWf99wSmF39/JUtw7Kw2qHqgGxv6vW
mkcIRRGuU27W4ZafWQRDhOjd6fVsQP8NcIaPDgeU/iYAbzGSN65GS4APRkGUq1FUjQ4HiyOwmX+1
gVUrq28xoVa6jz0YpTdPrAeGerY9r1qodFiVr2WSPn9OviZ9uB02vNRBI5vL92am/zMNqFH87yIA
Qeg9A1O0bxDhNniLOZ9lKxUhTn7+BA8C3yUoM63f5aFP7V2Evg0xFQuz232lHz9fXwh3dPdS1TkO
Z94AXOXkNDoBmEhR9ryL7+qDoDNWAHr7KEfSy/XwAFstplV3Br5HQz62CfFuz9qARocSEPj56PCS
nq8ZrNGnkVg7aOWxrXOyxEYd9FajDioZA9gcoGH87yIAs6eTN55egYcmr4TB+L8RLTXfB0/7Q59/
RYTn/Kvt/VS/7GpZYDosC1341tb+9tPL7HYTvtLcAhD++kr/6VWYS9yYHFuqnJxGZyUx2nHqWbjV
v7rWv+KM9Uwiuda/CUv9yWRikD1YHFu7MSEBTLQEQFgJes1No8New3dw/RVBz1eDSR8eVqbGenni
OfPP6tZBRWNAI/m/hN2hxZ7giqeIbZkLUUDUHzHIv8ty9+WNcpPWGNll6GrgqkkJ26NPvM/b98pQ
UERmbAQ4yL+kHxYWC6X0ZRv3MaBt+9j4jhAABKJGQxeeD4BAoAAgECgACAQKAAKBAoBAoAAgEDWF
xWpBO31RXxe1HLhbZKm0bgcx6icX2y71yFE/3xvP3NvNAkCa/UxRiRhH2JuXeuSo9Q0SwVNX94QK
JEmSds66cpfzGMwAGsc1Zo1Qf94jtiEOeX93jwD2bo/kdrLWH0bPSNxi7jog5+/RSbBLwxPJyuik
3mxiFzKp3jlKqAHtgREgH4dJBViP1H9+SLMkUp1ri+AcYE8JgDn/y+3hictgUQfekEi9FRNk+L2s
Ajm6etbPG/OAeisjuerI7swR0fARQFdn2PTWomVYtZwcjUeJWY9FeSUXLa96ZCnZlv4JfgfYfUB/
AETDgf4ACAQKAAKBAoBAoAAgECgAiEZBqnM6+Ga9M5RQABAIBdbvAJLF9N1+51WwiOuXI+KQPuIQ
SJJzZ6VjfJfQQtwp6AndnQXUj9okT7YaUecqv+Twj8gx+ytUGqMoaEa9MwSgYhDnb8nVaMIhNxbh
k0jO4JbDcsSFgp1N81inuv22cDUpEsUi08QaL29pzKJIBPl/ZwmA0ncpdp+SxsbGLevQJKN7Yx2g
2eGyX5IR39GR6hzh9XOqZUQikrUvdVAowl9qutxYJfGkNkRI5pdx0068xNLgJKDxGRYRAKdHgM0R
S4IcjwCzpyQ6hxDI14dLViM7Uojdci3fdA3LhUJBIwVNeC1DS0GOdY1C7BeJQIH3cZRmh4lEmaUt
+y2lumeYRwAkb1VitUJ2FoE4B3ySn5XKaRcXCjkS5jDbMYpMHCODYxpByipVvtJoZtsSWhHtABVI
9/y2SILkbfSRqjpUlSzZBOzs5tFDjeR17qlmB0pclgcQzT0H8MAWpejTkstEsbAK5GBfF/aR8k28
i4siqTBKiakkgpbUO24VqMBqqOSuOpu20iTvGCB5YtQcFSJPb048FTYnX1J8nCmvp/ZAeJdPAcof
QxuZoasA2DwCzImfboav3Ek5ikfODgpSjgaupXHtComxSGSnqm/GUNwM30HBfAB58zXp5l2ltJHJ
N6vPl4pYNhUiO2sO4PwwIxFv8cuS/rJ6DO9bNdli5ibwlZ939SfnVacjkdrktMt3CHJ+mCksv7bP
JaQMcStHaIwPN0X3bbPGdCQo2RRCkqQ68X89B32pzpK5AyWiZjUjkVqWqFjMkr8EkyrEqLWKVzoF
UjrZvSQEpJZNRmrLG0ViojEcYk8DBQCBAoBAoAAgEHsQ+c8HsE+iS1uqcnz5lxwr4TbTnQIeAuYq
rvmloZjtvnXJFy0Qyphh5vkwUzx+g0rqPSYp/B3AzeDAw3eQogLgYgqTG+4ItEue7VuvVNh233mO
AAJRggqk7fVvHhNgPQJA0k+LcDstwHlOgE7EGqjTlQrIXe4AhFyMqLUKlNOVmk4Bqq2AxQMACpwW
kOPNaPUssPoPWC3qC+lCJFe/8WC7nzv2ofAgShEAF/bL98xu+088f59wtfQkRVJYPXGh0NeoOm4e
itiNAiCVOL+wmjpL+YPyuQV46aFJccHMM4RhEyNKFQDi1ul6Y0+H5X8JZ8iUY4dfnu3+3kaM/VPC
drRdyW3+mWP0JvX+Mb8oOKlNjr60SEOjm9fdO6I+jGbWEp+25uK6/e2X2z5Su3JVMgnWZraeWN95
WoAExQcByW0AIAqKjjH2/AukQeTBOIX32PJlcX7uN2kdz5N7MyLpclLLvLhO2ZGI8rf+Yl55JA5I
8FuJornc8jGxhuXyCL9NcjbYL0Ha2CDGZUN5Rv/Rf6sJtF/KT0sIvSX0qv4P1iCTAouj0JUEhbU3
GOwCrMWUhJwyKXc67RyYaewvgFpQDg7NKpeJb/gCkY1gyp/4p025HYLrfojREPoXk7JbqXDL9SdP
snhtwuYDD8RPZuCv274KgX2ZjNZfz5rUNnxb0MJtQWDxz3zs2cOv+oGHtJZf4uu+fT2zWn6Ckl90
289dDjwQ+puNqpershGA6N2qeSHGZFP7bfa9RgpLCCHaXJhYoxErBdDpErMPJ86e3T7PtUUh+UYD
yMkHeT8/3vd0RkgB/xy8j4PWQOYJizL87Xno+J78rfcqPzan6T/H1gCCM/Rm5kNOSuIzNO2HztK7
s3cqD9KTAPdv3iEsKb+uDV7cNvLjnoPVACRDtM8G+NVmTctViQrUxEDb/YonATGmbqdGQBqGi9+G
ze8yHmrjzQjviELrU6mU2j1no9pT5Sb6iEYCFCLK7f6bwgCPKKH/oDzaejtl1tDDkTcrv4LT0SUj
v+/+Hnz7V9AqK9R/nKl2ufaCAJRju4/I0bWZZtIeCVJ2ewg2R2A4Csd8ZgTKUa99tWN/t8ohstLL
W/4UEqDr63QOkFywhzKWHFuEBZW/t6MQMPIbkcUHU/C/tzp6KNljVS/XnhAARFXwLh93mfJUoP0u
gEkRxCyAhZGi6/MPraqzxH9iM84DVLHphfaO3kAecoHD0NF+WNX7fRoVlXf9IshGfsCTT1CuTs2H
Inm4tsrlQgFAuCMbmGbq9eNH/hvloT44Q3l3IiUe1JcUotE/fI9yF/roBHTvEwAupiYWM6lf6N11
DrlfbEwsZDbUzvkLNPYdMshfUH5xvdBl5tca/HtKPRVlwtHHVb9cKAAIbwgf3f8wW0yZpJPJzTR3
E52Qjrd/QOeHHwxw7QnlbmH5vfxqkE68eqS/CLf+8NfykOv54ftCH4+oU9HPUh3mW/u49kHl11x6
tMXMb3qY6kvh9weSywC3t9a+XMWAp0QiSsLESKHQ+R5FXzlwOa9GMnH9un4r77sQrVO5PAlABf4A
Uok7LetbbZS5W46HAwOsDgeuBqWum31Yja49Oh3kmly7lUYn5XKKwe78UEFEX74gPmxo/pEFofFF
bbWtl+Rti2o3UkWm+p4ODJBybiQPLyXZgjw5Heh78RY8MIBYhMBKZtceHSDl5X9Ip43btSbg/wr9
AcyddA1LfykntmZWYbgJaBFzfATstzaKkj03Yx92I46SkhQZnHKsqK1vUnUpl/L4FUklGEYh6j8C
gKN78ugPAJZjAiSrjpMbDmBEAbuPgPM214UAchwIih0YQOwaXa7jm9uBASSPKHg5ysBuq+04AMGx
j5+Us5UkonkEoEgv5bpztHU3fNdDA6z3UuGciHvuBbbHLePIAfcDAxwKUZUODHAomaro4tEBzSkA
XvwBquZtUsCXwGtZajRnIdXOiLgKCbotN50AePIHqNbyBfE03pBSDwyQvBav0gMD8mZkV8jyCxAe
HdCMKlDRbsmyYGj7KbkzQs6pp3l7Ube9InLL4uXAAOJhQ2/P/bznowyKpMKOfmcIQI5LrUTclB77
aQHair5lI37XcHDu1e88gMAMIOC63X8JCpHrxv75Dyqwy1gBzc/1KIOi/O2SeOcdHbDbUPUvwa5s
0DR9Hx4YgChlFaiMCe3u4AIi1X3OjdgdIwACsZOA1qAIFIDaQ/T80EMYAlFbATgZAUgE6U1EM1eV
wxyfLcqTsfwP3+gWdKAArQPYNIhGCYD4R+MgvnuI3o2vq1zf8cTF+Y6is4UCm7oMuj0cKkBrCJsG
0SgB6OWOQQ8bAODYXb3Kk0x/NLoSVLtz+heL8iGRjQuBiEx/tQeDCZCDLGSC44JdNCTChWmIKPBE
GwbofySoP+8K8nxUfdjB33EyFQxMGGli7TdwE0oYAtEYAcj8CmBe/VB0k+rYzx+KzoNpyA1L88Fv
AHSelxc66S//BW4VnlO2rxiNZKQ1GiJlvk9DviHMb2ljAxsdLujP136YXr5Zfbg9f8vHei6sjgK0
qmEAXx97VEuAQNQafhenBN/pv4MH1I26vvgFhYOTGd9/DZB15Rn9O/SLv379fnr7FxCALTg0GV3+
Tqbjp+s0JPi5P3j0z2mCLJykIWPnomt9yn5fLFE8qj/fPAmB9lnl4Y//+uS74tHAu2lSNezQVPSk
GoZA1B5uH8J85n4tUXVbogCkxMOXzRgBiHIAw/RukkWC1KcffljZrmj5Xvmj8z16iLYjjE7LSCF3
y9sGJSUArNQQiIaqQJb1Hu2OEyG6bNmgRQaRJoyPj4+rKlL0ofaUys/Ji8LtlJHVkBYxZzlTe96+
/dSqI9dJgxoC0VABCPQZt4I6QgQPiWKHnzJpSlRmtZ3QRxmeXwISUuORIxPK9a6J6PwYQFqG52lI
qhcOatytCoL2/N8tvZ1p+5xszTWohmmIy9g2iEYJwO3G7RWqCjOX3d8jrwCstO//ByUVl36JToXf
zG2E1Xg/mHyHcv0f7+XbabzNDu7zNOSlDK/R/+h+5aI9H9zXw55PRKy5LnUEPh82VbMItg2iDnCz
BRIP6Pu1iD3zbip5DJdoELtYACCaTqo34a98xC0Rh7o6YjcLAAKxl+cACAQKAAKBAoBAoABUB+gR
gGhGuNkCwcmxzMTF81zHeiSifuCNHTp0gf5U74tb6bhFeXXaJeLfbOYnUiisTLgWPYZWRzgC5PS9
fzQO77s3852k4Q8A4+NpQVsa9fANwC1K2i3iYAEig9V/Wfx8gfAiAMwfIDUC/VuGP4AiFtug2PQz
f4COIJ+KMrt9mBACQQKQCAVJzPQXYFF4no4eiTAXUg700Iz/dR+CboEzPQL4VEqhZfoXBHSPgBtk
6IpNgHyD5kMAKS5wg2p1oeel+A/oz/WHE6o/QkjZjZ5mQel038BCtHhaueQwh7Z3KAC5YP4Ainpk
+AMw/idK1AvKj+0Lz0S3mN0+vE+UQ1Q1uvbpCzk6+/b8cgd9vpxZuk7tfMeVc147z8tcJ8AfhDPh
pO4R8Ex0v0JL9y/IMv8A1SMgfgVsxX8X3hDXfAgs58QaUNLmPD9xkZ0v+42V9CL7zvHt+fgbYHOK
BWjxtHJ1cheXkAdQAHIg/1i5HKbTg7drNmmxWE+aGXDOqB3mUnRkcDY6QtX6lADiMEDw7dEclX0u
KrDnARBM5ecdUfjDThDpg68sKsnstNKdamSa9ISW4ldpyAQzTCQ3RkCgccxzYnWoaXOevxRl58v+
J5r7dUq+T2ZAVsyatHhaudIz0ZeQB1AAcqD6A8jbtE+P+ow5wLppum+x4hfbs8x50m75D0bwcCwW
27Y+m1ZPQ5Y7wvrsO2CLnAWbR0BqC7Zmt8TNFE3xZZbCPCfWnlHO82PK+bJDlOCEEuXtmzCyaImn
lSsbzT2rFoECoPoDiGQOPKxFvtHX+TwYZ8E6UjCXATn3Ae1627OLTnPPuNMjIOon/mjrQX8U2rf7
2RBknhNrz8t8rjxMKBeLw0KgY8IaTyuXT8TVVhQAB5g/QNdV51nXKhTbOnH7/0wzJYMTgGnvur+A
gQ0ZompX36dymuZDsLmYYsrOpI39LP4FjHuVMG6dg8AfcoYPgXlObNyWl/Z8ckI9UfY6OENVoC8Y
uUOgf8EaTysXf0Z3WECgAJgCcDvA5YGbma5yRbEDuMO3K6b9c12K5b/uL2BAaudTalf/z6pHwNKb
uRRl8pV9ysmvgf3WyBb/AqatK2GXhi/Bd6YDhg+BeU7ssi0v7fnKaI+f/fwr7vfo7Hawg1t/Tg2/
FE9Z42nlWrqJb0Ue2NMoyx/AHU3kJYAOC4gKBKCoP4A7+HTTvBU6LCAqEQAEYi/PARAIFAAEAgUA
gUABqAbQGwDRnMjnD9AFPo4Y/gBym691U3qgCK0C5vauxv1fLmDx/+VNbBtEg0YA5g+QDGa+s4bn
AyD2ogAo/gAiXLeF5wMg9qIAqP4AYnsAzwdA7MU5ADsfAMT9m6EUng+A2OVw+xKs2TRE1zcs9g3i
4Y0NxcaG/rELl1G0lMkM+yV++uGgEip3yL65Hj2EWSSoZjlaIu05Ox9gcNx4qBE1qOkBCERDVCDt
fADmBIznAyD2ngAwf4DgPEwE8HwAxJ4UANqH//B27vplPB8AsRfnAHg+AGJPCwCeD4DY2wKAQOzl
OQACgQKAQKAAIBAoADUAugcgmgT5/AEAJs7NgnE+wKz5r2eU6h5Q58MCEAjI7w8A8Fv0zzgfoByU
6h5Q58MCEAjI7w8AXWxPW+v5AGoHruzdD1GeE1Kme0BKseTX9tyPkWCwG2SBhWjxtH36jd34FU+A
9hv05+oZA6rPAM+TLp5Fo2EhUT9nAN0DEHUUAMUfYF0xS7jJ8clLsd1PhjLWjTm7L7I9/42zAC6k
NuENig2FFk/bp7/z+xc3tbGBjg7+r+vP1TMGlIdb88tpeT6SVNIssSyUcwbQPQBRRwFg5wNM+JTd
xN+ea5M2q+zd3yrbduMfj86Ye+7DTPQfZMgo/jFaPG2f/vQ7onNmoumo/lw7Y4BhLiocn42yX/re
/uo5AwhEbZDPHyD81Ihi8aP6A6i2D/Res9ZPvHsb1gJW230WRqNMyIp7wIENqvlY4oFi6s9oubkH
iIeWhSF0D0A0ywjA/AEG7lP0bm0O7GcbMifMuMdS8yHVXFNU/9F341cHDLarvzWe7jggQsKWkfZc
O2MA3MIQiLoLAPMHoOzH9G7NH+AH7xFBfsE0VhZSytExEyl1N34Cvbz1LADgrlmwxvuCsRv/dWq4
5h6gPdfOGLAfFvAlk5ojDIGoqQDcbtxq/gAjfE8scv+i8Tj8/kBymUpJu7LLP0S5zJKy5/665uh1
aTJljaft07/0e7xfy0F1D9Ceh2/fz8h81HZYwBFzb39HGAJRyzlAqecDoIKO2FUCUOr5AOgegNhd
AoBA7OU5AAKBAoBAoAAgECgACAQKAAKBAoBAoAAgECgACAQKAAKBAoBAoAAgECgACAQKAAKBAoBA
oAAgECgACERz4/8HZl9YdaRToPEAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-10-08 11:21:53 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-006.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Chloroquine plus primaquine (14 days) versus chloroquine, outcome: 6.1 <I>P. vivax</I> parasitaemia detected &gt; 30 days after starting primaquine.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0IAAAIwCAMAAACcHSs4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-03 10:19:17 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-10-03 10:19:17 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-06-17 09:59:17 +0100" MODIFIED_BY="[Empty name]">Conference proceedings searched</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-03 10:19:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>First edition of the review (2007)</B>
</P>
<UL>
<LI>Vivax Malaria Research: 2002 and Beyond, Bangkok, Thailand, 3 to 8 February 2002;</LI>
<LI>The Third Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference, Arusha, Tanzania, 19 to 22 November 2002;</LI>
<LI>International Symposium on Malaria Control in the Mekong Region, Siem Reap, Cambodia, 10 to 13 December 2002;</LI>
<LI>The American Society of Tropical Medicine and Hygiene, 51st Annual Meeting, Denver, USA, 10 to 14 November 2002;</LI>
<LI>The Fourth Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference, Yaoundé, Cameroon, 13 to 18 November 2005.</LI>
</UL>
<P>
<B>Second edition of the review (2013)</B>
</P>
<UL>
<LI>American Society of Tropical Medicine and Hygiene 61st Annual Meeting, Atlanta, Georgia, USA: November 11 to 15, 2012;</LI>
<LI>American Society of Tropical Medicine and Hygiene 60th Annual Meeting Philadelphia, USA: December 4 to 8, 2011;</LI>
<LI>American Society of Tropical Medicine and Hygiene 59th Annual Meeting Atlanta, Georgia, USA: November 3 to 7, 2010;</LI>
<LI>American Society of Tropical Medicine and Hygiene 58th Annual Meeting Washington DC, USA: November 18 to 22, 2009;</LI>
<LI>American Society of Tropical Medicine and Hygiene 57th Annual Meeting, New Orlens, Louisiana, USA: December 7 to 11, 2008;</LI>
<LI>American Society of Tropical Medicine and Hygiene 56th Annual Meeting, Philadelphia, Pennsylvania, USA: November 4 to 8, 2007;</LI>
<LI>The Third ASEAN Congress of Tropical Medicine and Parasitology (ACTMP3), Bangkok, Thailand: May 22 to 23, 2008;</LI>
<LI>5th MIM Pan-African Malaria Conference, Nairobi, Kenya: 2 to 6 November 2009;</LI>
<LI>14th International Congress on Infectious Diseases (ICID) Miami, Florida, USA: March 9 to 12, 2010;</LI>
<LI>13th International Congress on Infectious Diseases (ICID) Kuala Lumpur, Malaysia: June 19 to 22, 2008;</LI>
<LI>11th International Congress on Infectious Diseases (ICID), Cancun, Mexico: March 4 to 7, 2004;</LI>
<LI>10th International Congress on Infectious Diseases (ICID), Singapore: March 11 to 14, 2002;</LI>
<LI>International Conference on Malaria: 125 years of Malaria research, New Delhi, India: November 4 to 6, 2005;</LI>
<LI>Keystone Symposia Global Health Series: Malaria (Immunology, pathogenesis and perspectives), Alpbach, Austria: June 8 to 13, 2008;</LI>
<LI>Gordon Research Conference, Malaria: The Science Behind Malaria Control and Eradication, Lucca (Barga), Italy: July 31 to August 5, 2011.</LI>
</UL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of studies included in quantitative synthesis (meta-analysis) = 15 (18 reports)&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of studies included in qualitative synthesis = 19 (22 reports)&lt;/p&gt;" WIDTH="115">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of studies included = 10 (14 reports)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of full-text reports assessed for eligibility = 24&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of records screened = 53&lt;/p&gt;" WIDTH="122">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of records after duplicates and irrelevant records removed = 53&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of records identified through database searching = 64&lt;/p&gt;&lt;p&gt;(2013 update search)&lt;/p&gt;" WIDTH="160"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of additional records identified through other sources = 3&lt;/p&gt;" WIDTH="119"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Number of studies excluded = 29&lt;/p&gt;&lt;p&gt;Not RCTs = 6&lt;/p&gt;&lt;p&gt;RCTs = 23&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Population: healthy volunteers = 2&lt;/li&gt;&lt;li&gt;Population: P. falciparum malaria = 2&lt;/li&gt;&lt;li&gt;Population: Mixed infections with vivax and falciparum = 2&lt;/li&gt;&lt;li&gt;Comparisions not appropriate = 16&lt;/li&gt;&lt;li&gt;Outcomes reported unreliable = 1&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="258"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Number of studies excluded = 9 (10 reports)&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Comparisons not appropriate = 8 (9 reports)&lt;/li&gt;&lt;li&gt;Outcome not appropriate = 1&lt;/li&gt;&lt;/ul&gt;" WIDTH="283"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;Number of studies included from 2007 review = 9 (8 reports; 2 trials described in the same report)&lt;/p&gt;" WIDTH="116"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Number of studies excluded from meta-analysis = 4&lt;/p&gt;&lt;p&gt;Ongoing studies = 4&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>